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Abstract
Physical Mechanism of Ca2+-ATPase Regulation by Phospholamban
Jason R. Waggoner
The goal of this research project was to elucidate the physical mechanism of Ca2+ATPase regulation by phospholamban in cardiac muscle. The Ca2+-ATPase transports
calcium into the sarcoplasmic reticulum in order to promote muscle relaxation.
Phospholamban regulates the Ca2+-ATPase in the heart by decreasing the apparent
calcium affinity of the Ca2+-ATPase, resulting in an inhibition of Ca2+-ATPase activity.
At present, the physical mechanism by which phospholamban regulates the Ca2+-ATPase
is unknown. Our central hypothesis was that phospholamban disrupts the Ca2+-ATPase
conformational transition from the low Ca2+ affinity state (the E2 intermediate) to the
high Ca2+ affinity state (the E1 intermediate), with concomitant inhibition of enzyme
activity. First, we developed the baculovirus-insect cell system to produce microsomes
containing cardiac Ca2+-ATPase alone or Ca2+-ATPase co-expressed with cardiac
phospholamban in sufficient quantities for kinetic and spectroscopic experiments. The
enzymatic properties of the expressed Ca2+-ATPase were similar to those observed in
native cardiac SR vesicles, and when co-expressed with phospholamban, the Ca2+ATPase was functionally coupled to phospholamban similar to that observed in cardiac
SR vesicles.

Next, we measured the effect of phospholamban on Ca2+-ATPase E2

phosphorylation by inorganic phosphate (Pi). The results showed that phospholamban
decreased the amount of Ca2+-ATPase phosphorylated by Pi without affecting the [Pi]dependence of phosphorylation. We then used fluorescence spectroscopy to determine
the effect of phospholamban on the Ca2+-dependent Ca2+-ATPase E2 to E1
conformational equilibrium. We found that phospholamban decreased the amount of
Ca2+-ATPase undergoing the E2 to E1(Ca2) transition in response to calcium, but
phospholamban did not alter the [Ca2+]-dependence of the transition. Taken together,
phospholamban decreased the number of enzymes undergoing a transition without
affecting the affinity of the enzyme for the ligand that stimulated the transition. This

suggested that phospholamban inhibits Ca2+-ATPase by sequestering the enzyme in a
conformation which resists the transition to E2P in the presence of Pi or to E1(Ca2) in the
presence of Ca2+. We propose that phospholamban stabilizes the Ca2+-ATPase into an
E2-like conformation, E, which is physically distinct from E2.
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Chapter 1: Introduction

Cardiac Sarcoplasmic Reticulum
The cardiac sarcoplasmic reticulum (SR) is a dense intracellular membranous
network in muscle cells that plays a key role in excitation-contraction coupling by
regulating the levels of intracellular [Ca2+]. Excitation-contraction coupling refers to the
mechanism by which an action potential leads to contraction of the myocyte (Walker and
Spinale, 1999). The key ion for inducing excitation-contraction coupling is calcium.
Inducement is achieved through the increase in cytosolic calcium levels from nanomolar
to micromolar concentrations (Berne and Levy, 1997). The cardiac SR is a calcium
reservoir that has two functions in imposing quick changes in intracellular calcium
concentrations: 1) accumulation of calcium drawn from the cytoplasm to induce muscle
relaxation; 2) calcium release to promote muscle contraction (Mintz and Guillan, 1997).
When an action potential reaches the myocyte, the wave of depolarization, particularly at
the T-tubular system, results in the activation of sarcolemmal voltage-sensitive L-type
calcium channels and calcium conductance (Walker and Spinale, 1999). Depolarization
of the myocyte plasma membranes and T-tubule opens both the voltage-gated Na+
channel and the voltage-gated Ca2+ channel. The initial cardiac action potential is caused
by the Na+ influx. The influx of Ca2+ through the L-type Ca2+ channels then maintains
the cardiac action potential. The influx of calcium induces the large-scale release of
calcium into the cytosol from the SR through the SR Ca2+ release channel (Meldrum et
al., 1996).
The SR Ca2+ release channel is located at the interface between the SR and the Ttubular system of the sarcolemma and is also known as the ryanodine receptor (FranziniArmstrong et al., 1997; Williams, 1997; Zhang et al., 1997). The ryanodine receptor is
responsible for calcium release from the SR and is sensitive to small fluxes in cytosolic
calcium levels. As mentioned before, the small but rapid influx of calcium through the
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L-type Ca2+ channels results in a large efflux of calcium into the myocyte cytosolic space
(Katz, 1992).
After calcium is released from the SR, a series of interactions occur within the
contractile protein of the sarcomere.

The fundamental proteins of the contractile

apparatus are myosin, actin, tropomyosin, and the troponin complex (Berne and Levy,
1997). Myosin, the thick filament, is composed of a filamentous tail and a globular head
region. The myosin head contains the actin binding site and the catalytic site for ATP
hydrolysis, which drives the muscle contraction. Actin is the major contractile protein
found in the thin filament. The interaction between the myosin globular head and the
actin unit in the presence of ATP results in crossbridge formation and sacromere
shortening, thus contraction. Tropomyosin, another protein found in the thin filament,
lies on either side of actin and adds rigidity to the thin filament. The function of
tropomyosin is to block actin and myosin binding, thereby preventing contraction. The
troponin complex is composed of three proteins: troponin T, C, and I. Troponin regulates
the extent of crossbridge formation and contributes to the structural stability of the
sacromere. Troponin T binds the troponin complex to tropomyosin and anchors the
complex to the thin filament. Calcium binding to troponin C on actin filaments induces a
conformational change in this inhibitory complex that allows actin and myosin to interact
and form cross bridges, activating the contractile apparatus.

Troponin I, when

phosphorylated, weakens the affinity of tropinin C for calcium (Berne and Levy, 1997).
Relaxation of the muscle requires the active transport of calcium back into the SR.
This energy requiring process is facilitated by a specific ATPase in the SR membrane, the
Ca2+-ATPase, which sequesters calcium from the cytosol into the SR lumen, thereby
removing calcium from the calcium-sensitive proteins of the myofilaments to promote
relaxation within cardiac muscle (Meldrum et al., 1996). There are other systems present
for calcium removal from the cytosolic compartment, including the Na+/Ca2+ exchanger
and the sarcolemmal Ca2+-ATPase. Additional calcium binding proteins like calmodulin
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and calsequestrin are also important.

The complex formed when calmodulin binds

intracellular calcium activates the sarcolemmal Ca2+-ATPase to extrude cytosolic calcium
(Feher et al., 1990; Sheu et al., 1986). Calsequestrin is the main SR calcium storage
protein in mammalian cardiac muscle and it prevents the precipitation of SR calcium and
lowers free calcium concentrations. These actions facilitate further uptake of calcium by
the SR Ca2+-ATPases (Jorgensen et al., 1979; Franzini-Armstrong et al., 1987). Overall,
SR function tightly controls the beat-to-beat cardiac cycle: the rate and extent of
myocardial relaxation is determined by the rate and extent of calcium uptake from the
myoplasm into the SR, and the rate and extent of myocardial contraction is determined by
the rate and extent of calcium release into the cytoplasm (Meldrum et al., 1996).
In cardiac, but not skeletal muscle, the Ca2+-ATPase is regulated by an integral
membrane phosphoprotein called phospholamban (PLB). Phospholamban is an inhibitor
of the SR Ca2+-ATPase in its dephosphorylated state. Phosphorylation of phospholamban
by protein kinase A (PKA) or calcium calmodulin-dependent kinase relieves this
inhibition. This results in a rapid rate of calcium re-sequestration into the SR and
increased rate of cardiac relaxation (Lindemann et al., 1983; Kranias, 1985; Inui et al.,
1986; Simmerman et al., 1986; Jones et al., 1988; Tada et al., 1988; Wegener et al., 1989;
Colyer, 1993; Katz, 1998; Simmerman and Jones, 1998). In effect, the degree of Ca2+ATPase regulation by phospholamban presents a fine-tuning mechanism for regulation of
muscle relaxation (Meldrum et al., 1996). Defining the regulation of the Ca2+-ATPase by
phospholamban is an important step toward understanding normal cardiac performance,
identifying abnormal cardiac function, and developing pharmaceutical strategies to
improve cardiac contractility in a variety of disease states (Schmidt et al., 2001).
Therefore, it is important to elucidate the molecular mechanism and regulation of calcium
transport in the heart, in order to help promote progress in the prevention and treatment of
abnormal calcium transport (Meldrum et al., 1996).
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Myocyte stimulation can occur through the β-adrenergic receptor system, which
exists in both activated and inactivated states. Under ambient conditions, both forms are
in equilibrium, but the inactivated state is predominant (Onaron et al., 1993).
Endogenous catecholamines and synthetic β-adrenergic agonists can bind to the βadrenergic receptor, resulting in a conformational change of the receptor, which in turn
begins the activation of a signal-transducing G protein resulting in adenylate cyclase
stimulation (Lodish et al., 1995). Cyclic adenosine monophosphate (cAMP) is then
generated by the action of adenylate cyclase on ATP. cAMP has the ability to activate
PKA, which can then phosphorylate numerous proteins in the myocyte. Two sites of
phosphorylation are extremely important. The first site is the voltage-dependent, L-type
calcium channel, which leads to a higher conductance along the membrane of the
myocyte during depolarization and subsequent higher [Ca2+] inside the cytosol (Meuse et
al., 1992).

PKA also phosphorylates residue Ser-16 on phospholamban.

This

phosphorylation uncouples phospholamban from the calcium pump, which significantly
increases the rate at which the SR can resequester calcium and enhance relaxation
(Meuse et al., 1992; Simmerman et al., 1986).
Ca2+-ATPase
Sarco(endo)plasmic

reticulum

Ca2+-ATPases

(SERCAs)

are

110

kDa

transmembrane proteins that transport calcium ions from the cytoplasm to the lumen of
the SR utilizing ATP as an energy source. Two calcium ions are transported per each
ATP molecule utilized (Inesi et al., 1980). The Ca2+-ATPase is typical of the P-type
ATPase class, which forms a phosphoprotein intermediate and undergoes conformational
changes during the enzymatic cycle (de Meis and Vianna, 1979). There are three known
isoforms of the Ca2+-ATPase: SERCA1, which is expressed in skeletal muscle,
SERCA2a, which is expressed in heart, and SERCA3, which is expressed in non-muscle.
SERCA1 and 2a share 84% sequence identity; however most differences are
conservative, so the sequence similarity is about 98% (Brandl et al., 1986). In fact,
SERCA1 was expressed in the heart of transgenic mice and found to be a fully functional
4

substitute for SERCA2a (Ji et al., 1999). The primary sequence of the Ca2+-ATPase
(Figure 1-1) was established by MacLennan and co-workers (MacLennan et al., 1985;
MacLennan et al., 1997), after sequencing the encoding DNA. The protein comprises a
unique polypeptide of 994 amino acids and has 10 transmembrane helical domains.
There is a central segment consisting of 440 residues, which forms the major cytoplasmic
region and contains the phosphorylation site at Asp-351 and the nucleotide-binding
region. Phosphorylation of Asp-351 by ATP and the occupation of both sites calciumbinding sites by calcium leads to the coordinated movements of both cytoplasmic and
transmembrane domains. This results in calcium transport through the membrane. The
affinity of the calcium binding sites facing the SR lumen is very low, facilitating release
of calcium from the enzyme.
Stokes and co-workers (Zhang et al., 1998) published an 8 Å structure of the
Ca2+-ATPase in its Ca2+ free form, which provided detail on the folding of the protein,
including the three dimensional arrangement of the ten transmembrane helices (Figure 12, left). Shortly afterwards, Toyoshima and co-workers (Ogawa et al., 1998) published a
9 Å structure of the Ca2+-ATPase in the Ca2+-bound form that showed large
conformational differences between the Ca2+-ATPase in the presence and absence of
calcium (Figure 1-2, right). They proposed that these conformational changes most likely
represented the changes triggered by the binding of calcium ions to the high-affinity
binding sites on the enzyme and that the Ca2+-dependent rearrangements of the
transmembrane segments are transmitted to the catalytic site in the cytoplasmic domain
through changes in the stalk domain. The arrows indicate the direction of movement and
numbers the order of the segmental movements. Calcium binding in the membrane
triggers rearrangements of the transmembrane segments (1), which are transmitted to the
cytoplasmic domain (3 and 4) through the change in inclination of the stalk segment (2)
(Ogawa et al., 1998).
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Figure 1-1.

Primary amino acid sequence of the Ca2+-ATPase (SERCA1a).

Proposed model of the Ca2+-ATPase secondary structure based upon hydropathy analysis
of the primary sequence of 994 amino acids (MacLennan et al. 1985; MacLennan et al.,
1997).

Green shading represents amino acid mutations that result in no change in

enzyme activity, mutations resulting in moderate suppression of activity are shaded
yellow, and those mutations that totally inhibit activity are shaded red. The site of
phosphorylation by ATP is Asp-351, located in the cytoplasmic domain. The sites of
calcium binding are located within the transmembrane domain and consist of two sites.
Site I residues include Asn-768, Glu-771 (M5), Thr-799, Asp-800 (M6), and Glu-908
(M8). Site II is almost entirely formed by helix M4 with residues Val-304, Ala-305, Ile307, Glu-309 and residues from M6, Asn-796, and Asp-800 contributing to calcium
binding and transport.

Reprinted with permission from the American Society for

Biochemistry and Molecular Biology (MacLennan, D.H., Rice, W.J., and Green, N.M.
1997. The Mechanism of Ca2+ Transport by Sarco(Endo)plasmic Reticulum Ca2+ATPases. J. Biol. Chem. 272: 28815-28818).
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Figure 1-2.

The effect of calcium on the Ca2+-ATPase structure.

Electron

micrograph studies (Ogawa et al., 1998) of the Ca2+-ATPase in the (a) E2 conformation
(low affinity for Ca2+) versus the (b) E1(Ca2) (high affinity for calcium) showed the
effect of calcium on the global structure of the enzyme.

Panels (c) and (d) are

illustrations of domain movements in the Ca2+-ATPase in response to high affinity
calcium binding, deduced from the corresponding EM studies.

Reprinted with

permission from the Biophysical Journal (Ogawa, H., Stokes, D.L., Hiroyuki, S., and
Toyoshima, C. 1998. Structure of the Ca2+ Pump of Sarcoplasmic Reticulum: A View
along the Lipid Biolayer at 9-Å Resolution. Biophys. J. 75: 41-52).
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Figure 1-3. 2.6 Å crystal structure of the Ca2+-ATPase. The cytoplasmic domain
consists of three parts labeled (A, N and P), which stand for actuator, nucleotide binding,
and phosphorylation domains, respectively. Asp-351, which is phosphorylated by ATP,
is located in the phosphorylation domain. The ten transmembrane helices are labeled
M1-M10 and the two purple spheres indicate the calcium bound in its transmembrane
sites. The binding sites for phospholamban and thapsigargin are marked. Also marked
are the major digestion sites for Trypsin (T1 and T2) and proteinase K (PrtK). Reprinted
with permission from Nature (http://www.nature.com/) (Toyoshima, C., Nakasako, M.,
Nomura, H., and Ogawa, H. 2000. Crystal Structure of the calcium pump of sarcoplasmic
reticulum at 2.6-Å resolution. Nature. 405: 647-655).
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Toyoshima (Toyoshima et al., 2000) published a 2.6 Å structure of the Ca2+ATPase (Figure 1-3) that shows the structure of the amino acids of the pump in the Ca2+bound form. The high-resolution structure largely confirmed earlier predictions based on
the amino-acid sequence (MacLennan et al., 1985; MacLennan et al., 1997; Brandl et al.,
1986; Andersen, 1995; Moller et al., 1996). Three distinct and separated domains make
up the cytoplasmic domain. The first is the A domain, which may work as an actuator or
an anchor for the N domain, which binds the nucleotide. The third is the P domain,
which contains Asp-351, the site of phosphorylation by ATP. The structure of the Ca2+ATPase crystallized in the presence of Ca2+ and the ATP analog 2’3’-0-(2,4,6trinitrophenyl)-adenosine monophosphate (TNP-AMP) shows TNP-AMP binding to the
surface of the N domain, more than 25 Å away from Asp-351 (Figure 1-3). Very large
domain motion is necessary for the γ-phosphate of bound ATP to reach the
phosphorylation site, since the adenosine moiety is known to bind around Lys-515, Lys492, and Phe-487 in the N domain, and because the phosphorylation site (Asp-351) on
the P domain is approximately 25 Å away in the crystal structure of the Ca2+ bound (E1)
state (Toyoshima et al., 2000). Mutation of these residues (Lys-515, Lys-492, and Phe487) had direct effects on nucleotide binding to the substrate site of the
dephosphoenzyme (Clasuen et al., 2003a).
Toyoshima and co-workers (Toyoshima et al., 2000) were able to determine the
structure of the high affinity Ca2+ binding sites. They discovered two high-density peaks,
termed site I and site II (MacLennan et al., 1997), surrounded by the transmembrane
helices M4-M6 and M8. The two sites are at similar depths with respect to the membrane
surface and are 5.7 Å apart (Toyoshima et al., 2000). Site I is located in a space between
the M5 and M6 helices with little contribution from M8. The side-chain oxygen atoms of
Asn-768, Glu-771 (M5), Thr-799, Asp-800 (M6), and Glu-908 (M8) contribute to site I.
In contrast, site II is formed almost entirely by helix M4 with some contribution from
M6. The main-chain carbonyl oxygen atoms of Val-304, Ala-305, and Ile-307 (M4) and
side-chain oxygen atoms of Asn-796, Asp-800 (M6), and Glu-309 (M4) all contribute to
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site II. This kind of geometry is only possible because helix 4 is unwound between Ile307 and Gly-310. It is believed that the correct positioning of Asp-800 must be important
because it is coordinated to both of the calcium atoms. Mutational analysis distinguished
two groups of amino acids within the transmembrane domain: The first group includes
Glu-771 (M5), Thr-799 (M6), Asp-800 (M6), and Glu-908 (M8), whose individual
mutations totally inhibited binding of the two calcium ions required for activation of one
ATPase molecule. The second group includes Glu-309 (M4) and Asn-796 (M6), whose
individual or combined mutations inhibited binding of only one and the same calcium ion
(Zhang et al., 2000). The first group, as mentioned above, is part of the residues that
contribute to site I, whereas the second group contributes to site II. The area around the
calcium-binding site can be viewed in Figure 1-4. The two calcium-binding sites are
stabilized by hydrogen-bond networks between the coordinating residues and between
residues on other helices (Toyoshima et al., 2000). These hydrogen-bond networks are
thought to be important for cooperative binding of the two Ca2+ ions (Inesi et al., 1980).
The Ca2+ free E2 state was recently crystallized at 3.1 Å resolution (Fig. 1-5) and
was stabilized by thapsigargin (Toyoshima and Nomura, 2002). Thapsigargin (TG) is an
inhibitor of the Ca2+-ATPase and stabilizes the enzyme in a Ca2+ free E2TG state that is
analogous to the E2 state (Stokes and Lacapere, 1994; Sagara et al., 1992; Wictome et al.,
1992). There are significant differences between the Ca2+ E1 state and the Ca2+ free E2
state. All three cytoplasmic domains undergo rearrangements between the E1 and E2
states that involve shifts normal to the membrane.

Analysis of the two structures

revealed that the P domain inclined about 300 with respect to the membrane, and the N
domain moved about 500 relative to the P domain.

Surprisingly, given the large

movements by the P and N domains, the structures of the two domains remained similar
in both the E1 and E2 states (Toyoshima and Nomura, 2002). Besides the movement of
the cytoplasmic domains between the E1 and E2 states, there are large movements of six
out of the ten transmembrane domains. One transmembrane helix specifically, M5, looks
like it could play an important part in conformational changes in the Ca2+-ATPase. It
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Figure 1-4. Calcium-binding sites in the Ca2+-ATPase. Transmembrane calciumbinding sites viewed approximately normal to the membrane from the cytoplasmic side.
The arrows show the direction of movement in E1(Ca2) to E2 (TG) transition. Small red
circles indicate approximately positions of carbonyl oxygens that contribute to the
binding of calcium in site II. This figure was reproduced from the following publication:
Toyoshima, C., Nomura, H., and Sugita, Y. (2003a) Structural basis of ion pumping by
Ca2+-ATPase of sarcoplasmic reticulum. FEBS Lett. 555: 106-110.
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Figure 1-5. 3.1 Å crystal structure of the Ca2+-ATPase. Ribbon representation of SR
Ca2+-ATPase in the absence of calcium but in the presence of thapsigargin (TG). Colors
change gradually from the amino terminus (blue) to the carboxy terminus (red). Red
circles indicate extra hydrogen bonds in the structure. The binding site for thapsigargin is
marked. Also marked are the major digestion sites for Trypsin (T2) and proteinase K
(PrtK). This figure was reproduced from the following publication: Toyoshima, C., and
Nomura, H. (2002) Structural changes in the calcium pump accompanying the
dissociation of calcium. Nature. 418: 605-611. (http://www.nature.com/)
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runs through the center of the enzyme from the transmembrane region to the upper end of
the helix that moves with the P domain. This would suggest that helix M5 could transmit
structural changes resulting from the binding of calcium to the cytoplasmic domains. M3
and M4 are also connected to the P domain through hydrogen bonding (Toyoshima and
Nomura, 2002).
Toyoshima and Nomura (2002) also compared the region around the two high
affinity calcium-binding sites between the E1 and E2 crystal structures.

After the

dissociation of calcium, three critical residues that included Asn-796, Thr-799, and Asp800 rotated nearly 900. Thr-799 moved away from the Site I and was replaced by Asp800. Asn-768 moved away from Site I toward Site II. The change in inclination of M5
above Gly-770 decreased the possible number of oxygen atoms that could contribute to
Site I. The movement of Asp-800 toward Site I moved it away from Site II. Also, Glu309 rotated completely to face away from Site II (Toyoshima and Nomura, 2002).
Therefore, there are many significant changes occurring in the cytoplasmic domain as
well as in the calcium-binding sites that could explain the decrease of affinity for calcium
in the E2 state. It is thought that phospholamban interaction with the Ca2+-ATPase in the
E2 state is a way the apparent affinity for calcium by the calcium pump is decreased.
Biochemical experiments also confirmed the more compact structure of the E2
crystal form, specifically in regards to the A domain. The A domain rotates almost 1100
on its axis from an open position in the presence of calcium to a more compact position
in the absence of calcium (Toyoshima and Nomura, 2002). The Ca2+-ATPase E1P state
was characterized by a strong resistance to proteinase K (Lys-120 and Asp-243) and V8
protease digestion, but a weak resistance to trypsin digestion at the T2 site (Arg-198).
However, this was in contrast to E2P, which was completely resistant to all three
digestions (Danko et al., 2001a). Although the Ca2+-ATPase was resistant to the above
digestion attacks, it was still susceptible to attack by trypsin at the T1 site (Arg-505)
(Danko et al., 2001b). This would be expected after looking at the E1 and E2 crystal
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structures (Fig. 1-3 and Fig. 1-5) and seeing that the T1 site is still exposed in the more
compact E2 structure. Toyoshima and Nomura (2002) suggested several possibilities for
the compact structure of the calcium pump in the E2 state. First, the Ca2+-ATPase
undergoes large-scale movements involving both the cytoplasmic and transmembranes
domains in the absence of calcium and it seems that the P domain is the hinge point of
these movements. Therefore, they believed that the SR vesicles loaded with calcium
would show leakage and a compact conformation of the E2 state would limit the largescale movements and also prevent the leakage. Second, they believed that the compact
conformation would stop the reaction cycle. ATP can bind in the absence of calcium, but
calcium is needed for the reaction cycle to proceed. In the compact conformation, the γphosphate of ATP cannot reach the phosphorylation residue, Asp-351. The binding of
calcium fixed the transmembrane domains such that the P domain cannot tilt to form a
compact conformation. Thus, ATP could reach the phosphorylation residue from the N
domain and continue through the reaction cycle (Toyoshima and Nomura, 2002).

Overview of Transport Mechanism
As a P-type ATPase, the reaction mechanism of calcium transport by the Ca2+ATPase is usually described in terms of two conformations that the Ca2+-ATPase can
adopt during the transport cycle (Figure 1-6) (Makinose, 1971; de Meis and Vianna,
1979; Lutsenko and Kaplan, 1995; Stokes and Green, 2003). The resting enzyme exists
as a mixture of E1 and E2 states, which represent the high Ca2+-affinity and low Ca2+affinity conformations of the Ca2+-ATPase, respectively. When the enzyme is in its E2
state after a round of cycling, the presence of micromolar calcium shifts the
conformational equilibrium (step 8) toward E1(Ca2) (Froud and Lee, 1986; Inesi, 1985;
Wakabayshi et al., 1990). When the pump is in the E1 form, the two calcium transport
sites have a high affinity for calcium (sub-micromolar affinity) and an outward cytosolic
orientation (Makinose, 1971). By mass action, calcium binding to E1 (step 1) to form
E1(Ca2) will deplete E1, inducing E2 to convert to E1, according to the net equilibrium
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Figure 1-6. Reaction cycle of the Ca2+-ATPase. Either ATP or calcium can bind first
to the E1 conformation of the Ca2+-ATPase. A series of conformational changes leads to
the intermediate E1'(Ca2)·ATP which undergoes phosphorylation to give E1P(Ca2),
which then undergoes further conformational changes to give E2P(Ca2). Calcium is then
released into the lumen and the E2·Pi state is hydrolyzed to form E2, which can return to
E1 to start the cycle over again.
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for this step (Inesi et al., 1980). The E1(Ca2) state binds MgATP with high affinity
(Dupont, 1980) and this interaction triggers a conformational change to E1′(Ca2)•ATP
(step 2; Lewis and Thomas, 1992; Coan and Keatting, 1982). Then ATP-dependent
phosphorylation and formation of the phosphoenzyme occurs (step 3). Once in the
E1P(Ca2) state, the calcium ions are occluded, thus preventing exchange or uptake of any
more cytoplasmic Ca2+.

Formation of the phosphoenzyme is followed by calcium

translocation that involves a rapid conformational change (step 4; Froehlich and Heller,
1985). The conformational change to the E2P(Ca2) state orients the calcium transport
sites toward the lumen of the SR, and decreases the affinity of the sites (to mM affinity).
After the translocation, calcium is released into the SR lumen (step 5; Froehlich and
Heller, 1985; Beeler and Keffer, 1984) and the E2P state is rapidly hydrolyzed to E2 and
Pi (steps 6 and 7; de Meis, 1988), resulting in the regeneration of the E2 conformational
state.
The Ca2+-ATPase cycle is reversible and can lead to ATP synthesis, provided that
intact vesicles are loaded with calcium and given Mg2+, ADP and Pi in the absence of
external calcium (Makinose, 1971; Makinose and Hasselbach, 1971). Also, incubation of
the Ca2+-ATPase with inorganic phosphate (Pi) in the absence of lumenal calcium led to
phosphorylation of the Ca2+-ATPase to form E2P (Lacapere et. al, 1981). To summarize
the reverse cycle, first the Ca2+-deprived Ca2+-ATPase (E2 state) is spontaneously
phosphorylated by Pi in the presence of Mg2+ (Kanazawa and Boyer, 1973; Masuda and
de Meis, 1973). In the absence of lumenal calcium, i.e. when the vesicles are empty, E2P
is stable, whereas when the vesicles are loaded with calcium, E2P formation is followed
by lumenal calcium binding and a subsequent conformational change to E1P(Ca2) (Prager
et al., 1979). Because of the calcium load, the calcium bound E1P is stable, but ADP
readily binds to E1P(Ca2), and the covalently bound phosphate is transferred to ADP.
ATP then dissociates from the enzyme, as well as the calcium ions. Thus, ATP synthesis
is coupled to calcium efflux and persists as long as there is a calcium gradient from the
lumen to the cytoplasm, and substrates (Pi and ADP) in the external medium. In the

18

presence of low cytoplasmic calcium levels, the E1 to E2 equilibrium is shifted toward
the E2 state (low affinity for calcium) and, thus increases the likelihood of reverse
cycling when an outward calcium gradient exists.
MacLennan et al. (1992) proposed a model to illustrate the physical mechanism of
calcium transport by SERCA type Ca2+-pumps. In the E1 conformational state,
cytoplasmic calcium has access to high affinity binding sites made up from specific
residues located near the middle of transmembrane helices M4, M5, M6 and M8 but these
sites are not exposed to the SR lumen. Calcium binding at these sites stimulates ATPdependent phosphoenzyme formation in the cytoplasmic domain and then the Ca2+ATPase forms the E1P(Ca2) intermediate. When phosphorylated, the calcium pump
undergoes a series of conformational changes that transform it to a low energy E2P
intermediate. These conformational changes are directly coupled to alterations in the
orientations of transmembrane sequences that lead to reorientation of the calcium-binding
sites. This model is supported by EM studies on the effect of calcium on the global
structure of the enzyme (Figure 1-2) (Ogawa et al., 1998). Evidence for conformational
changes during the enzymatic cycle has been provided using different biochemical
techniques, including fluorescence spectroscopy (Suzuki et al., 1987; Obara et al., 1988;
Suzuki et al., 1989; Suzuki et al., 1994; Suzuki and Kanazawa, 1996; Li et al., 1998;
Chen et al., 1999; Negash et al., 1999; Waggoner et al., 2001), electron paramagnetic
resonance (Lewis and Thomas, 1992; Mahaney et al., 1995), and phosphorescence
anisotropy spectroscopy (Birmachu and Thomas, 1990; Huang and Squier, 1998; Huang
et al., 1998; Negash et al., 1999).
The crystal structures of the E1 and E2 states of the Ca2+-ATPase combined with
mutational studies has allowed for a better understanding of the mechanism whereby
calcium binding produces catalytic activation and enzyme phosphorylation causes
translocation of calcium ions. The distance between the calcium-binding sites and the
catalytic site is approximately 50 Å. Therefore, some sort of long-range interaction is
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required between the N and P domains (Bigelow and Inesi, 1992; Inesi et al., 1992).
Inesi et al. (2002) characterized several calcium-binding mutants and showed that
occupancy of the calcium sites was required for catalytic activation in the forward
direction of the ATPase cycle. They noted that the long-range effect of calcium binding
is due to engagement of Glu-309 along with displacement of the transmembrane segment
M4, which is connected to the phosphorylation site residue Asp-351 (Inesi et al., 2002).
The peptide segment that extends from the phosphorylation site to the transmembrane
helix M4 showed sequence similarity to corresponding segments of other ATPases. Point
mutations in this region resulted in strong inhibition of catalytic and transport function
(Zhang et al. 1993; Zhang et al., 1995).

The M4 helix has a prominent role in

transmitting the perturbation produced by the phosphorylation of Asp-351 by ATP to the
helices in the transmembrane domain that bind calcium (Zhang et al., 1995). Along with
the displacement of transmembrane helices M4 and M5, the M6/M7 loop is also
displaced. This movement of the M6/M7 loop led to changes in the phosphorylation site
region (Sorensen and Andersen, 2000; Zhang et al., 2001). M5 looks to be important
because the combination of it and the stalk S5 helix forms an almost continuous 60 Å αhelical structure located in the center of the Ca2+-ATPase. Together, the two (M5 and
S5) connect the transmembrane domain region and the calcium-binding structure
comprised by transmembrane helices M4, M5, M6, and M8 (Sorensen and Andersen,
2000). Mutation of residues in M4, M5, and M6 resulted in the determination of shortand long-range functions. Short-range function included involvement of amino acids in
calcium binding and long-term function involved membrane amino acids that had an
influence on enzyme phosphorylation by ATP (Chen et al., 1996). Other studies showed
that mutation of aspartic residues in the M6/M7 loop resulted in a strong reduction of
calcium binding along with overall enzyme activity (Falson et al., 1997; Menguy et al.,
1998).

Interestingly, the mutation of Asp-351 produced total inhibition of ATP

utilization but had no significant effect on calcium binding (Zhang et al., 2000).
Therefore, there is strong evidence for long-term interactions occurring between the
calcium-binding sites and the phosphorylation site of the Ca2+-ATPase, and disruption of
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this interaction leads to decreased levels of Ca2+-ATPase activity. This will be discussed
more in the interaction of phospholamban with the Ca2+-ATPase later on.
Along with determining the interaction between the calcium-binding sites and the
phosphorylation site, there is great interest in understanding the pathway for the initial
migration of calcium ions from the cytoplasm to the binding sites in the Ca2+-ATPase.
Most of the interest has focused on transmembrane helix M3. This helix is linked to the
A domain and is part of the hydrogen bonding between the P domain and the M6/M7
loop (Clausen and Andersen, 2003b).

There have been several studies looking at

thapsigargin interaction with the enzyme because it forms a dead-end complex with the
Ca2+-ATPase and it binds next to M3 (Norregaard et al., 1993; Norregaard et al., 1994;
Zhong and Inesi, 1998; Yu et al., 1998; Young et al., 2001; Stokes and Green, 2003).
The Ca2+ free crystal structure (Fig. 1-5), that has thapsigargin bound, shows a possible
channel between M1 and M3 (Clausen and Andersen, 2003b). This observation led to
mutational studies of key residues located on M3 that showed mutation of these residues
led to changes in the migration of calcium ions in the enzyme (Clausen and Andersen,
2003b; Andersen et al., 2001).
Toyoshima (Toyoshima et al., 2000) reported that large-scale motion within the N
and P domains must occur during ATP-hydrolysis.

As mentioned before, the

phosphorylation site (Asp-351) on the P domain is more than 25 Å away from the bound
nucleotide site on the N domain (visualized using the non-hydrolyzable ATP analog
TNP-AMP). Therefore, domain closure must occur during ATP-hydrolysis. Nakamoto
and Inesi (1984) reported physical evidence for this motion by showing that fluorescence
from TNP-AMP bound to the Ca2+-ATPase increased upon calcium binding to the
enzyme or reverse phosphorylation by Pi, indicating a conformational change at the
nucleotide binding site. Likewise, time-resolved phosphorescence spectroscopy of the
probe erythrosine isothiocyanate attached to Lys-464 in domain N showed large domain
motion induced by the binding of calcium (Huang et al., 1998). Also, in the presence of
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ATP and calcium, glutaraldehyde can cross-link two specific Ca2+-ATPase residues (Lys492 and Arg-678) that are separated by more than 25 Å in the absence of calcium and/or
ATP (McIntosh, 1992). Finally, ATP pyridoxal labels both Lys-492 and Lys-684 in the
absence of calcium, but only Lys-684 in the presence of calcium (Yamamoto et al.,
1989). These results indicate that the N domain is mobile in the presence of calcium, but
fixed in its absence.

Also, the N domain comes close to the P domain in the

phosphorylated states by conformation changes induced by ATP-binding. This was seen
in the crystal structure in the absence of Ca2+ (Toyoshima and Nomura, 2002). Ma et al.
(2003) suggested that nucleotide binding occurred by collision with the N domain in the
Ca2+-dependent open conformation of the enzyme headpiece. They also determined that
the nucleotide-dependent approximation of the headpiece domain occurred only when
both calcium-binding sites were filled. Toyoshima et al. (2003a) presented a model of
the distinct arrangements of the cytoplasmic domains (Figure 1-7). In the E2P form, the
A domain is pulled towards the P domain, forming a sealed environment around the
phosphorylation residue. They suggested that the interfaces between the N, P, and A
domains must be critical and would have to be altered in order for the cytoplasmic
domains to move during the reaction cycle.

The binding of calcium and the

phosphorylation of Asp-351 would have the most affect on the interaction between all
three domains (Toyoshima et al., 2003a).

Phospholamban
Phospholamban (PLB), meaning “phosphate receptor,” is an integral membrane
phosphoprotein that regulates the Ca2+-ATPase of the cardiac SR and is therefore a major
modulator of myocardial contractility (Tada et al., 1974; Tada, 1992). Dephosphorylated
phospholamban acts as an inhibitor of the Ca2+-ATPase and phosphorylation of
phospholamban relieves this inhibition (Autry and Jones, 1997; Tada et al., 1974; Hicks
et al., 1979). Phospholamban has 52 amino acids and has been predicted to contain three
domains (Figure 1-8). Domain IA, amino acids 1-20, is highly charged, largely helical
(Simmerman and Jones, 1998; Smith et al., 2001), and contains sites of regulatory
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Figure 1-7.

Model for reaction cycle of the cytoplasmic domains in the Ca2+-

ATPase. Schematic models for four distinct arrangements of the three cytoplasmic
domains in the reaction cycle of Ca2+-ATPase. D351 is the residue of phosphorylation.
Transfer of ‘occluded’ Ca2+ to the luminal side is thought to take place between E1P and
E2P.

This figure was reproduced from the following publication: Toyoshima, C.,

Nomura, H., and Sugita, Y. (2003a) Structural basis of ion pumping by Ca2+-ATPase of
sarcoplasmic reticulum. FEBS Lett. 555: 106-110.
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Figure 1-8. Structural model of phospholamban. Domain IA, amino acids 1-20,
contains sites of regulatory phosphorylation by protein kinase A at Serine16 and by
Ca2+/calmodulin-dependent kinase at Threonine17.

Domain IB, amino acids 21-30,

contains a high proportion of Asn and Gln residues. Domain II, amino acids 31-52,
forms a transmembrane helix.

This figure was provided by John Voss and David

Thomas.
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phosphorylation by cAMP-dependent protein kinase at Ser-16 and by Ca2+/calmodulindependent protein kinase at Thr-17 (MacLennan and Kranias, 2003; Brittsan and Kranias,
2000). Phosphorylation at Ser-16 is required first before phosphorylation at Thr-17 (Luo
et al., 1998). Domain IB, amino acids 21-30, is polar, a β-hairpin, and contains a high
proportion of Gln and Asn residues. Domain II, amino acids 31-52, is neutral, very
hydrophobic, and forms a transmembrane helix (Simmerman and Jones, 1998; Smith et
al., 2001).
Phospholamban runs both as a pentamer (Mr = 30 kDa) and monomer (Mr = 6
kDa) on SDS gels, and in native cardiac SR vesicles, pentameric phospholamban is in
equilibrium with monomeric phospholamban.

It appears that phospholamban forms

homo pentamers in membranes (Simmerman and Jones, 1998), but current models show
that monomeric phospholamban binds to and regulates the Ca2+-ATPase.

Alanine

scanning mutagenesis studies of phospholamban domain II (Kimura et al., 1997; Adams
et al., 1995; Arkin et al., 1995; Simmerman et al., 1996) have demonstrated that the
phospholamban pentamer is held together by a series of leucine zippers (Simmerman et
al., 1996). Mutations to individual residues on one face of the zipper motif enhanced
monomer formation and increased phospholamban potency (Kimura et al., 1996). The
authors proposed that the phospholamban monomer is the active form because increasing
amounts of monomeric phospholamban increased Ca2+-ATPase inhibition. Also, Thomas
and co-workers (Reddy et al., 1999) used fluorescence energy transfer to study the
oligomeric structure of phospholamban.

They found that phospholamban existed

primarily as an oligomer in membranes in the absence of Ca2+-ATPase. In contrast, the
presence of Ca2+-ATPase decreased the population of phospholamban oligomers because
the calcium pump bound individual phospholamban monomers.

Their results also

suggested that the active inhibitory species of phospholamban was the monomer. They
proposed higher oligomeric forms of phospholamban might serve as a storage reservoir
for phospholamban when it is not associated with the Ca2+-ATPase. Measurements of the
effect of phosphorylation on the concentration of phospholamban monomers also
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supported the view that phospholamban monomers are the inhibitory species of the Ca2+ATPase (Cornea et al., 1997). Another study saw that phosphorylated phospholamban
had more loose helical packing than nonphosphorylated phospholamban (Pollesello and
Annila, 2002). This would also support the view that the phosphorylated phospholamban
would accumulate in the oligomer form.
Calcium Transport by Ca2+-ATPase and Regulation by Phospholamban
Cytoplasmic interactions between phospholamban and SERCA2a appear to be
important for function, because mutations of the amino acids that comprised the
phospholamban domain Ia or the residues KDDKPV-402 of the Ca2+-ATPase resulted in
the decreased ability of phospholamban to inhibit the Ca2+-ATPase (James et al., 1989;
Toyofuku et al., 1994a; Toyofuku et al., 1994b). Transmembrane interaction between
phospholamban and the Ca2+-ATPase appear important for regulatory interactions
between the two proteins. Mutation of amino acids on one face of the phospholamban
transmembrane helix led to the loss of phospholamban inhibition of the Ca2+-ATPase
(Kimura et al., 1996).

Likewise, MacLennan and co-workers (Asahi et al., 1999)

observed that the mutation of Leu-802, which is located on the transmembrane helix M6
of the Ca2+-ATPase, decreased phospholamban inhibitory function and decreased the
physical association of phospholamban and its interaction with transmembrane helix M6
of the Ca2+-ATPase.
A recent report (Li et al., 2003) showed that phosphorylation of phospholamban at
Ser-16 stabilized the helical structure in the cytosolic domain through the formation of a
salt bridge. They suggested that this stabilization caused by phosphorylation induced a
conformational rearrangement between phospholamban and the Ca2+-ATPase that led to a
conformation of phospholamban that no longer restricted domain motions by the N
domain needed during the catalytic cycle. This work followed a previous study (Negash
et al., 1999), which showed phosphorylation of phospholamban modified the orientation
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of domain elements of the Ca2+-ATPase. They also showed that calcium activation and
phospholamban phosphorylation were distinct processes that resulted in different
structural changes to the Ca2+-ATPase.

In the same study, it was also seen that

phospholamban phosphorylation altered the structural interactions of phospholamban
with the Ca2+-ATPase. More interestingly, the structural coupling between the cytosolic
portion of phospholamban and the Ca2+-ATPase responsible for enzyme activation did
not involve dissociation of phospholamban from the Ca2+-ATPase (Negash et al., 2000).
No dissociation was also seen between the transmembrane regions of the Ca2+-ATPase
and phospholamban after phospholamban phosphorylation (Chen and Bigelow, 2002).
This was in contrast to previous reports that stated otherwise (James et al., 1989;
MacLennan et al., 1998; Thomas et al., 1998). Therefore, in its nonphosphorylated state,
phospholamban is able to bind to the Ca2+-ATPase in sites that inhibit function (Hutter et
al., 2002; Toyoshima et al., 2003b). Another study showed that the nonphosphorylated
phospholamban inhibited calcium transport by stabilizing α-helical elements to rigidify
the Ca2+-ATPase that could lead to diminished transport function (Tatulian et al., 2002).
The effect of phospholamban on calcium transport by the Ca2+-ATPase has been
well established. The predominant, physiologically relevant effect of phospholamban is
decreased apparent affinity of the ATPase for calcium (Simmerman and Jones, 1998).
The sigmoidal dependence of activity on [Ca2+] is characterized in terms of maximum
activity (Vmax) and the calcium concentration that induces half maximal ATPase activity
(denoted K0.5 or KCa). In the dephosphorylated form, phospholamban inhibits Ca2+ATPase by decreasing its apparent affinity for calcium, as evidenced by a rightward shift
in KCa to higher levels of calcium, relative to that observed in the presence of
phosphorylated phospholamban. The phosphorylation of phospholamban increases the
calcium sensitivity of the Ca2+-ATPase. Since calcium transport is coupled to ATP
hydrolysis, similar results are obtained for calcium uptake activity (Autry and Jones,
1997; Autry and Jones, 1998). Experimentally, the use of a monoclonal antibody against
phospholamban, 2D12, can uncouple phospholamban from the calcium pump similar to
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phospholamban phosphorylation (Autry and Jones, 1997; Autry and Jones, 1998;
Antipenko et al., 1997). Ferrington et al. (2002) determined that phospholamban was
expressed in 4-fold molar excess of the Ca2+-ATPase in SR isolated from cardiac SR.
They also saw nearly identical ∆KCa values for the Ca2+-ATPase and phospholamban over
a wide range (1 to 5 moles phospholamban per mole Ca2+-ATPase) in SR isolated from
rat and rabbit slow-twitch soleus and cardiac muscle, but maximal levels of ∆KCa were
attained at one mol phospholamban per mol Ca2+-ATPase. They suggested that the
abundance of phospholamban expression in cardiac SR might help to control the
sensitivity of the Ca2+-ATPase to kinase activation (phospholamban phosphorylated) or
phosphatase inactivation (phospholamban nonphosphorylated) because the additional
phospholamban would provide empty substrates for kinase phosphorylation that would
result in no functional effects seen because there is no Ca2+-ATPase associated with those
phospholamban molecules.
The co-expression of the phospholamban transmembrane sequence alone with the
Ca2+-ATPase has been shown to inhibit calcium transport activity at sub-micromolar
calcium concentrations (Kimura et al., 1996). This suggested that only transmembrane
interactions between the Ca2+-ATPase and phospholamban were important for regulation.
This result was confirmed by Karim et al. (2000) using chemical synthesis, functional
reconstitution, and electron paramagnetic resonance. They saw that the transmembrane
domain of phospholamban was sufficient for inhibitory function and the oligomeric
stability of phospholamban did not determine its inhibitory activity. However, another
report (Hughes et al., 1996) showed that the effects of phospholamban on the Ca2+ATPase are the sum of the effects of its hydrophobic and hydrophilic domains. They
concluded that the hydrophilic domain bound to the Ca2+-ATPase and inhibited the
calcium transport step.

Phospholamban could inhibit either the Ca2+-ATPase as a

hydrophilic peptide or part of the whole phospholamban structure that is anchored to the
membrane by the hydrophobic domain (transmembrane region).

The hydrophobic

domain would also be in a position that would allow the hydrophilic domain to reach its
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possible biding sites on the cytoplasmic domains of the Ca2+-ATPase. Another group
used equilibrium fluorescence studies to prove that there is an interaction between the
cytoplasmic areas of phospholamban and the Ca2+-ATPase (Sharma et al., 2001). They
believed that the cytoplasmic region of phospholamban prevented the Ca2+-ATPase N
and P domains from assuming conformations that are required for phosphoenzyme
formation after nucleotide binding.

Kimura and Inui (2002) developed a screening

system to determine whether select compounds could remove the inhibition of the Ca2+ATPase by phospholamban. Their initial results showed that phospholamban could bind
the Ca2+-ATPase in the absence of the transmembrane portion of phospholamban and
mutations in the cytoplasmic domain that did not inhibit Ca2+-ATPase activity paralleled
the disruption of the association between phospholamban and the Ca2+-ATPase. They do
mention that there are several interactions between phospholamban and the Ca2+-ATPase
and disruption of any of these interactions would probably lead to loss of the
phospholamban inhibitory effect.

Therefore, there is still an ongoing debate in the

literature on what part of phospholamban is actually responsible for its inhibitory
properties on the Ca2+-ATPase.
A possible model for phospholamban regulation of Ca2+-ATPase function may
involve phospholamban inhibiting enzyme conformational changes that facilitate calcium
binding or those that are triggered by calcium binding. Asahi et al. (2000) proposed a
model by which phospholamban regulates Ca2+-ATPase function via long-range
structural coupling. The region of the Ca2+-ATPase that phospholamban would regulate
Ca2+-ATPase function is the cytoplasmic loop (L67) between M6 and M7. The most
likely site of interaction between phospholamban and the Ca2+-ATPase is residue Asp813 of the calcium pump, which is close to M6.

By interacting with Asp-813,

phospholamban could stabilize its interaction with the Ca2+-ATPase. Consistent with
phospholamban binding to the L67 residue Asp-813 of the calcium pump, mutational
analysis of Asp-813 has shown a decrease in the amount of phosphorylated intermediate
formed along with a reduced affinity for calcium (Asahi et al., 2000). Consistent with
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this model, dephosphorylated phospholamban has been shown to modulate the calcium
activation of the Ca2+-ATPase, resulting in reduced transport activity at sub-micromolar
calcium concentrations as a result of decreased levels of phosphoenzyme intermediate
(Cantilina et al., 1993). A follow up study showed phospholamban domain IB formed an
interaction with the L67 of the Ca2+-ATPase (Asahi et al., 2001). Modeling studies
suggested that phospholamban interacted with transmembrane helices M2, M4, M6, and
M9 and extended across the cytoplasm to the KDDKPV-402 stretch in the N domain of
the Ca2+-ATPase. The interaction of phospholamban with the transmembrane helix M2
occurred in the E2 state but the phospholamban helix collided with M2 in the E1 state
because the presence of calcium caused the large movement of M2 toward M9
(Toyoshima et al., 2003b). There have been several elegant cross-linking experiments
that have given the location where phospholamban interacts with the Ca2+-ATPase.
Jones et al. (2002) used a 10 Å long cross-linker to link Cys-318 of the Ca2+-ATPase with
a Cys-30 (mutated from Asn-30) residue of the phospholamban. A follow up study
(Chen et al., 2003) showed that there was cross-linking between Lys-328 of the Ca2+ATPase and Cys-27 (mutated from Asn-27) and Cys-30 (mutated from Asn-30) of
phospholamban using cross-linkers of 10 Å and 15 Å, respectively. The cross-link
established in both studies placed phospholamban close to transmembrane helix M4 of
the Ca2+-ATPase, which would place it in an ideal location to regulate calcium transport
for several reasons. First, M4 is directly connected to the phosphorylation site residue.
Therefore, phospholamban could interfere with the transmission of conformational
changes between the phosphorylation site and the calcium binding sites. Second, Cys318 is only 9 residues away from Glu-309, which is a critical calcium ligand residue.
Even though phospholamban may not bind specifically to Cys-318, it could bind in the
region and thus, it is reasonable to assume that at this location phospholamban could
affect calcium binding directly or indirectly.
The most recent studies of the physical mechanism of Ca2+-ATPase inhibition by
phospholamban have focused on the effect of phospholamban on Ca2+-ATPase
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conformational flexibility and transitions. Squier and co-workers (Negash et al., 1999)
used fluorescence and phosphorescence spectroscopy to show that the N domain of the
Ca2+-ATPase in the E1(Ca2) state (Fig. 1-3) undergoes large amplitude motion, sampling
a wide variety of conformations. When ATP binds to the N domain, the N domain adopts
a time-averaged closed conformation, which brings the terminal phosphate of ATP in
close proximity to Asp-351 in the P domain. Following enzyme phosphorylation and
calcium translocation, the cytoplasmic domain retains a time-averaged closed structure
with the transmembrane helices in the low calcium affinity orientation, the E2 state (Fig.
1-5). Nevertheless, there is significant conformational flexibility in the transmembrane
helices and in the cytoplasmic domains, allowing the enzyme to constantly fluctuate
between the calcium free E2 state and the E1 conformation that allows cytoplasmic
calcium to access its high affinity binding sites of the enzyme. When calcium binds and
the enzyme converts back to the E1(Ca2) state, the enzyme again adopts the timeaveraged, open and conformationally flexible structure.
Phospholamban is also conformationally flexible. Best modeled as two rigid
helices connected by a flexible linker, Squier and co-workers (Li et al., 2004) have shown
that the cytoplasmic helix of phospholamban can adopt a wide variety of conformations
relative to the transmembrane helix, which is oriented more-or-less along the membrane
normal. However, when phospholamban comes in contact with the Ca2+-ATPase, the
cytoplasmic phospholamban helix adopts one unique orientation that exhibits very little
flexibility. Likewise, when the Ca2+-ATPase binds phospholamban, the enzyme loses a
significant amount of flexibility observed in the E2 state. In essence, phospholamban and
Ca2+-ATPase interactions shift the conformational dynamics of the enzyme toward the
less flexible, E2-like state. This “stabilization” of the E2 state decreases the likelihood of
the enzyme adopting the E1 conformation, with a concomitant decrease in calcium
binding and ATP-dependent phosphorylation.
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Physiological Role of the Ca2+-ATPase and Phospholamban
Abnormal Ca2+-ATPase regulation by phospholamban has been implicated as a
causative factor for diastolic dysfunction, cardiac hypertrophy and heart failure.

A

common characteristic, contributing to the impaired contractile performance in human
and experimental heart failure, is depressed SR Ca2+-cycling (Hasenfuss, 1998;
Beuckelmann et al., 1992). This has led to a great deal of interest in understanding the
physical and functional interaction between the Ca2+-ATPase and phospholamban
(reviewed by Frank et al., 2003).
The role of SERCA2a in the regulation of calcium homeostasis and contractility
in the heart has been defined by generating mice in which SERCA2 is either over
expressed or knocked-out (Baker et al., 1998; Greene et al., 2000; Kiriazis and Kranias,
2000; del Monte et al., 2001). In mouse hearts that over express SERCA2a, there was an
increase in the maximum velocity of the calcium uptake rate (Vmax), without a change in
the KCa for calcium transport. Homozygous SERCA2a knock-out mutants were not
observed, and the ratio of wild-type:heterozygous offspring was very close to the 1:2
Mendelian ratio that would be expected if loss of homozygous mutants was occurring
during embryonic development (Periasamy et al., 1999).

Therefore, mice with

heterozygous mutant hearts were used that expressed 55% of the mRNA and 65% of the
protein levels of SERCA2 compared with wild type hearts (100%). The heterozygous
mutant hearts had a decrease in the maximum velocity of the calcium uptake rate, without
a change in the K0.5 for calcium transport. The decreased SERCA2a levels and calcium
transport correlated with decreased systolic ventricular pressure, rates of contraction and
relaxation, and mean arterial blood pressure. Therefore, two alleles of the SERCA2a
gene were needed to maintain proper levels of the Ca2+-ATPase in order to have normal
heart function (Kiriazis and Kranias, 2000). Having a heart with heterozygous SERCA2a
levels could be a major factor for heart disease. As seen above, a heterozygous mutant
heart had a decrease in the maximum velocity of the calcium uptake rate and this could
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lead to problems with heart muscles relaxing and causing irregularities with blood flow
because of insufficient contraction and relaxation by the heart muscle. One area of focus
for current vascular cardiac research is looking for patients with heterozygous mutant
hearts and correlating it with the onset of heart disease.
The physiological role of phospholamban in modulating basal myocardial
contractility was confirmed through the use of transgenic mice with altered levels of
phospholamban expression (Luo et al., 1994; Luo et al., 1996; Wolska et al., 1996; Li et
al., 1998; Kiriazis and Kranias, 2000). Over expression of phospholamban increased the
rightward shift in the EC50 value that corresponded to a decrease in the affinity of
SERCA2a for calcium. Also, 2-fold over expression of phospholamban led to decreased
Ca2+-affinity of the SR Ca2+-ATPase and decreases in contractile parameters (Kadambi et
al., 1996).

These inhibitory effects could be completely reversed by β-agonist

stimulation, which resulted in the phosphorylation and inactivation of phospholamban
inhibitory action on the Ca2+-ATPase (Kadambi et al., 1996; Kadambi et al., 1998).
Ablation of phospholamban induced a leftward shift in the EC50 value that corresponded
to an increase in the affinity of SERCA2a for calcium. It also led to increased SR Ca2+load and calcium release, and to hyperdynamic cardiac function (Luo et al., 1994; Hoit et
al., 1995; Luo et al., 1996; Lorenz and Kranias, 1997; Kiriazis and Kranias, 2000).
Ablation of phospholamban also resulted in enhanced contractility in the mice that
remained throughout the aging process (Slack et al., 2001). Another study generated
transgenic mice that over expressed a phospholamban Val-49 → Gly-49 mutant that is a
super inhibitor of SR Ca2+-ATPase affinity for calcium (Haghighi et al., 2001). They saw
that the over expression of the phospholamban mutant in vivo resulted in super inhibition
of cardiac contractility and cardiac remodeling, which then progressed to dilated
cardiomyopathy and early mortality. They suggested that enhanced inhibition of the
Ca2+-ATPase by phospholamban might serve as the causative factor for the onset and
progression of heart failure. Over expression of the monomeric, dominant acting super
inhibitory Leu-37 → Ala-49 and Ile-40 → Ala-40 mutants in mice caused depression of
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contractile parameters and also led to the onset of cardiac hypertrophy (Zvaritch et al.,
2000).
The phosphorylation status of phospholamban is another important determinant
in cardiac regulatory effects. As mentioned before, phosphorylation of phospholamban
during β-agonist stimulation relieves the inhibitory effects of phospholamban on the
Ca2+-ATPase.

Studies have shown evidence in human heart failure that indicated

decreased phospholamban phosphorylation, which would result in increased inhibitory
effects on the Ca2+-ATPase leading to decreased levels of calcium transport (Schwinger
et al., 1999; Dash et al., 2001). A human phospholamban mutation (R9C: Arg → Cys),
which had no effects on SERCA2a activity under basal conditions but trapped PKA, was
associated with dominant inheritance of dilated cardiomyopathy (Schmitt et al., 2003).
Studies in mice found that disruption of the phospholamban gene or expression of a
dominant negative phospholamban mutant led to enhanced cardiac function, whereas in
humans, the absence of phospholamban led to development of lethal dilated
cardiomyopathy (Haghighi et al., 2003). A transgenic mouse that over expressed a nonphosphorylatable form of phospholamban, to prevent compensatory reactions in vivo,
resulted in saturation of the functional phospohalmban:Ca2+-ATPase ratio.

It was

determined that approximately 40% of the SR calcium pumps were functionally
interacting with and regulated by phospholamban in native SR (Brittsan et al., 2000).
This could mean that there is a basal level of calcium transported across the membrane
and the presence of phospholamban is used for graded responses and that control of just
40% of the calcium pumps is still very important physiology. The idea of graded
responses by phospholamban has been discussed before (Ferrington et al., 2002; Yao et
al., 2001).
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Overview of Dissertation Research
The link between abnormal Ca2+-ATPase:phospholamban interaction and heart
disease is well established. Therefore, a key step in understanding important cardiac
pathologies and developing pharmaceutical strategies in the fight against heart disease is
elucidating the molecular details of the phospholamban Ca2+-ATPase interaction
(Schmidt et al., 2001).

Despite considerable progress toward understanding the

functional interaction of phospholamban with the Ca2+-ATPase, fundamental questions
remain

concerning

the

physical

mechanism

of

Ca2+-ATPase

regulation

by

phospholamban. Therefore, the goal of this dissertation research was to determine the
physical mechanism by which phospholamban regulates Ca2+-ATPase kinetics, and in
particular, how phospholamban physically reduces Ca2+-ATPase affinity for calcium. We
tested the hypothesis that phospholamban disrupts the Ca2+-ATPase E2 to E1
conformational change, which facilitates high affinity calcium binding to the enzyme E1
state. To test this hypothesis and its alternatives, we used fluorescence spectroscopy to
measure directly the physical effects of phospholamban on the Ca2+-ATPase E2 to E1
conformational change, correlated with kinetic measurements of inorganic phosphate (Pi)
binding to the E2 state. For this work, we employed a baculovirus-insect cell expression
system to produce samples containing cardiac Ca2+-ATPase expressed in the absence
(control) and presence of co-expressed phospholamban. Extensive experiments were
carried out to characterize the physical and functional properties of the expressed
proteins, which have not been conducted previously. In particular, we have pursued the
following specific aims:
Aim 1: Characterize the expression of phospholamban and the Ca2+-ATPase in
High-Five insect cells. We have used the baculovirus insect cell expression system in
order to express phospholamban and the Ca2+-ATPase in High-Five insect cells. The
expressed proteins were isolated in cellular microsomes, and the physical and functional
properties of the expressed proteins were analyzed and compared directly to the Ca2+-
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ATPase and phospholamban in native myocardial microsomes isolated from dog heart.
These studies are described in Chapter 3.
Aim 2: Determine the effect of phospholamban on Ca2+-ATPase phosphorylation by
inorganic phosphate (Pi).

We have used [32P]-labeled inorganic phosphate (Pi) to

measure Pi phosphorylation of the Ca2+-ATPase E2 intermediate, as affected by
phospholamban. These studies are described in Chapter 4.
Aim 3: Determine the effect of phospholamban on the Ca2+-ATPase E2 to E1
conformational transition. We have used fluorescence spectroscopy of IAEDANSlabeled Ca2+-ATPase to measure the Ca2+-dependent E2 to E1 enzyme transition, as
affected by phospholamban. These studies are described in Chapter 5.
Understanding the normal mechanism of phospholamban regulation is important
for identifying the pathological regulation of the Ca2+-ATPase by phospholamban, which
has been demonstrated to be a causative factor in several cardiac disease states. The
results provide new insights into the mechanisms of catalysis and regulation of calcium
transport in cardiac muscle SR, which is a critical step toward understanding cardiac
performance and malfunction.
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I-labeled protein A was purchased from Perkin Elmer Life Sciences.
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CaCl2,

[γ-32P]ATP, and [32P]H3PO4 were purchased from ICN. Prestained molecular weight
standards and polyvinylidene difluoride (PVDF) membranes were purchased from BioRad.

High-Five insect cells and medium were purchased from Invitrogen, and the

BaculoGold system was obtained from Pharmingen-BD Biosciences. The antibodies
used in this study were a gift from Dr. Larry Jones, Indiana University School of
Medicine.

Protein Expression and Isolation
Recombinant baculoviruses containing cDNA inserts for canine cardiac Ca2+ATPase or canine phospholamban were prepared using the BaculoGold system and
titered by plaque assay, both as described previously (Autry and Jones, 1997). Wild type
canine SERCA2a and canine phospholamban were expressed in High-Five cells grown in
suspension (1.67 X 106 cells/ml) at 27 oC in Sf-900 II SFM medium (Invitrogen)
supplemented with 10 units/ml Heparin (Sigma). For expression of the Ca2+-ATPase
alone, a multiplicity of infection of 10 (plaque-forming virus units per cell) was used.
For co-expression of the Ca2+-ATPase and phospholamban, a multiplicity of infection of
15 was used for SERCA2a and 5 for phospholamban. Virus-infected High-Five cells in
600 ml of suspension (1 X 109 cells) were sedimented and then washed twice with 150 ml
of an ice-cold solution of phosphate-buffered saline (PBS) containing 137 mM NaCl, 2.7
mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4 (pH 7.4), by centrifugation for 10 min at
1500 rpm at 4 oC in an IEC GP8R refrigerated centrifuge. The washed cells were
resuspended in 60 ml of ice-cold 10 mM NaHCO3 and 0.2 mM CaCl2. Then 60 ml of
ice-cold 500 mM sucrose, 300 mM KCl, 6 mM MgCl2, and 60 mM histidine were added.
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Both solutions contained 10 µg/ml aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin A, and
0.1 mM pefabloc. The cells were placed on ice and transferred to a cold room. The cells
were homogenized for 90 s with a Brinkman Polytron on maximum speed.

The

homogenized cells were left on ice for about 10 minutes to allow the foam to settle, and
then the homogenate was centrifuged for 20 min at 3000 rpm (1,075 X g), 4 oC, in a
Sorvall SS34 rotor. The supernatant was collected and 30 ml of ice-cold 3 M KCl
containing 10 µg/ml aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin A, and 0.1 mM
pefabloc was added. The mixture was centrifuged for 20 min at 9000 rpm (9,680 X g), 4
o

C, in a Sorvall SS34 rotor. The supernatant was collected and the High-Five insect cell

microsomes were pelleted by centrifugation for 38 min at 26,000 rpm (52,858 X g), 4 oC,
in a Beckman Ti45 rotor. The pellets were resuspended in 5 ml of 250 mM sucrose, 10
mM histidine (pH 7.2) and stored in small aliquots at –50 oC. Protein concentrations
were determined by the method of Lowry et al. (1951), using bovine serum albumin
(Sigma) as a standard.

The average yield per 600 ml of infection was 80 mg of

microsomal protein.

Immunofluorescence
Wild type canine SERCA2a and canine phospholamban were expressed in High
Five cells grown in tissue culture chambered slides (Falcon) at 27 oC in Sf-900 II SFM
medium supplemented with 10 units/ml Heparin. Cells to be infected with baculoviruses
were plated at 4 X 105 cells/well and the control-uninfected cells were plated at 2 X 105
cells/well. The difference in plating was to allow for differences in cell growth and
doubling between the control and infected cells during the infection period. For coexpression of the Ca2+-ATPase and phospholamban, a multiplicity of infection of 15 was
used for SERCA2a and 5 for phospholamban. Following 48 hours of infection, the cells
were washed for 15 min with 1% PBS, after which the cells were fixed in 2%
formaldehyde/PBS (pH 7.4) for 15 min at 20 oC. After formaldehyde fixation, the cells
were washed twice with 1% PBS for 3 min each and permeabilized with 0.2% Triton X-
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100/PBS for 5 min. The cells were then washed three times with 1% PBS for 5 min each.
The cells were then dehydrated in 70%, 90%, and 100% ethanol for 5 min each. Before
primary antibodies were used, the cells were blocked for 45 min at room temperature in a
humidified chamber in 1x blocking buffer (Roche). After the blocking step, the cells
were incubated with monoclonal antibodies (Affinity Bioreagents) specific to SERCA2a
(IID8, 20 µg/ml mouse IgG1 in 1x blocking buffer/PBS) or phospholamban (2D12, 20
µg/ml mouse IgG2a in 1x blocking buffer/PBS) for 1 h at room temperature in a
humidified chamber. The cells were then washed three times with 1% PBS for 10 min
each. After the washes, the cells were incubated for 1 h at room temperature in a
humidified chamber in the presence of indodicarbocyanine (CY5)-conjugated goat antimouse IgG1 (Southern Biotech: 4 µg/ml in 1x blocking buffer/PBS) for detecting
SERCA2a and rhodamine-conjugated goat anti-mouse IgG2a (Southern Biotech; 4 µg/ml
in 1x blocking buffer/PBS) for detecting phospholamban.

The cells were then washed

three times with 1% PBS for 10 min each. For background staining, the cells were
incubated in 1% PBS containing a 1:4,000 dilution of the short chain carbocyanine
DiOC6 (Molecular Probes) for 10 min at room temperature to visualize the endoplasmic
reticulum. Afterwards, the cells were washed twice with 1% PBS for 10 min. In some
cases, the cells were incubated in 1% PBS containing a 1:10,000 dilution of 4’,6’diamidino-2-phenylindole (DAPI; Sigma) for 4 min as a DNA counter-stain. The cells
were then washed twice with 1% PBS for 10 min. Following the washes, the cells were
mounted on a microscope slide using fluoromount-G (Fisher). Control uninfected cells
were treated identically to the infected cells, except for the omission of viruses.
The immunofluorescence staining of the microsomal preparations were visualized
by excitation at 488 nm for DiOC6, 633 nm for CY5 and 543 nm for Rhodamine, with
emission spectra detected between 505-550 nm, 650 nm, and 560-615 nm, respectively,
using a Zeiss Laser Scanning Microscope 510. Differential interference contrast images
(DIC) were also collected. Each image is representative of the entire population of cells
on the slide.
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Electrophoresis and Immunoblotting
Prior to electrophoresis, samples were solubilized at 37 oC for 5 minutes in a
dissociation medium that consisted of 62.5 mM Tris (pH 6.8), 5% glycerol, 5% sodium
dodecyl sulfate (SDS), 40 mM dithiothreitol, and 0.0025% bromphenol blue. SDSPAGE gel electrophoresis was conducted by the method of Porzio and Pearson (1977),
using 8% polyacrylamide (BioRad Mini-Protean II system). Kaleidoscope prestained
molecular weight markers (BioRad) were used as standards. Gels were stained using
gelcode blue stain reagent (Pierce), or proteins were transferred (BioRad Mini-Trans blot
system) to PVDF membranes (BioRad) for immunoblotting. The transfer protocol was
carried out according to instructions provided by the manufacturer, with the exception
that methanol was omitted from the transfer buffer. Mahaney et al. (2000) reported that
methanol in the transfer medium decreased SERCA2a and PLB protein transfer. The
PVDF membranes were probed with anti-SERCA2a monoclonal antibody 2A7-A1 for
detection of SERCA2a or with anti-phospholamban monoclonal antibody 2D12 for
detection of phospholamban (Movsesian et al., 1994). Antibody binding was visualized
by using [125I] – protein A and quantitated using Molecular Dynamics Phosphoimager SI.
For quantitative immunoblotting, purified canine SERCA2a and phospholamban were
used as standards to quantify the amount of SERCA2a and phospholamban in the HighFive insect cell microsomes (Jones et al., 2002). No GelCode Blue-stained protein bands
in the vicinity of SERCA2a or phospholamban were retained on the polyacrylamide gel
after transfer to the PVDF membranes.

SERCA2a ATPase Assay
The [Ca2+]-dependent ATPase activity of SERCA2a in High Five insect cell
microsomes was measured at 37 oC colorimetrically using a malachite green-ammonium
molybdate assay (Lanzetta et al., 1979; Mahaney et al., 2000). SERCA2a incubation
tubes contained 0.05 mg/ml microsomal protein in 50 mM MOPS (pH 7.0), 3 mM
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MgCl2, 100 mM KCl, 1 mM EGTA and 0 to 1.0 mM CaCl2, to give the desired ionized
[Ca2+], as previously determined (Autry and Jones, 1997).

To initiate the ATPase

reaction, 5 mM MgATP was added to the incubation tube. After ten minutes of reaction
at 37 oC, a 50 µl aliquot of the incubation mixture was transferred into an assay tube
containing 1.6 ml of malachite green-ammonium molybdate reagent at room temperature.
After 30 sec, the colorimetric reaction was quenched by the addition of 200 µl of 34%
sodium citrate (Sigma) into the assay tube.

For the determination of phosphate, a

standard curve was constructed using aliquots of a 0.65 mM phosphate standard solution
(Sigma), assayed in a similar fashion. Following 30 min of color development, the
absorbance of the malachite green reagent was measured at 660 nm. SERCA2a samples
were pre-treated with 20 µg of the Ca2+ ionophore A23187 (CalBiochem) per mg of total
protein prior to addition to the incubation tubes. Prior to preparation of the incubation
tubes, the SERCA2a samples were incubated for 20 minutes on ice without or with antiphospholamban monoclonal antibody 2D12, at an antibody to total protein weight ratio of
1:1 (Autry and Jones, 1997).

The arbitrary selection of a 10-minute incubation period

was validated by specific time-based ATPase activity assays preformed for all samples at
a saturating Ca2+ level (15 µM), which showed that Pi liberation was linear for ≥ 15
minutes.
Ca2+ Uptake Assay
The [Ca2+]-dependent Ca2+ uptake activity of SERCA2a in High-Five cell
microsomes was measured at 37 oC radiometrically using the Millipore filtration
technique (Autry and Jones, 1997). SERCA2a incubation tubes contained 0.1 mg/ml
microsomal protein in 50 mM MOPS (pH 7.0), 3mM MgCl2, 100 mM KCl, 10 mM
sodium oxalate, with 1 mM EGTA and 0-1.0 mM CaCl2 (containing trace amounts of
radioactive 45CaCl2), to give the desired ionized [Ca2+], as previously determined (Briggs
et al., 1992). Ca2+ uptake was started with the addition of 5 mM MgATP, and was
terminated by vacuum filtering 7.5 µg of membrane protein through Millipore HWAP
filters. The filters were quickly washed twice with 5 ml of 150 mM NaCl.
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45

Ca2+

accumulated inside the microsomes was assayed by liquid scintillation counting. Prior to
preparation of the incubation tubes, the SERCA2a samples were incubated for 20 minutes
on ice without or with anti-phospholamban monoclonal antibody 2D12, at an antibody to
total protein weight ratio of 1:1 (Autry and Jones, 1997). The arbitrary selection of a 5
minute incubation period was validated by specific time-based

45

Ca2+ uptake activity

assays preformed for all samples at a saturating Ca2+ level (15 µM), which showed that
45

Ca2+ uptake by the microsomes was linear for ≥ 15 minutes.

45

Ca2+ Efflux Assay
45

Ca2+ efflux from High-Five cells was measured as described previously (Autry

and Jones, 1997) using the Millipore filtration technique. Briefly, Ca2+ loading was
performed at 37 oC with incubation tubes that contained 0.1 mg/ml protein in 50 mM
MOPS (pH 7.0), 100 mM KCl, 3 mM MgCl2, 10 mM sodium oxalate, 1 mM EGTA, 0.9
mM CaCl2, and an additional 50 µM added 45CaCl2. Ca2+ accumulation was started with
the addition of 5 mM MgATP to the incubation mix and allowed to proceed for 15 min.
Following this incubation, 20 mM EGTA was added to the incubation mixture to make
the extravesicular Ca2+ as close to zero as possible.

45

Ca2+ efflux from the loaded

microsomes was monitored at serial times by vacuum filtering 7.5 µg of membrane
protein through Millipore HWAP filters, which were washed once with 5 ml of 150 mM
NaCl. Prior to preparation of the efflux tubes, the SERCA2a samples were incubated for
20 minutes on ice without or with anti-phospholamban monoclonal antibody 2D12, at an
antibody to total protein weight ratio of 1:1 (Autry and Jones, 1997). As a control,
calcium efflux was also initiated at time zero by adding 20 µg/ml of the Ca2+ ionophore
A23187, which resulted in the rapid loss of Ca2+ from the microsomes. Additional efflux
assays were conducted utilizing microsomes pre-incubated with 2 µM thapsigargin (a 5
min incubation) after the 15 min microsome Ca2+ loading step but before the addition of
the EGTA to initiate efflux. Independent measurements of SERCA2a ATPase activity
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showed that under these assay conditions, a five-minute incubation with 2 µM
thapsigargin was sufficient to completely inhibit the enzyme.
Labeling of Ca2+-ATPase with IAEDANS
The Ca2+-ATPase expressed in insect cell microsomes was labeled by 5-(2((iodoacetyl)amino)ethyl) aminonaphthalene-1-sulfonic acid (IAEDANS) according to
Suzuki et al. (1987) with substantial modifications. The microsomes (5 mg/ml) were
labeled with 85 µM IAEDANS in the presence of labeling buffer (20 mM MOPS, 80 mM
KCl, 1 mM CaCl2, 5 mM MgCl2), and 5 mM ATP at pH 6.88 for 30 min at room
temperature. Excess reagent was removed by centrifugation for 30 min at 30,000 rpm
(70,000 X g), 4 oC, in a Beckman Ti45 rotor. The pellet, containing the IAEDANSlabeled Ca2+-ATPase, was resuspended in 0.3 M sucrose, 20 mM MOPS, 0.1 mM CaCl2
(pH 7.0). The amount of IAEDANS bound to Ca2+-ATPase was determined by using an
extinction coefficient of 6.1 X 103 M-1·cm-1 at 340 nm.

Fluorescence Measurements
Measurements of the fluorescence intensity were performed at 25 oC on a
spectrofluorimeter (Photon Technology International, QM-2000-4) which was equipped
with a cuvette stirrer. Excitation wavelength was determined to be 352 nm and emission
wavelength to be 475 nm. The fluorescence intensity changes were measured in a
standard buffer (50 mM MOPS, 100 mM KCl, 3mM MgCl2, 1 mM EGTA, pH 7.0)
containing either 0 mM CaCl2 (0 µM Ca2+(Free)) representing the E2 state or 1.0 mM
CaCl2 (15 µM Ca2+(Free)) representing the E1 state. The addition of 1.25 mM Ca2+ (final
ionized [Ca2+] ~ 15 µM) to the standard buffer with 0 mM CaCl2 promoted formation of
the E1·Ca2 conformation, whereas the addition of 1.25 mM EGTA (final ionized [Ca2+] ~
0 µM) to the standard buffer with 1.0 mM CaCl2 promoted formation of the E2
conformation.

The fluorescence intensity was measured by summing the total
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fluorescence emission over 20 s before and after the respective additions and then
determining the percent change.
To measure the [Ca2+]-dependent fluorescent enhancement, insect cell
microsomes containing IAEDANS-labeled Ca2+-ATPase were incubated initially in the
standard buffer containing 0 mM CaCl2 (0 µM Ca2+(Free)) representing the E2 state.
CaCl2 was added in 0.1 mM increments up to 1 mM final Ca2+ (~15 µM ionized Ca2+) in
stepwise addition. Total volume of added CaCl2 was 20 µl. Total fluorescence emission
over 20 s after each addition of CaCl2 was summed and then the percent change from the
initial fluorescence level was determined.

Phosphoenzyme Formation from Pi
Inorganic phosphate-dependent phosphoenzyme formation was carried out at 25
o

C using insect cell microsomes (1.0 mg/ml) suspended in a solution containing 10 mM

MgCl2, 1 mM EGTA (~ 0 free Ca2+), and 50 mM MES (pH 6.0).

To initiate

32

phosphorylation, an equal volume of an identical solution containing [ P]Na2HPO4 (but
no protein) was added to the microsomes and vortexed. The reaction was quenched after
15 min by the addition of 3% perchloric acid + 2 mM H3PO4 (final concentrations).
Bovine serum albumin (0.25 mg) was added to each sample as a carrier protein. The
quenched vesicles were pelleted in a tabletop centrifuge and then washed three times with
a solution of 5% trichloroacetic acid, 4 mM H3PO4 (non-radio labeled) and 6%
polyphosphate. The final pellets were dissolved in 5 ml of 1 N NaOH, and the [32P]
phosphoenzyme was assayed by scintillation counting.

For the [Pi]-dependence EP

studies, the concentration of [32P]Na2HPO4 was varied between 0 and 8 mM, and the
amount of radio-labeled Pi was adjusted to maintain the ratio of labeled to unlabeled Pi in
the reaction mixture (about 5500 CPM per 1 mM Pi). For the [Ca2+]-dependent EP
inhibition experiments, microsomes (1.0 mg/ml) were suspended in a solution at 25 oC
containing 10 mM MgCl2, 1 mM EGTA (~ 0 free Ca2+), and 50 mM MES (pH 6.0). To
initiate phosphorylation, an equal volume of a solution containing 4 mM [32P]Na2HPO4,
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10 mM MgCl2, 1 mM EGTA, 50 mM MES (pH 6.0) and various levels of CaCl2 were
added to the microsomes and vortexed. The final [CaCl2] varied between 0 – 1.2 mM,
which provided ionized [Ca2+] levels of 0 – 200 µM in the reaction mixture. The reaction
and analyses were followed as described above.

Curve Fitting
[Ca2+]-dependent

SERCA2a

Ca2+

ATPase,

uptake

activity

data,

and

phosphoenzyme kinetics data were fit using the program KFIT written by N. C. Millar.
[Ca2+]-dependent ATPase activity data were fit by the log form of the Hill equation:

v=

Vmax
1 + 10 n ( Km −[Ca ])

where v is the enzyme velocity at any given [Ca2+], Vmax is the maximum velocity at
saturating [Ca2+], n is the Hill coefficient, Km is the log [Ca2+] required for half-maximal
velocity, and [Ca2+] is the log ionized Ca2+ level for each particular assay.
Phosphoenzyme kinetics data were fit by the Hill equation seen above and the
hyperbolic equation:
v=

Vmax [ S ]
[ S ] + Km

where v is the level of phosphoenzyme formation at any given [Pi], Vmax is the maximum
phosphoenzyme formation at saturating [Pi], [S] is the [Pi] for each particular assay, and
Km is the [Pi] required for half-maximal velocity.
Ca2+ efflux data were fit by a one exponential function:

(

)

v = Vmax ∗ 1 − 10 ( − R∗T ) + (S ∗ T )

where v is the amount of Ca2+ still present in the microsomes at a given time, Vmax is the
maximum amount of Ca2+ at T = 0, R is the determined rate, S is the determined slope,
and T is the time for each particular assay. The best fits of the data were chosen on
minimization of the sum-of-squares error, χ2.
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Abstract
The Ca2+-ATPase accounts for the majority of Ca2+ removed from the cytoplasm
during cardiac muscle relaxation. The Ca2+-ATPase is regulated by phospholamban, a 52
amino acid phosphoprotein, which inhibits Ca2+-ATPase activity by decreasing the
apparent affinity of the ATPase for Ca2+. In order to study the physical mechanism of
Ca2+-ATPase regulation by phospholamban using spectroscopic and kinetic experiments,
large amounts of both proteins are required. Therefore, we developed a Ca2+-ATPase and
phospholamban preparation based on the baculovirus-insect cell expression system using
High-Five insect cells to produce large amounts of microsomal vesicles that contain
either Ca2+-ATPase expressed alone or Ca2+-ATPase co-expressed with phospholamban.
The expressed proteins were characterized using immunofluorescence spectroscopy,
Ca2+-ATPase activity assays, Ca2+ uptake and efflux assays, and western blotting. Our
purification method yields 140 mg of microsomal protein per liter of infection (1.7x109
cells), and the Ca2+-ATPase and phospholamban account for 16% and 1.4%, respectively,
of the total microsomal protein by weight, yielding a phospholamban:Ca2+-ATPase ratio
of 1.6 : 1, similar to that observed in native cardiac SR vesicles. The enzymatic
properties of the expressed Ca2+-ATPase are also similar to those observed in native
cardiac SR vesicles, and when co-expressed with phospholamban, the Ca2+-ATPase is
functionally coupled to phospholamban similar to that observed in cardiac SR vesicles.
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Introduction
The Ca2+-ATPase of cardiac sarcoplasmic reticulum (CSR) is a 110 kDa integral
membrane protein that utilizes ATP to drive the transport of Ca2+ ions into the SR to
promote muscle relaxation [1]. In cardiac SR, the sarco(endo)plasmic reticulum Ca2+ATPase isoform (SERCA2a) is regulated by phospholamban, a 52-amino acid
phosphoprotein, which inhibits Ca2+-ATPase activity by decreasing the apparent affinity
of the ATPase for Ca2+ [2]. Ca2+-ATPase inhibition is relieved by phosphorylation of
phospholamban at Ser-16 or Thr-17, resulting in a marked increase in Ca2+-ATPase
activity, an increase in the rate of relaxation of cardiac muscle, and a positive inotropic
effect [3].
Much attention has been devoted to understanding the physical and functional
interaction between Ca2+-ATPase and phospholamban, because abnormal Ca2+-ATPase
regulation by phospholamban has been implicated as a causative factor for diastolic
dysfunction, cardiac hypertrophy and heart failure [4]. Most recently, Seidman and
coworkers [5] have shown that a naturally occurring phospholamban missense mutation
(Arg → Cys) results in heart disease in humans. Likewise, Kranias and coworkers [6]
found that humans lacking phospholamban developed lethal dilated cardiomyopathy,
which is in contrast to mice, where disruption of the phospholamban gene or expression
of a dominant negative phospholamban mutant led to enhanced cardiac function.
Elucidating the molecular details of the phospholamban Ca2+-ATPase interaction is
therefore an important step in understanding key cardiac pathologies and developing
pharmaceutical strategies in the fight against heart disease [7].
Several groups have developed expression systems to produce wild type and
mutant forms of Ca2+-ATPase and phospholamban for in vitro physical and functional
studies. Most notably, the baculovirus-Sf21 insect cell method developed by Autry and
Jones [8] has been the most beneficial in producing Ca2+-ATPase and phospholamban in
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sufficient quantities for detailed physical, functional and kinetics studies [8-18].
However, certain spectroscopic experiments, such as electron paramagnetic resonance
[19], and kinetics experiments, such as rapid-mixing kinetics [20], require even larger
amounts of protein, especially if these studies are conducted in parallel to correlate
directly spectroscopic and kinetics data using the same preparation [21]. While one could
easily scale-up the Sf21 cell prep to accommodate the high protein demands of these
experiments, the use of large amounts of serum-containing medium in conjunction with
this scaled-up process imposes a high cost burden to this approach. Therefore, it would
be advantageous to modify the baculovirus-insect cell expression system to utilize cells in
a serum-free medium that can produce large amounts of microsomal Ca2+-ATPase and
phospholamban with physical and functional properties similar to those of the proteins in
native cardiac SR vesicles.
Here we describe a baculovirus expression system using High-Five insect cells to
produce large amounts of microsomal vesicles that contain either SERCA2a expressed
alone or SERCA2a co-expressed with phospholamban.

Detailed analyses of the

preparations indicated that the expressed proteins have physical and functional
characteristics similar to those observed for the Ca2+-ATPase and phospholamban in
native cardiac SR vesicles. The results validate the preparation for use in biochemical
and biophysical experiments.
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Materials and Methods

Materials
125

I-labeled protein A was purchased from Perkin Elmer Life Sciences.

45

CaCl2

and [γ-32P]ATP were purchased from ICN. Prestained molecular weight standards and
polyvinylidene difluoride (PVDF) membranes were purchased from Bio-Rad. High-Five
insect cells and medium were purchased from Invitrogen, and the BaculoGold system
was obtained from Pharmingen-BD Biosciences.

Protein Expression and Isolation
Recombinant baculoviruses containing cDNA inserts for canine cardiac Ca2+ATPase or canine phospholamban were prepared using the BaculoGold system and
titered by plaque assay, both as described previously [8]. Wild type canine SERCA2a
and canine phospholamban were expressed in High-Five cells grown in suspension (1.67
X 106 cells/ml) at 27 oC in Sf-900 II SFM medium (Invitrogen) supplemented with 10
units/ml Heparin (Sigma). For expression of the Ca2+-ATPase alone, a multiplicity of
infection of 10 (plaque-forming virus units per cell) was used. For co-expression of the
Ca2+-ATPase and phospholamban, a multiplicity of infection of 15 was used for
SERCA2a and 5 for phospholamban.

Virus-infected High-Five cells in 600 ml of

suspension (1 X 109 cells) were sedimented and then washed twice with 150 ml of an icecold solution of phosphate-buffered saline (PBS) containing 137 mM NaCl, 2.7 mM KCl,
4.3 mM Na2HPO4, 1.4 mM KH2PO4 (pH 7.4), by centrifugation for 10 min at 1500 rpm
at 4 oC in an IEC GP8R refrigerated centrifuge. The washed cells were resuspended in
60 ml of ice-cold 10 mM NaHCO3 and 0.2 mM CaCl2. Then 60 ml of ice-cold 500 mM
sucrose, 300 mM KCl, 6 mM MgCl2, and 60 mM histidine were added. Both solutions
contained 10 µg/ml aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin A, and 0.1 mM
pefabloc. The cells were placed on ice and transferred to a cold room. The cells were
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homogenized for 90 s with a Brinkman Polytron on maximum speed. The homogenized
cells were left on ice for about 10 minutes to allow the foam to settle, and then the
homogenate was centrifuged for 20 min at 3000 rpm (1,075 X g), 4 oC, in a Sorvall SS34
rotor. The supernatant was collected and 30 ml of ice-cold 3 M KCl containing 10 µg/ml
aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin A, and 0.1 mM pefabloc was added. The
mixture was centrifuged for 20 min at 9000 rpm (9,680 X g), 4 oC, in a Sorvall SS34
rotor. The supernatant was collected and the High-Five insect cell microsomes were
pelleted by centrifugation for 38 min at 26,000 rpm (52,858 X g), 4 oC, in a Beckman
Ti45 rotor. The pellets were resuspended in 5 ml of 250 mM sucrose, 10 mM histidine
(pH 7.2) and stored in small aliquots at –50 oC. Protein concentrations were determined
by the method of Lowry et al.[22], using bovine serum albumin (Sigma) as a standard.
The average yield per 600 ml of infection was 80 mg of microsomal protein.

Immunofluorescence
Wild type canine SERCA2a and canine phospholamban were expressed in High
Five cells grown in tissue culture chambered slides (Falcon) at 27 oC in Sf-900 II SFM
medium supplemented with 10 units/ml Heparin. Cells to be infected with baculoviruses
were plated at 4 X 105 cells/well and the control-uninfected cells were plated at 2 X 105
cells/well. The difference in plating was to allow for differences in cell growth and
doubling between the control and infected cells during the infection period. For coexpression of the Ca2+-ATPase and phospholamban, a multiplicity of infection of 15 was
used for SERCA2a and 5 for phospholamban. Following 48 hours of infection, the cells
were washed for 15 min with 1% PBS, after which the cells were fixed in 2%
formaldehyde/PBS (pH 7.4) for 15 min at 20 oC. After formaldehyde fixation, the cells
were washed twice with 1% PBS for 3 min each and permeabilized with 0.2% Triton X100/PBS for 5 min. The cells were then washed three times with 1% PBS for 5 min each.
The cells were then dehydrated in 70%, 90%, and 100% ethanol for 5 min each. Before
primary antibodies were used, the cells were blocked for 45 min at room temperature in a
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humidified chamber in 1x blocking buffer (Roche). After the blocking step, the cells
were incubated with monoclonal antibodies (Affinity Bioreagents) specific to SERCA2a
(IID8, 20 µg/ml mouse IgG1 in 1x blocking buffer/PBS) or phospholamban (2D12, 20
µg/ml mouse IgG2a in 1x blocking buffer/PBS) for 1 h at room temperature in a
humidified chamber. The cells were then washed three times with 1% PBS for 10 min
each. After the washes, the cells were incubated for 1 h at room temperature in a
humidified chamber in the presence of indodicarbocyanine (CY5)-conjugated goat antimouse IgG1 (Southern Biotech: 4 µg/ml in 1x blocking buffer/PBS) for detecting
SERCA2a and rhodamine-conjugated goat anti-mouse IgG2a (Southern Biotech; 4 µg/ml
in 1x blocking buffer/PBS) for detecting phospholamban.

The cells were then washed

three times with 1% PBS for 10 min each. For background staining, the cells were
incubated in 1% PBS containing a 1:4,000 dilution of the short chain carbocyanine
DiOC6 (Molecular Probes) for 10 min at room temperature to visualize the endoplasmic
reticulum. Afterwards, the cells were washed twice with 1% PBS for 10 min. In some
cases, the cells were incubated in 1% PBS containing a 1:10,000 dilution of 4’,6’diamidino-2-phenylindole (DAPI; Sigma) for 4 min as a DNA counter-stain (Fig. A-1).
The cells were then washed twice with 1% PBS for 10 min. Following the washes, the
cells were mounted on a microscope slide using fluoromount-G (Fisher).

Control

uninfected cells were treated identically to the infected cells, except for the omission of
viruses.
The immunofluorescence staining of the microsomal preparations were visualized
by excitation at 488 nm for DiOC6, 633 nm for CY5 and 543 nm for Rhodamine, with
emission spectra detected between 505-550 nm, 650 nm, and 560-615 nm, respectively,
using a Zeiss Laser Scanning Microscope 510. Differential interference contrast images
(DIC) were also collected. Each image is representative of the entire population of cells
on the slide.
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Electrophoresis and Immunoblotting
The amount of expressed SERCA2a and phospholamban was quantified by gel
electrophoresis and immunoblotting using methods described previously [15]. Briefly,
the proteins were separated by SDS-PAGE and then transferred to PVDF membranes for
immunoblotting. The membranes were probed with anti-SERCA2a monoclonal antibody
2A7-A1 for detection of SERCA2a and anti-phospholamban monoclonal antibody 2D12
for detection of phospholamban [23]. Antibody binding was visualized using [125I]protein A, and labeling intensities from both membranes were quantified using a
Molecular Dynamics Phosphorimager SI.

For quantitative immunoblotting, purified

canine SERCA2a and phospholamban were used as standards to quantify the amount of
SERCA2a and phospholamban in the High-Five insect cell microsomes. The purification
procedures and quantitation methods for the purified SERCA2a and phospholamban are
provided elsewhere [11 and references therein].

SERCA2a ATPase Assay
The [Ca2+]-dependent ATPase activity of SERCA2a in High Five insect cell
microsomes was measured at 37 oC colorimetrically using a malachite green-ammonium
molybdate assay [15, 24]. SERCA2a incubation tubes contained 0.05 mg/ml microsomal
protein in 50 mM MOPS (pH 7.0), 3 mM MgCl2, 100 mM KCl, 1 mM EGTA and 0 to
1.0 mM CaCl2, to give the desired ionized [Ca2+], as previously determined [8]. To
initiate the ATPase reaction, 5 mM MgATP was added to the incubation tube. After ten
minutes of reaction at 37 oC, a 50 µl aliquot of the incubation mixture was transferred
into an assay tube containing 1.6 ml of malachite green-ammonium molybdate reagent at
room temperature. After 30 sec, the colorimetric reaction was quenched by the addition
of 200 µl of 34% sodium citrate (Sigma) into the assay tube. For the determination of
phosphate, a standard curve was constructed using aliquots of a 0.65 mM phosphate
standard solution (Sigma), assayed in a similar fashion. Following 30 min of color
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development, the absorbance of the malachite green reagent was measured at 660 nm.
SERCA2a samples were pre-treated with 20 µg of the Ca2+ ionophore A23187
(CalBiochem) per mg of total protein prior to addition to the incubation tubes. Prior to
preparation of the incubation tubes, the SERCA2a samples were incubated for 20 minutes
on ice without or with anti-phospholamban monoclonal antibody 2D12, at an antibody to
total protein weight ratio of 1:1 [8].

The arbitrary selection of a 10-minute incubation

period was validated by specific time-based ATPase activity assays preformed for all
samples at a saturating Ca2+ level (15 µM), which showed that Pi liberation was linear for
≥ 15 minutes (data not shown).
Ca2+ Uptake Assay
The [Ca2+]-dependent Ca2+ uptake activity of SERCA2a in High-Five cell
microsomes was measured at 37 oC radiometrically using the Millipore filtration
technique [8]. SERCA2a incubation tubes contained 0.1 mg/ml microsomal protein in 50
mM MOPS (pH 7.0), 3mM MgCl2, 100 mM KCl, 10 mM sodium oxalate, with 1 mM
EGTA and 0-1.0 mM CaCl2 (containing tracer amounts of radioactive
2+

2+

the desired ionized [Ca ], as previously determined [25]. Ca

45

CaCl2), to give

uptake was started with

the addition of 5 mM MgATP, and was terminated by vacuum filtering 7.5 µg of
membrane protein through Millipore HWAP filters. The filters were quickly washed
twice with 5 ml of 150 mM NaCl.

45

Ca2+ accumulated inside the microsomes was

assayed by liquid scintillation counting. Prior to preparation of the incubation tubes, the
SERCA2a samples were incubated for 20 minutes on ice without or with antiphospholamban monoclonal antibody 2D12, at an antibody to total protein weight ratio of
1:1 [8]. The arbitrary selection of a 5 minute incubation period was validated by specific
time-based

45

Ca2+ uptake activity assays preformed for all samples at a saturating Ca2+

level (15 µM), which showed that 45Ca2+ uptake by the microsomes was linear for ≥ 15
minutes (data not shown).
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45

Ca2+ Efflux Assay
45

Ca2+ efflux from High-Five cells was measured as described previously [8]

using the Millipore filtration technique. Briefly, Ca2+ loading was performed at 37 oC
with incubation tubes that contained 0.1 mg/ml protein in 50 mM MOPS (pH 7.0), 100
mM KCl, 3 mM MgCl2, 10 mM sodium oxalate, 1 mM EGTA, 0.9 mM CaCl2, and an
additional 50 µM added

45

CaCl2. Ca2+ accumulation was started with the addition of 5

mM MgATP to the incubation mix and allowed to proceed for 15 min. Following this
incubation, 20 mM EGTA was added to the incubation mixture to clamp the
extravesicular Ca2+ to near zero.

45

Ca2+ efflux from the loaded microsomes was

monitored at serial times by vacuum filtering 7.5 µg of membrane protein through
Millipore HWAP filters, which were washed once with 5 ml of 150 mM NaCl. Prior to
preparation of the efflux tubes, the SERCA2a samples were incubated for 20 minutes on
ice without or with anti-phospholamban monoclonal antibody 2D12, at an antibody to
total protein weight ratio of 1:1 [8]. As a control, calcium efflux was also initiated at
time zero by adding 20 µg/ml of the Ca2+ ionophore A23187, which resulted in the rapid
loss of Ca2+ from the microsomes. Additional efflux assays were conducted utilizing
microsomes pre-incubated with 2 µM thapsigargin (a 5 min incubation) after the 15 min
microsome Ca2+ loading step but before the addition of the EGTA to initiate efflux.
Independent measurements of SERCA2a ATPase activity showed that under these assay
conditions, a five-minute incubation with 2 µM thapsigargin was sufficient to completely
inhibit the enzyme (data not shown).

Curve Fitting
Calcium-dependent SERCA2a ATPase and Ca2+ uptake activity data were fit using the
program KFIT written by N. C. Millar, which was obtained from Dr. Carl Frieden’s
website: www.wuarchive.wustl.edu/packages/kinsim/uploads. The best fits of the data
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were chosen on the basis of optimization of the determination coefficient, R2, and/or
minimization of the sum-of-squares error, χ2.
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Results and Discussion
Expression and Immunofluorescent Detection of the Ca2+-ATPase and Phospholamban in
High-Five Cells
For these studies, canine SERCA2a was expressed in High-Five insect cells alone
or co-expressed with canine phospholamban using separate recombinant baculovirus
constructs containing the individual cDNAs encoding these proteins [8]. As a first step,
we used immunofluorescence microscopy to determine whether the High-Five cells could
successfully co-express and co-localize SERCA2a and phospholamban. High-Five cells
grown on a microscope slide were co-infected with the baculoviruses, and 48 hours later
the cells were prepared for immunofluorescence as described in Methods. Separate
fluorescent probes were used to individually detect the presence of the SERCA2a and
phospholamban in the cells. Indodicarbocyanine (CY5)-conjugated goat anti-mouse IgG1
was used to detect the SERCA2a pre-incubated with an anti-SERCA2a mouse IgG1
monoclonal antibody, IID8. Likewise, rhodamine-conjugated goat anti-mouse IgG2a was
used to detect phospholamban pre-incubated with an anti-phospholamban mouse IgG2a
monoclonal antibody, 2D12. For the purposes of this study, the CY5-labeled SERCA2a
was pseudocolored green and the rhodamine-labeled phospholamban was pseudocolored
red.

We used the short chain carbocyanine DiOC6 to visualize the endoplasmic

reticulum, which was pseudocolored blue for contrast.
Using a wide-field view of all the cells on the microscope slide, and comparing
multiple slides, we observed that about 75-85% of the High-Five cells contained both
SERCA2a and phospholamban, whereas the remaining cells contained only
phospholamban. The cells had the typical appearance of baculovirus-infected cells: they
were swollen, circular in shape, had an enlarged nucleus that occupied most of the cell
and the space between the nucleus and the plasma membrane was filled with endoplasmic
reticulum.

There was no evidence of endogenous SERCA2a or phospholamban in

76

control cells that were not infected with either baculovirus (Fig. A-2). For economy, the
images of multiple cells are not shown. Rather, Figure 3-1 shows a representative cell
that contained both SERCA2a and phospholamban co-localized to the endoplasmic
reticulum within the cell. Because of the swollen features of the cells and the low
resolution of the image, it was not possible to resolve any fine structure in the cell or to
unambiguously localize the two proteins to individual membranes of the endoplasmic
reticulum. Nevertheless, it was quantitatively clear from the functional data presented in
Figures 3-3 and 3-4 (presented below) that the two proteins were co-localized to the same
membrane.

Isolation of High-Five Insect Cell Microsomes containing SERCA2a and Phospholamban
Our next goal was to quantitate the expression levels of the Ca2+-ATPase and
phospholamban in the High-Five cells and also determine the functional characteristics of
the expressed proteins. To do this, we first isolated insect cell microsomes from the
infected High-Five cells. High-Five cells grown in suspension (109 cells in 600 ml
medium) were co-infected with separate SERCA2a- and phospholamban-containing
baculoviruses. Forty-eight hours post-infection, the infected cells were harvested and
homogenized using a polytron homogenizer. Differential centrifugation was used to
remove cell debris and dense components such as mitochondria and nuclei. Cellular
microsomes were harvested by ultra-centrifugation and resuspended in a sucrose/histidine
buffer. The details of the preparation are provided in the Methods. Microsomes were
also isolated from High-Five insect cells that were not infected with baculoviruses, and
these served as control microsomes.
SERCA2a and phospholamban protein levels and SERCA2a ATPase activities
were characterized at each step of the purification process (Table 3-1), as described
below. Each preparation fraction (i.e., pellet and supernatant) contained SERCA2a and
phospholamban protein and Ca2+-ATPase activity, except the supernatant of the
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Figure 3-1.

Immunofluorescent detection of Ca2+-ATPase and phospholamban

expression. SERCA2a and phospholamban were expressed in High-Five cells grown in
tissue culture chambered slides. All pictures are of the same cell. (A) The short chain
carbocyanine DiOC6, which stains primarily ER membranes, was pseudocolored blue and
used as a background stain. (B) SERCA2a was detected with an anti-SERC2a mouse
IgG1 antibody and visualized with a goat anti-mouse IgG1 secondary antibody
conjugated to CY5, which was pseudocolored green. (C) Phospholamban was detected
with an anti-phospholamban mouse IgG2a antibody and visualized with a goat antimouse IgG2a secondary antibody conjugated to rhodamine, which was pseudocolored
red. (D) A differential interference contrast image (DIC) of the cell. (E) Panels (B), (C),
and (D) were overlaid and SERCA2a and phospholamban co-localization was
pseudocolored yellow.
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Table 3-1
Isolation of SERCA2a and phospholamban co-expressed in High-Five insect cellsa
Preparation
Fractionb
Homogenate
1,075g Spin (S)
9,680g Spin (S)
52,885g Spin (P)
a

Volume
(mL)
250
237
285
9.7

Protein
(mg)
3208
2031
1593
128

Activityc
(U)
438
345
297
63

Specific Activityd
(U mg-1)
0.14
0.17
0.19
0.49

Yield
(%)
100
79
68
14

Fold
Purification
1
1.24
1.37
3.61

Representative data obtained from a single SERCA2a + phospholamban

preparation. The starting material was 1.2 L of cell culture. The average expression and
activity data for all SERCA2a and SERCA2a + phospholamban preparations are
presented in Table 3-2.
b

Preparation fractions denoted as supernatant (S) or resuspended pellet (P)

c

ATPase activity assays of each sample were done at 37 oC as described in Fig. 3-

3. Activity units (U) defined as µmol Pi produced•min-1.
d

Specific activity is defined as U per mg total microsomal protein.
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ultracentrifuge spin where the final microsomes were pelleted. For example, in one
representative preparation (out of 11 total) the cellular homogenate contained ~ 3,200 mg
of total cellular protein, in which SERCA2a and phospholamban accounted for
approximately 7% and 0.5% of the total protein, respectively. A large amount of protein
(1,177 mg total protein) was discarded with the pellet following the initial (1,075 x g)
centrifugation of the cellular homogenate, which contained 9.5% SERCA2a and 0.7 %
phospholamban by weight. In addition, approximately 20% of the total (non-specific)
ATPase activity was discarded with this pellet, but the specific ATPase activity of the
remaining protein (in the supernatant) increased by about 20%.

SERCA2a and

phospholamban were also lost with the protein discarded during the intermediate (9,680 x
g) centrifugation step. The composition of SERCA2a and phospholamban and the total
ATPase activity of the discarded intermediate pellet were similar to those of the first
centrifugation, such that the specific ATPase activity only improved modestly (about
12%) during this step. The largest amount of protein (1,465 mg total protein) was
discarded with the supernatant after the final (52,885 x g) centrifugation to pellet the
microsomes. However, SERCA2a and phospholamban accounted for only 0.2% and
0.02% percent, respectively, by weight of the total protein in the supernatant, and only ~
5% of the total ATPase activity remained in the supernatant. In contrast, the final
microsomal pellet (~130 mg total protein) contained 14.5% and 0.7% SERCA2a and
phospholamban, respectively, by weight total protein. The increased SERCA2a in this
pellet resulted in 2.5-fold increase in the specific ATPase activity over the sample of the
previous centrifugation, and a 3.6-fold increase over that of the initial cellular
homogenate.

Similar SERCA2a expression and activity results were obtained for

microsome preparations from cells infected with a SERCA2a-baculovirus only, except
that no phospholamban was detected in any of the preparation fractions (Table A-1).
Despite the finding that significant amounts of SERCA2a and phospholamban
were lost during each centrifugation step, we elected to focus our analysis on the final
microsomes since they contained the highest specific ATPase activity and had
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membrane-associated SERCA2a and phospholamban protein at a ratio consistent with
that observed for native cardiac SR vesicles (see below). It should be pointed out,
however, that if one utilizes detergent-purified and reconstituted Ca2+-ATPase for
experiments, it would be expedient to simply use the crude cellular homogenate to
maximize the yield of SERCA2a for purification because crude homogenates are
sufficient for most measurements and scale-up applications [26].

Determination of the Expression Levels of SERCA2a and Phospholamban in the HighFive Cell Microsomes
SDS-PAGE (Fig. 3-2, A) and immunoblotting (Fig. 3-2, B) of the High-Five
microsomes indicated that High-Five cells produced similar amounts of recombinant
Ca2+-ATPase when expressed alone (Fig. 3-2, A and B, Lane 2) or when co-expressed
with phospholamban (Fig. 3-2, A and B, Lane 3).

As expected, there was no

phospholamban present in the SERCA2a only samples. The amount of SERCA2a and
phospholamban in the High-Five microsome samples was determined by quantitative
immunoblotting (Fig. 3-2, B-D), using purified SERCA2a and phospholamban samples
as standards. As shown in Fig. 3-2 (C and D), the purified proteins (empty symbols)
provided linear standard curves, which showed microsomes with SERCA2a expressed
alone contained 15.8 ± 1.6% SERCA2a and no phospholamban (n = 9 preparations) and
microsomes containing co-expressed SERCA2a and phospholamban had 15.7 ± 0.4%
SERCA2a and 1.4 ± 0.2% phospholamban (n = 11 preparations) (Table 3-2). These
results were in comparison to native cardiac SR vesicles that contained 35.9 ± 1.8%
SERCA2a and 2.0 ± 0.0% phospholamban (n = 1 preparation) (Table 3-2). Based on
these expression levels, we determined the molar stoichiometry of phospholamban to
SERCA2a in the isolated SERCA2a + phospholamban microsomes and the cardiac SR
vesicles, which were 1.6 ± 0.2:1 and 1.0 ± 0.1:1 phospholamban:SERCA2a, respectively.
The results indicated that the expressed SERCA2a + phospholamban in the insect cell
microsomes had a molar stoichiometry comparable to that observed for native cardiac SR
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Figure 3-2. SDS-PAGE and immunoblotting of SERCA2a and phospholamban
expressed in High-Five microsomes. (A) GelCode Blue–stained SDS gel showing
cardiac sarcoplasmic reticulum (cardiac SR) vesicles (lane 1), High-Five microsomes
containing SERCA2a alone (lane 2), and High-Five microsomes containing SERCA2a +
phospholamban (lane 3).

Each lane contained 25 µg microsomal protein.

(B)

Quantitative immunoblot of the expressed samples developed with SERCA2a antibody
2A7-A1 (top) or phospholamban antibody 2D12 (bottom). PLBP denotes pentameric
phospholamban and PLBM denotes monomeric phospholamban. Lanes A-E contain 0.21.0 µg purified SERCA2a (top) or 0.02-0.1 µg purified phospholamban (bottom). Lane 1
contains 1.66 µg of cardiac SR vesicles.

Lanes 2-3 contain 5 µg of High-Five

microsomal protein per lane and correspond to SERCA2a alone and SERCA2a +
phospholamban, respectively. These amounts of protein were used in order to have the
samples fall on the standard curves. (C and D) Standard curves (empty symbols) were
constructed using purified SERCA2a and phospholamban, respectively, showing the
relationship between blot intensity and amount of protein loaded. The filled symbols
correspond to the blot intensities obtained using cardiac SR vesicles (●) or High-Five
microsomes containing SERCA2a alone (▲), and SERCA2a + phospholamban (■),
which were used in conjunction with the standard curves to determine the amount of
SERCA2a or phospholamban in each of the sample types studied. The data shown
represents one representative preparation of each type. The average data from multiple
preparations is presented in Table 3-2.
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Table 3-2
Characterization of SERCA2a and phospholamban co-expressed in High-Five insect cells
SERCA2a ATPase Activityc

Expression
PLB:SERCA2a
a

SERCA2a

a

PLB

Ratio

b

Vmax
- Ab
-1

Vmax

KCa

KCa

+ Ab

- Ab

+ Ab

-1

Sample Type

(% total protein)

(% total protein)

(mol:mol)

SERCA2a alone

15.82 ± 1.56

0.00

0:1

0.85 ± 0.06

0.84 ± 0.06

290 ± 40

300 ± 30

SERCA2a + PLB

15.66 ± 0.39

1.35 ± 0.17

1.55 ± 0.18 : 1

0.67 ± 0.04

0.68 ± 0.05

590 ± 50

340 ± 40

Cardiac SR

35.85 ± 1.77

1.96 ± 0.04

1.00 ± 0.06 : 1

2.39 ± 0.06

2.38 ± 0.09

550 ± 30

310 ± 20

a

(nM)

(µmol•mg •min )

The amount of SERCA2a or phospholamban by weight (% total protein) in the High-Five microsomes was obtained

from standard curves constructed using various amounts of purified SERCA2a (0 to 1 µg) or phospholamban (0 to 0.1 µg)
included on the same gel as the expressed samples (Fig. 3-2).
b

The molar ratio of SERCA2a to phospholamban in each sample was determined using the weight of each protein

divided by the respective molecular weight (110,000 g/mol for SERCA2a and 6,080 g/mol for phospholamban).
c

ATPase activity assays of each sample were done at 37 oC as described in Figure 3-3. Samples were preincubated in

the absence (-Ab) or presence (+Ab) of anti-phospholamban monoclonal antibody, 2D12, for 20 minutes on ice prior to the
start of the activity assays. The maximum activity (Vmax) and [Ca2+] required for half-maximal activity (KCa) were determined
from Hill fits of the [Ca2+]-dependent ATPase activity for each sample. The values represent the mean of nine separate
SERCA2a preparations and eleven separate SERCA2a + phospholamban preparations, and the error represents the standard
error of the mean.
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vesicles (Table 3-2).

Despite the difference in phospholamban to SERCA2a molar

stoichiometry in our insect cell microsome preparation (1.6:1) versus native cardiac SR
vesicles (1.0:1), our activity assays showed that phospholamban had a nearly identical
functional effect on the Ca2+-ATPase activity in the microsomes as in native cardiac SR
vesicles (see below).
The SERCA2a and phospholamban expression was carried out using separate
SERCA2a- and phospholamban-containing recombinant baculoviruses, rather than a
single virus containing both cDNA constructs. Having found an expression ratio for the
different viruses that provides expression levels that mimic those observed in native
cardiac SR helps to validate the insect cell microsome as a model system for the Ca2+ATPase-phospholamban interaction. Furthermore, the use of two separate viruses should
provide flexibility for physical and kinetics studies investigating the effects of varied
Ca2+-ATPase to phospholamban molar ratios on Ca2+-ATPase function, as identified in a
number of heart disease states [27].
Functional Regulation of the Ca2+-ATPase by Phospholamban
The Ca2+-ATPase activity of the expressed SERCA2a samples in High-Five cell
microsomes pre-treated with the Ca2+ ionophore A23187 was measured at 37 oC at a
series of [Ca2+]. The ionophore was included to prevent Ca2+ gradient formation across
the microsomal membrane.

The functional coupling between SERCA2a and

phospholamban in the microsomal membrane was also measured by pre-incubating the
samples in the absence and presence of the anti-phospholamban monoclonal antibody,
2D12, which reverses the inhibitory interaction between phospholamban and SERCA2a
[8, 15].

The expressed SERCA2a ATPase activity displayed a sigmoidal [Ca2+]

dependence, and the maximum steady-state activities per mg of microsomal protein for
the two sample types were 0.85 ± 0.06 µmol•mg total protein-1•min-1 for microsomes
containing SERCA2a expressed alone and 0.67 ± 0.04 µmol•mg total protein-1•min-1 for
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microsomes containing SERCA2a + phospholamban. Pretreatment of the microsomes
with 2D12 had no effect on the Vmax of either sample type (Table 3-2). In the absence of
Ca2+ ionophore pretreatment, both microsomal samples displayed a 2-3-fold decrease in
activity, indicating that the microsomes were well sealed for Ca2+ and that ATPase
activity was coupled to Ca2+ transport (Data not shown).
Because the activity of the SERCA2a + phospholamban preparations were
depressed relative to the SERCA2a alone preparations, we normalized the activity data
from the SERCA2a and SERCA2a + phospholamban samples to their respective Vmax
values to facilitate a direct comparison of the [Ca2+]-dependence of each sample (Fig. 33). SERCA2a expressed without phospholamban had a high apparent Ca2+ affinity,
expressed as KCa (the ionized [Ca2+] giving half-maximal activation of the Ca2+-ATPase),
which was 290 ± 40 nM), and this value was unaffected by pre-treatment of the sample
with anti-phospholamban monoclonal antibody, 2D12.

When co-expressed with

phospholamban, the SERCA2a activity curve was shifted to the right relative to that of
SERCA2a expressed alone, resulting in an increase in the KCa to 590 ± 50 nM (∆KCa =
300 nM). Treatment of the phospholamban-containing sample with 2D12 shifted the
activation curve to the left, resulting in a two-fold decreased KCa value, equivalent to that
obtained for SERCA2a in the absence of phospholamban (Table 3-2). These results show
phospholamban was functionally coupled to the Ca2+-ATPase in the phospholamban coexpressed samples. For comparison, the KCa values measured for the Ca2+-ATPase in
native dog cardiac SR vesicles were 550 ± 30 nM and 310 ± 20 nM (∆KCa = 240 nM) for
the sample without and with pre-treatment with 2D12, respectively, similar to the
expressed SERCA2a + phospholamban sample. This result indicated that the functional
coupling of expressed phospholamban and Ca2+-ATPase in the insect cell microsomes
was an accurate model for that in native cardiac SR vesicles.
To

determine

the

relationship

between

phospholamban:Ca2+-ATPase

stoichiometry and the shift in the calcium-concentration necessary for half-maximal
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Figure 3-3. Effect of phospholamban on [Ca2+]-dependent Ca2+-ATPase activity.
The ATPase activity of High-Five cellular microsomes containing either the Ca2+ATPase expressed alone (□, ■) or co-expressed with phospholamban (○, ●) was
measured at 37 oC using 5 mM MgATP in 50 mM MOPS (pH 7.0), 3 mM MgCl2, 100
mM KCl, 1 mM EGTA and various [Ca2+] (between 0 – 1mM) to promote an ionized
[Ca2+] between 10 nM and 10 µM. Regulatory phospholamban decreased the apparent
Ca2+ affinity of the Ca2+-ATPase (i.e., increased the [Ca2+] required for half-maximal
activity) relative to the sample treated with anti-PLB monoclonal antibody 2D12 (●),
which uncoupled phospholamban from the Ca2+-ATPase. There was no change in the
apparent Ca2+ affinity for the SERCA2a sample expressed alone when the antiphospholamban monoclonal antibody (■) was added. The data were normalized to the
calculated Vmax for both of SERCA2a and SERCA2a + phospholamban samples,
respectively. Curves represent the nonlinear least-squares fits to the Hill equation for the
data. Symbols represent the average of the individual microsomal preparations made
(SERCA2a alone: n = 9; SERCA2a + phospholamban: n = 11) and the error bars
represent the standard error of the mean.
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activation ∆ΚCa, we plotted the corresponding ∆ΚCa and phospholamban : Ca2+-ATPase
ratio values for each SERCA2a + phospholamban preparation used in this study (Fig. 3-4,
filled squares). For comparison, we included the values from dog cardiac SR vesicles
(open square), which we found had a phospholamban to Ca2+-ATPase molar ratio of 1
(Table 3-2). The plot shows that within the range of 1.2 to 2.3 moles phospholamban per
mole Ca2+-ATPase, the ∆ΚCa values of the expressed Ca2+-ATPase + phospholamban
samples do not differ significantly from one another or from that observed for dog
cardiac SR vesicles. This result is similar to that reported by Ferrington et al. [28], who
obtained nearly identical ∆KCa values for the Ca2+-ATPase and phospholamban over a
wider range (1 to 5 moles phospholamban per mole Ca2+-ATPase) in SR isolated from rat
and rabbit slow-twitch soleus and cardiac muscle.

Thus, while the ratio of

phospholamban:SERCA2a was lower than those observed by Ferrington et al. [28], we
observed nearly identical functional effects of phospholamban on the Ca2+-ATPase. This
shows that our expressed system is mimicking the functional regulation of Ca2+-ATPase
by phospholamban observed in native cardiac SR vesicles.
One of our preparations had a molar stoichiometry of 0.5:1 phospholamban:Ca2+ATPase and a much smaller ∆ΚCa value of 90 nM, consistent with previous findings
showing that sub-stoichiometric levels of phospholamban are insufficient for maximal
Ca2+-ATPase inhibition [29]. A distinct advantage of this expression system is that one
can change the phospholamban to SERC2a ratio by changing the multiplicity of infection
for either (or both) of the viruses during the infection to obtain lower phospholamban to
SERC2a ratios in the insect cell microsomes with a concomitant gradation of the effect of
phospholamban on Ca2+-ATPase ΚCa values.

Likewise, one can overexpress

phospholamban relative to SERCA2a to obtain phospholamban:SERCA2a ratios in insect
cell microsomes that mimic those engineered in the hearts of transgenic mice that lead to
cardiac dysfunctions [29]. This would facilitate detailed physical and functional studies
of the effects of phospholamban over expression in a controlled membrane environment,
free of compensatory mechanisms that can complicate transgenic mouse studies [30].
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Figure 3-4. Molar stoichiometry of phospholamban and regulation of the Ca2+ATPase. The phospholamban-dependent shift in the calcium-concentration necessary for
half-maximal activation (∆ΚCa), represented as ∆Ca1/2 in the figure, and the molar
stoichiometry of phospholamban to SERCA2a for each SERCA2a + phospholamban
preparation (■) and for cardiac SR (□) was compared. The shift in ∆ΚCa values reached a
maximum around one mol of phospholamban to one mol of SERCA2a. ∆ΚCa values
represent triplicate determinations for each individual preparation with the error bars
representing the standard error of the mean. The molar ratio of phospholamban to
SERCA2a in each preparation was determined using the weight of each protein divided
by the respective molecular weight (6,080 g/mol for phospholamban and 110,000 g/mol
for SERCA2a) and represent triplicate determinations for each individual preparation,
with the error bars representing the standard error of the mean.
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To further test the functional properties of the expressed Ca2+-ATPase and
phospholamban in the insect cell microsomes, Ca2+ uptake assays were conducted at 37
o

C at a series of [Ca2+] in the presence and absence of the anti-phospholamban

monoclonal antibody, 2D12.

Ca2+ uptake of the expressed SERCA2a displayed a

sigmoidal [Ca2+] dependence and when normalized the curves (Fig. A-3) were very
similar to those obtained from the ATPase assay experiments shown in Figure 3-3.
SERCA2a expressed without phospholamban had a high apparent Ca2+ affinity (ionized
[Ca2+] giving half-maximum uptake of Ca2+ by the Ca2+-ATPase, KCa = 125 ± 4 nM),
which was not significantly affected by pre-treatment with 2D12 (Table 3-3). When coexpressed with phospholamban, the SERCA2a uptake curve was shifted to the right
relative to that of SERCA2a expressed alone, resulting in an increase in the KCa to 185 ±
5 nM.

Treatment of the phospholamban-containing sample with 2D12 shifted the

activation curve to the left, resulting in a decreased KCa value of 113 ± 10 nM, consistent
with that obtained for SERCA2a in the absence of phospholamban. These results are
similar to those reported by Autry and Jones [8] for Ca2+-ATPase and phospholamban coexpressed in Sf21 insect cells.

Furthermore, the results show that phospholamban

regulates Ca2+-ATPase Ca2+ uptake activity in the High-Five insect cell microsomes in a
manner analogous to the regulation of SERCA2a ATPase activity.
We also tested the rate of Ca2+ efflux from the SERCA2a-containing High-Five
cell microsomes, in order to determine whether the presence of phospholamban affected
the rate of Ca2+ efflux. Microsomes were preloaded with 45Ca2+ and efflux was initiated
by clamping the extra-vesicular [Ca2+] to near zero with excess EGTA. The time course
of Ca2+ efflux for both sample types was biphasic, consisting of an initial exponential
decay (k1) followed by a slower linear decrease (k2) in intravesicular Ca2+ (Fig. 3-5). As
shown in Table 3-4, there were no significant differences (or at most, only minor
differences) between the exponential phase of efflux for SERCA2a alone (0.93 ± 0.05
min-1) or SERCA2a + phospholamban (0.69 ± 0.15 min-1), or the linear phase of efflux
for SERC2a alone (-0.008 ± 0.001 nmol Ca2+ min-1) or SERCA2a + phospholamban (-
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Table 3-3
Phospholamban regulation of SERCA2a Ca2+ uptake in High-Five insect cells

Sample Type
SERCA2a alone
SERCA2a + PLB
a

Ca2+ uptake Kca valuesa
- Ab
+ Ab
(nM)
125 ± 4
185 ± 5

136 ± 6
113 ± 10

Ca2+ uptake assays of each sample were done at 37 oC. Samples were pre-

incubated in the absence (-Ab) or presence (+Ab) of anti-phospholamban monoclonal
antibody, 2D12, for 20 minutes on ice prior to the start of the uptake assays. The
maximum activity (Vmax) and [Ca2+] required for half-maximal uptake (KCa) were
determined from Hill fits of the [Ca2+]-dependent Ca2+ uptake for each sample. The data
were normalized to the calculated Vmax for both of SERCA2a and SERCA2a +
phospholamban samples, respectively. The values represent the average of three separate
preparations each of SERCA2a and SERCA2a + phospholamban and the error represents
the standard error of the mean.
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Figure 3-5. Effect of phospholamban on Ca2+ efflux from High-Five microsomes.
High-Five cellular microsomes containing either the Ca2+-ATPase expressed alone (□, ■)
or co-expressed with phospholamban (○, ●) were loaded with

45

Ca2+ at 37 oC in an

incubation that contained 0.1 mg/ml protein in 50 mM MOPS (pH 7.0), 100 mM KCl, 3
mM MgCl2, 10 mM sodium oxalate, 1 mM EGTA, 0.9 mM CaCl2, and 50 µM added
45

Ca2+. Active Ca2+ uptake was started with the addition of 5 mM MgATP and allowed

to proceed for 15 min in order to accumulate Ca2. Afterwards, efflux of radioactive Ca2+
from the microsomes was initiated by addition of 20 mM EGTA to clamp the
extravesicular [Ca2+] to zero. As a control, calcium efflux was also initiated by adding 20
µg/ml of the Ca2+ ionophore A23187 to the SERCA2a alone (∆), and SERCA2a +
phospholamban (▲) samples, respectively. Regulatory phospholamban had no effect on
the k1 (exponential decay) or k2 (slower linear decrease) values (Table 3-4) relative to the
sample treated with anti-phospholamban monoclonal antibody 2D12 (●), which
uncoupled phospholamban from the Ca2+-ATPase. There was no change in the k1 or k2
values for the SERCA2a sample expressed alone when the anti-phospholamban
monoclonal antibody (■) was added. The data was normalized to the initial Ca2+ load
(nmol/mg protein) before the addition of EGTA for both of the SERCA2a and SERCA2a
+ phospholamban samples, respectively. Curves represent the nonlinear least squares fits
of the data. Symbols represent the average measurement from three separate preparations
and the error bars represent the standard error of the mean.
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Table 3-4
Ca2+ efflux from SERCA2a-containing High-Five insect cells
Ca2+ Efflux valuesa
Sample Type

k1
min-1

k2
nmol Ca2+ min-1

SERCA2a
SERCA2a (+Ab)

0.93 ± 0.05
0.70 ± 0.08

-0.008 ± 0.001
-0.006 ± 0.001

SERCA2a + PLB
SERCA2a + PLB (+Ab)

0.69 ± 0.15
0.55 ± 0.10

-0.005 ± 0.002
-0.004 ± 0.001

a

Ca2+ efflux assays of each sample were done at 37 oC. Samples were pre-

incubated in the absence (-Ab) or presence (+Ab) of anti-phospholamban monoclonal
antibody, 2D12, for 20 minutes on ice prior to the start of the efflux assays. Microsomes
were actively loaded with 45Ca2+, and Ca2+ efflux was then initiated by chelation of all of
the extravesicular Ca2+ with EGTA, as described under Methods.

The data were

normalized to the initial Ca2+ load (nmol/mg protein) before the addition of EGTA for
both SERCA2a and SERCA2a + phospholamban samples, respectively. The constants k1
(exponential decay) and k2 (slower linear decrease) values were determined by the
nonlinear least squares fit to the exponential curve equation for the observed data (Fig. 35). The values represent the average of three separate preparations each of SERCA2a
and SERCA2a + phospholamban and the error represents the standard error of the mean.
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0.005 ± 0.002 nmol Ca2+ min-1). Furthermore, pre-treatment of each sample type with
anti-phospholamban monoclonal antibody 2D12 had no significant effects on the efflux
time course for either sample (Table 3-4).

As a control, we added the Ca2+ ionophore

A23187 to the Ca2+-loaded microsomes, which resulted in the rapid release of all of the
accumulated Ca2+ in both SERCA2a and SERCA2a + phospholamban samples,
respectively (Fig. 3-5). As an additional control, the microsomes were treated with 2.0
µM thapsigargin after Ca2+ loading of the microsomes but before the addition of the
EGTA. The efflux time course for the SERCA2a and SERCA2a + phospholamban
samples following thapsigargin treatment was nearly identical to that observed for the
untreated samples (data not shown). Because thapsigargin has been shown to block
SERCA2a-dependent Ca2+ efflux from cardiac SR membranes [31], the results suggested
that Ca2+ efflux occurred by a pathway other than the Ca2+-ATPase, both in the presence
and absence of phospholamban.
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Summary
We have expressed canine cardiac Ca2+-ATPase and canine phospholamban using
the baculovirus-High-Five cell expression system, and isolated the expressed proteins in
cellular microsomes.

The yield of Ca2+-ATPase from a one liter cell infection is

approximately 22 mg, with an enrichment of approximately 3-fold relative to the initial
cell homogenate and 50% greater yield than previous Sf21 experiments [8].

The

enzymatic properties of the expressed Ca2+-ATPase are similar to those observed in
native cardiac SR vesicles, and when co-expressed with phospholamban, the Ca2+ATPase is functionally coupled to phospholamban similar to that observed in cardiac SR
vesicles. Using this improved system will facilitate production of sufficient quantities of
protein to study the biophysical interaction between the Ca2+-ATPase and
phospholamban using techniques such as EPR spectroscopy, fluorescence spectroscopy,
kinetic radioisotope tracer assays, etc. Coupled with site-directed mutagenesis of the
Ca2+-ATPase and/or phospholamban, detailed physical studies of mutant proteins are
facilitated as well.
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Abstract
We have measured the effect of phospholamban on cardiac muscle Ca2+-ATPase
(SERCA2a) phosphorylation by radiolabeled inorganic phosphate (Pi), in order to test the
hypothesis that phospholamban stabilizes the Ca2+-ATPase in the E2 intermediate state.
Ca2+-ATPase expressed either alone or co-expressed with phospholamban in High-Five
insect cells was isolated as insect cell microsomes. In the absence of phospholamban,
Ca2+-ATPase phosphorylation displayed a hyperbolic dependence on [Pi], with halfmaximum phosphorylation (KPi) occurring at 0.21 ± 0.03 mM Pi and a maximum
phosphorylation level of 1.72 ± 0.06 nmol

32

P/ mg Ca2+-ATPase. The presence of

phospholamban decreased the maximum level of phosphorylation to 0.79 ± 0.01 nmol
32

P/ mg Ca2+-ATPase but there was no significant effect on KPi.

In addition,

2+

phospholamban had no significant effect on the [Ca ]-dependent inhibition of Ca2+ATPase phosphorylation by Pi apart from the initial phosphoenzyme level formed in the
absence of calcium. Our results show phospholamban decreased Ca2+-ATPase reactivity
toward Pi, suggesting that phospholamban stabilizes the Ca2+-ATPase in the E2
conformation, which decreases the number of E2 units available to bind phosphate to
form the E2-P complex.
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Introduction
The sarcoplasmic reticulum (SR) Ca2+-ATPase is a 110 kDa integral membrane
protein that utilizes ATP to drive the transport of calcium ions into the SR to promote
muscle relaxation (1). In cardiac SR, the Ca2+-ATPase is regulated by phospholamban, a
52-amino acid phosphoprotein, which inhibits Ca2+-ATPase activity by decreasing the
apparent affinity of the ATPase for calcium (2). Ca2+-ATPase inhibition is relieved by
phosphorylation of phospholamban at Ser-16 or Thr-17, resulting in a marked increase in
Ca2+-ATPase activity, an increase in the rate of relaxation of cardiac muscle, and a
positive inotropic effect (3).
Abnormal Ca2+-ATPase regulation by phospholamban has been implicated as a
causative factor for diastolic dysfunction, cardiac hypertrophy and heart failure. This has
led to a great deal of interest in understanding the physical and functional interaction
between the Ca2+-ATPase and phospholamban (4). Recently, Seidman and co-workers
(5) have shown that a naturally occurring phospholamban missense mutation (Arg →
Cys) results in heart disease in humans. Studies in mice found that disruption of the
phospholamban gene or expression of a dominant negative phospholamban mutant led to
enhanced cardiac function, whereas in humans, the absence of phospholamban led to
development of lethal dilated cardiomyopathy (6). Therefore, a key step in understanding
important cardiac pathologies and developing pharmaceutical strategies in the fight
against heart disease is elucidating the molecular details of the phospholamban Ca2+ATPase interaction (7).
The majority of phospholamban and Ca2+-ATPase studies show that
phospholamban inhibition of Ca2+-ATPase is most potent when [Ca2+] is low, whereas
micromolar

[Ca2+]

disrupts

the

phospholamban and Ca2+-ATPase.

physical

and

functional

interaction

between

This suggests that phospholamban interacts

preferentially with the E2 (Ca2+-free) versus the E1 (Ca2+-bound) conformation of the
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enzyme. Direct physical evidence for this was provided by Jones and co-workers (8, 9),
who reported site-specific phospholamban-Ca2+-ATPase cross-linking in the absence of
calcium that was abolished in the presence of micromolar [Ca2+]. The data suggest that
phospholamban inhibits the Ca2+-ATPase by stabilizing the enzyme in the E2
conformation, thereby inhibiting the enzyme E2 to E1 conformational transition. In this
model, calcium binding to the Ca2+-ATPase can overcome the phospholamban
stabilization by mass action, but higher [Ca2+] is required for E1·Ca2 formation, giving
rise to an apparent decrease in enzyme calcium affinity without an actual change in
calcium binding affinity (10).
Inorganic phosphate (Pi) can phosphorylate the Ca2+-free enzyme state (E2) to
form the E2P intermediate (11, 12). Furthermore, it is well documented that Ca2+ATPase E2P formation from Pi is inhibited in presence of calcium, since calcium
stimulates the E2 to E1·Ca2 state, which does not react with Pi. Because phospholamban
interacts specifically with the calcium-free Ca2+-ATPase E2 intermediate (8, 9), one
would expect the enzyme to be less reactive toward Pi in the presence of phospholamban
than in its absence. Cantilina et al. (10) previously reported that phospholamban has no
effect on the [Ca2+]-dependent inhibition of the Ca2+-ATPase Pi phosphorylation reaction.
However, the authors did not report the effect of phospholamban on the [Pi]-dependence
or the maximum amplitude of E2P formation from Pi, two key factors in understanding
the effect of phospholamban on Ca2+-ATPase reactivity toward Pi. Reexamination of the
Pi phosphorylation data reported in that study [c.f., Figure 9 (10)] suggests that
phospholamban decreased E2P formation from Pi by perhaps as much as 20%. If true,
these data would provide important kinetic information into the mechanism by which
phospholamban regulates the Ca2+-ATPase.
Therefore, in the present study, we have determined the effect of phospholamban
on Ca2+-ATPase phosphorylation by [32P]Pi, to test the hypothesis that phospholamban
stabilizes the enzyme in the E2 conformation. For this work, we used the baculovirus-

105

High Five insect cell Ca2+-ATPase / phospholamban expression system and prepared
cellular microsomes that contained the Ca2+-ATPase (the SERCA2a isoform) either alone
or with phosphospholamban (13). Use of the expression system allowed the direct
comparison of Ca2+-ATPase phosphorylation by Pi in the absence and presence of
phospholamban.

The results of our study show that phospholamban decreased the

amplitude of E2P formation without affecting the affinity of the enzyme for Pi, and that
phospholamban did not affect the calcium concentration range that inhibits the
phosphorylation reaction, consistent with phospholamban stabilization of the Ca2+ATPase E2 state.
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Materials and Methods

Materials
[32P]H3PO4 was purchased from ICN, and
from Perkin Elmer Life Sciences.

125

I-labeled protein A was purchased

Prestained molecular weight standards and

polyvinylidene difluoride (PVDF) membranes were purchased from Bio-Rad. High-Five
insect cells were purchased from Invitrogen, and the BaculoGold system was obtained
from Pharmingen-BD Biosciences.

All other reagents were of the highest purity

available.

Protein Expression, Isolation, and Characterization
Canine cardiac Ca2+-ATPase (the SERCA2a iosform) and canine phospholamban
were co-expressed in High-Five cells as described elsewhere (13). Microsomes were
harvested 48 h after baculovirus infections and stored in small aliquots at –50 oC. Protein
concentrations were determined by the method of Lowry et al. (14), using bovine serum
albumin (Sigma) as a standard. The amount of SERCA2a and phospholamban in the
microsomes was quantified by gel electrophoresis and immunoblotting, and the [Ca2+]dependent ATPase activity of the SERCA2a, as affected by phospholamban, were
measured using methods described previously (13). Microsomes were also prepared
from control, uninfected cells (denoted control microsomes) and were assayed in a
similar fashion to those containing the expressed proteins. The control microsomes
contained no detectible SERCA2a or phospholamban protein.

Phosphoenzyme Formation from Pi
Inorganic phosphate-dependent phosphoenzyme formation was carried out at 25
o

C using insect cell microsomes (1.0 mg/ml) suspended in a solution containing 10 mM
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MgCl2, 1 mM EGTA (~ 0 free Ca2+), and 50 mM MES (pH 6.0).

To initiate

phosphorylation, an equal volume of an identical solution containing [32P]Na2HPO4 (but
no protein) was added to the microsomes and vortexed. The reaction was quenched after
15 min by the addition of 3% perchloric acid + 2 mM H3PO4 (final concentrations).
Bovine serum albumin (0.25 mg) was added to each sample as a carrier protein. The
quenched vesicles were pelleted in a tabletop centrifuge and then washed three times with
a solution of 5% trichloroacetic acid, 4 mM H3PO4 (non-radio labeled) and 6%
polyphosphate. The final pellets were dissolved in 5 ml of 1 N NaOH, and the [32P]
phosphoenzyme was assayed by scintillation counting.

For the [Pi]-dependence EP

studies, the concentration of [32P]Na2HPO4 was varied between 0 and 8 mM, and the
amount of radio-labeled Pi was adjusted to maintain the ratio of labeled to unlabeled Pi in
the reaction mixture (about 5500 CPM per 1 mM Pi). For the [Ca2+]-dependent EP
inhibition experiments, microsomes (1.0 mg/ml) were suspended in a solution at 25 oC
containing 10 mM MgCl2, 1 mM EGTA (~ 0 free Ca2+), and 50 mM MES (pH 6.0). To
initiate phosphorylation, an equal volume of a solution containing 4 mM [32P]Na2HPO4,
10 mM MgCl2, 1 mM EGTA, 50 mM MES (pH 6.0) and various levels of CaCl2 were
added to the microsomes and vortexed. The final [CaCl2] varied between 0 – 1.2 mM,
which provided ionized [Ca2+] levels of 0 – 200 µM in the reaction mixture. The reaction
and analyses were followed as described above.

Curve Fitting
Calcium-dependent ATPase activity data and phosphoenzyme kinetics data were
fit using the program KFIT written by N. C. Millar, which was obtained from Dr. Carl
Frieden’s website: www.wuarchive.wustl.edu/packages/kinsim/uploads. The best fits of
the data were chosen on minimization of the sum-of-squares error, χ2.
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Results

Protein Expression and Characterization
For these studies, the SERCA2a Ca2+-ATPase isoform was expressed in HighFive insect cells alone or co-expressed with phospholamban, isolated as High-Five insect
cell microsomes, and assayed for enzyme activity and Ca2+-ATPase-phospholamban
coupling, all as detailed previously (13). Three separate preparations each were used
from the eleven Ca2+-ATPase alone and nine Ca2+-ATPase + phospholamban sample
preparations prepared by Waggoner et al. (13). The Ca2+-ATPase and phospholamban
protein content in the microsomes was determined by quantitative immunoblotting (Table
4-1).

Based on the expression data, the molar stoichiometry of phospholamban to

SERCA2a was determined to be 1.3 ± 0.1 phospholamban to 1 Ca2+-ATPase. The
[Ca2+]-dependent ATPase activity of the expressed pump, as affected by phospholamban,
was characterized by enzyme assay (Figure 4-1 and Table 4-1). In the absence of
phospholamban, the [Ca2+] producing half-maximal activity (KCa) was 290 ± 70 nM,
whereas the presence of phospholamban shifted the KCa value to 600 ± 80 nM, consistent
with well documented finding that phospholamban decreases the apparent Ca2+ affinity of
the Ca2+-ATPase (2). We have previously demonstrated for these same samples (13) that
uncoupling phospholamban from the Ca2+-ATPase using the anti-phospholamban
monoclonal antibody 2D12 shifted the KCa value of the [Ca2+]-dependent enzyme activity
curve to 350 ± 50 nM, which resembles that of the enzyme expressed in insect cell
microsomes in the absence of phospholamban (Table 4-1).

These results show

2+

phospholamban is functionally coupled to the Ca -ATPase in these phospholamban coexpressed samples and are suitable for our studies presented here. Also apparent from
the data in Table 4-1 is the finding that the ATPase activity at saturating [Ca2+] (i.e.,
Vmax) for the microsomes containing Ca2+-ATPase only is approximately 20% higher
than that for the sample containing Ca2+-ATPase co-expressed with phospholamban,
despite the fact that both microsome preparations contain the same amount of Ca2+-
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Figure 4-1. Effect of phospholamban on [Ca2+]-dependent Ca2+-ATPase activity.
The ATPase activity of High-Five cellular microsomes containing either the Ca2+ATPase expressed alone (■) or co-expressed with phospholamban (●) was measured at
37 oC using 5 mM MgATP in 50 mM MOPS (pH 7.0), 3 mM MgCl2, 100 mM KCl, 1
mM EGTA and various [Ca2+] (between 0 – 1mM) to promote an ionized [Ca2+] between
10 nM and 10 µM. Regulatory phospholamban decreased the apparent Ca2+ affinity of
the Ca2+-ATPase (i.e., increased the [Ca2+] required for half-maximal activity) relative to
the SERCA2a alone sample that had no phospholamban present.

To allow direct

comparison of the two curves, the data were normalized to the maximum ATPase activity
for both of SERCA2a and SERCA2a + phospholamban samples, respectively. The raw
activity data are provided in Table 4-1. The symbols represent the average of three
individual microsomal preparations made (SERCA2a alone or SERCA2a +
phospholamban) and the error bars represent the standard error of the mean.
represent the nonlinear least-squares fits of the Hill equation to the data.
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Curves

Table 4-1
Characterization of Ca2+-ATPase and phospholamban co-expressed in High-Five insect cellsa
Expression
2+

Sample Type
2+

Ca -ATPase alone
Ca2+-ATPase + PLB
a

Ca -ATPase
(% total protein)

PLB
(% total protein)

15.7 ± 0.6
15.8 ± 0.7

0.00
1.42 ± 0.1

SERCA2a ATPase Activity
Vmax
Vmax
KCa
-Ab
+Ab
-Ab
(µmol•mg protein-1•min-1)
0.88 ± 0.06
0.71 ± 0.03

0.91 ± 0.07
0.73 ± 0.04

0.29 ± 0.07
0.60 ± 0.08

KCa
+Ab
(µM)
0.28 ± 0.08
0.35 ± 0.05

Ca2+-ATPase and phospholamban were co-expressed using the baculovirus High-Five insect cell expression system

and isolated as insect cell microsomes, as previously reported (13). Three separate preparations each of Ca2+-ATPase alone
and Ca2+-ATPase + phospholamban from Waggoner et al. (13) were used for this study. Protein expression was determined by
quantitative immunoblotting, using purified Ca2+-ATPase and purified phospholamban as standards. Using the molecular
weight of 110,000 g / mol for Ca2+-ATPase and 6,080 g / mol for phospholamban, the molar stoichiometry of phospholamban
to Ca2+-ATPase was determined to be 1.3 ± 0.1 : 1 . Ca2+-ATPase activity was assayed as inorganic phosphate liberation at 37
o

C. The effects of phospholamban on Ca2+-ATPase activity were determined by pre-incubating the samples in the absence (-

Ab) or presence (+Ab) of the anti-phospholamban monoclonal antibody 2D12 prior to the activity assay. The maximum
activity (Vmax) and [Ca2+] required for half-maximal activity (KCa) were determined from Hill fits of the [Ca2+]-dependent
ATPase activity for each sample. Additional characterization of the samples is presented in (13). Values represent the mean of
three separate preparations each of Ca2+-ATPase alone and Ca2+-ATPase + phospholamban, and the error represents the
standard error of the mean.
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ATPase by weight.

This activity difference is most likely due to phospholamban-

dependent inhibition of the enzyme, even at saturating [Ca2+], rather than to an enzyme
that is inactive due to denaturation or aggregation (13). As reported previously, the
phospholamban-containing sample displayed the same Vmax value before and after
antibody treatment (10, 13, 15, 16).

[Pi]-Dependence of Phosphoenzyme Formation
The effect of phospholamban on the [Pi] dependence of phosphoenzyme levels
formed at 25 oC for SERCA2a expressed alone or SERCA2a co-expressed with
phospholamban in High-Five insect cell microsomes was measured first (Fig. 4-2). The
phosphoenzyme level of each sample type displayed a hyperbolic dependence on [Pi].
There was a significant difference between the maximum levels of phosphoenzyme
formation between the two sample types.

For SERCA2a, the maximum level of

phosphoenzyme formation was 1.72 ± 0.06 nmol

32

Pi / mg SERCA2a (n = 4). The

presence of phospholamban resulted in a 54% decrease in the maximum phosphoenzyme
level to 0.79 ± 0.01 nmol

32

Pi / mg SERCA2a (n = 4). However, the [Pi] required for

half-maximal phosphorylation, KPi, was not significantly different between the two
samples: SERCA2a KPi = 0.21 ± 0.03 mM (n = 4) and SERCA2a + phospholamban KPi =
0.25 ± 0.04 mM (n = 4). The similarity of the [Pi]-dependence of phosphoenzyme
formation for the two samples was made clearer by overlaying the curves after
normalizing each of them to their respective maximum phosphoenzyme level (Fig. 4-2,
insert). For these experiments, the anti-phospholamban monoclonal antibody 2D12 was
not used to uncouple phospholamban from the Ca2+-ATPase due to the very large amount
of antibody needed for each experiment. Likewise, we did not use phospholamban
phosphorylation methods to uncouple phospholamban from the enzyme. Due to very low
Pi-dependent phosphorylation levels in the sample, we wanted to avoid ATP-dependent
phosphorylation of the Ca2+-ATPase and physical damage to the labile membrane during
removal of the reagents used during phospholamban phosphorylation.
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Control

Figure 4-2. Effect of phospholamban on the [Pi]-dependence of E2P Formation.
SERCA2a expressed in High-Five insect cell microsomes (■) or SERCA2a co-expressed
with phospholamban in High-Five insect cell microsomes (●) were suspended (1.0
mg/ml) in a buffer containing 10 mM MgCl2, 1 mM EGTA (~ 0 free Ca2+), and 50 mM
MES (pH 6.0).

To initiate the phosphorylation reaction, increasing levels of

[32P]Na2HPO4 in the same buffer were added to the samples. Following incubation for
15 min at 25 oC, the reaction was quenched with acid and processed for determination of
phosphoenzyme levels. The symbols represent the average of four separate experiments
and the error bars represent the standard error of mean. The lines were fit by a hyperbolic
function, which provided the maximum level of phosphoenzyme formation (EP) and the
[Pi] required for half-maximum phosphoenzyme formation (KPi). There was a significant
difference between the maximum E2P levels (nmol 32Pi / mg Ca2+-ATPase) for SERCA2a
alone (1.72 ± 0.06) and SERCA2a + phospholamban (0.79 ± 0.01), p < 0.05, but there
was no significant difference between the KPi levels (mM) for SERCA2a alone (0.21 ±
0.03) and SERCA2a + phospholamban (0.25 ± 0.04), p > 0.05. The inset shows the data
sets normalized to the maximum phosphoenzyme level, indicating there was no change in
the KPi value for the two curves.
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microsomes tested in parallel experiments showed little [32P]Pi incorporation, with
phosphorylation levels less than 10% of that observed for the SERCA2a only and
SERCA2a + phospholamban samples (data not shown). Because the control microsomes
contained no detectable SERCA2a protein, this level of phosphorylation represented the
background, non-specific level of phosphorylation.
[Ca2+]-Sensitivity of Phosphoenzyme Formation
We next measured the effect of phospholamban on the [Ca2+]-dependent
inhibition of phosphoenzyme formation at 25 oC for SERCA2a expressed alone or
SERCA2a co-expressed with phospholamban in High-Five insect cell microsomes (Fig.
4-3). The phosphoenzyme level of each sample type displayed a sigmoidal dependence
on [Ca2+] as expected, where increasing [Ca2+] significantly decreased the level of
phosphoenzyme formation. There was a significant difference between the maximum
levels of phosphoenzyme formation between the two sample types. For SERCA2a, the
maximum level of phosphoenzyme formation was 2.20 ± 0.06 nmol 32Pi / mg SERCA2a
(n = 4). The presence of phospholamban resulted in a 42% decrease in the maximum
phosphoenzyme level to 1.29 ± 0.02 nmol 32Pi / mg SERCA2a (n = 4). However, the KCa
values of the curves were not significantly different from one another. For SERCA2a, the
[Ca2+] required for half-maximum phosphoenzyme formation (KCa) was 568 ± 44 nM (n
= 4). In the presence of phospholamban the KCa was 676 ± 124 nM (n = 4). The
similarity of the [Ca2+]-dependence of the inhibition of phosphoenzyme formation for the
two samples was made clearer by overlaying the curves after normalizing each of them to
their respective maximum phosphoenzyme level (Fig. 4-3, insert). Control microsomes
displayed lowered levels of phosphoenzyme formation (less than 10% that of the
SERCA2a-containing

samples)

and

no

detectible

[Ca2+]-dependence

for

the

phosphoenzyme levels (data not shown). The microsomes used for the experiments of
Figures 4-2 and 4-3 were from different preparations, resulting in quantitative differences
in the EP levels between the two sets of experiments. Nevertheless, the magnitude of the
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Figure 4-3. Effect of phospholamban on the [Ca2+]-dependent inhibition of E2P
formation. SERCA2a expressed in High-Five insect cell microsomes (■) or SERCA2a
co-expressed with phospholamban in High-Five insect cell microsomes (●) were
suspended (1.0 mg/ml) in a buffer containing 10 mM MgCl2, 1 mM EGTA (~ 0 free
Ca2+), and 50 mM MES (pH 6.0). To initiate the phosphorylation reaction, 4 mM
[32P]Na2HPO4 with various levels of [Ca2+] in the same buffer were added to the samples.
The [Ca2+] varied between 0 – 1.2 mM, which provided ionized Ca2+ levels of 0 – 200
µM in the reaction mixture. Following incubation for 15 min at 25 oC, the reaction was
quenched with acid and processed for determination of phosphoenzyme levels. The
symbols represent the average of four separate experiments and the error bars represent
the standard error of mean. The lines were determined by a Hill fit, which provided the
maximum level of phosphoenzyme formation (EP) and the [Ca2+] required for halfmaximum phosphoenzyme formation (KCa). There was a significant difference between
the maximum E2P levels (nmol 32Pi / mg Ca2+-ATPase) for SERCA2a alone (2.20 ± 0.07)
and SERCA2a + phospholamban (1.29 ± 0.05), p < 0.05, but there was no significant
difference between the KCa levels (nM) for SERCA2a alone (568 ± 44) and SERCA2a +
phospholamban (676 ± 124), p > 0.05. The inset shows the data sets normalized to the
maximum phosphoenzyme level, indicating there was no change in the KCa value for the
two curves.
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phospholamban-dependent inhibition of EP formation was similar between the
preparations.
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Discussion
The purpose of this study was to measure Ca2+-ATPase phosphorylation by Pi, as
affected by phospholamban. We wanted to test the hypothesis that phospholamban
inhibits the Ca2+-ATPase by stabilizing the enzyme in the E2 state, thus making the
enzyme resistant to the binding of ligands that stimulate transitions out of the Ca2+ATPase E2 state.
It is clear from the activity data in Table 4-1 that the presence of phospholamban
decreases Ca2+-ATPase activity by about 20%, even at saturating [Ca2+] levels. This Vmax
effect has been described before (17-19), and it suggests that phospholamban holds about
20% of the Ca2+-ATPase in an inactive state, effectively decreasing the concentration of
enzyme by this amount. However, the phospholamban-dependent inhibition of Ca2+ATPase phosphorylation by Pi we observed was much greater, averaging 48% between
the experiments shown in Figures 4-2 and 4-3.

This suggests that phospholamban

inhibited the Pi-dependent reaction in a second population of enzymes. Presumably, this
population of enzyme is reversibly inhibited by phospholamban, since uncoupling
phospholamban from the Ca2+-ATPase by phospholamban phosphorylation or treatment
with anti-phospholamban antibody can overcome this inhibition (Table 4-1). It is this
reversibly inhibited enzyme that we focus on here.
The results of our study show that phospholamban decreased the level of Ca2+ATPase phosphorylation by Pi without affecting the [Pi]-dependence of phosphorylation
or the [Ca2+]-dependence of inhibition of E2P formation by Pi. To understand this
behavior, we considered the following model for the effect of phospholamban on Ca2+ATPase phosphoenzyme formation (Scheme 4-1).
Scheme 4-1:
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In this model, we assume a non-competitive relationship between phospholamban and Pi,
because phospholamban and Pi do not bind to the same site. This is supported by recent
crosslinking studies (8, 9, 20), which show that phospholamban binds near but not inside
of the Rossman fold within the P domain, which contains the phosphorylation site, Asp351 (21).

Hence, Pi can interact with the phospholamban-bound E2 state PLB·E2·Pi

(step 1, Scheme 4-1), but the enzyme does not progress to the phosphorylated complex,
PLB·E2-P (step 2, Scheme 4-1). Here, the initial Pi binding event is not blocked by
phospholamban. Rather, phospholamban inhibits covalent phosphorylation in the second
step by either slowing the rate of the forward reaction (k2) or by increasing the rate of the
reverse reaction (k-1). If k-1 is increased by phospholamban, the equilibrium of the
reaction will be shifted to the left and Pi will never completely phosphorylate the enzyme
even at high [Pi]. Our results show that phospholamban decreased E2P formation at
saturating Pi levels relative to Ca2+-ATPase in the absence of phospholamban, which
favors the interpretation that phospholamban increased k-1. If phospholamban slowed the
rate of formation of the inhibitory complex (k2), then the onset of Pi inhibition would be
slower and the apparent enzyme affinity for Pi would be reduced. This is because the
effect of the second step is to form a tighter phosphoenzyme complex (i.e., covalent E2P) than E2·Pi. Likewise, the forward reaction of step 2 competes with the reversal of step
1 such that if phospholamban makes step 2 slower, this would weaken the binding of Pi to
the phospholamban-Ca2+-ATPase complex, giving rise to a reduced Pi affinity. However,
this is inconsistent with our data, which showed that phospholamban did not affect the
K0.5 for Pi phosphorylation of the Ca2+-ATPase, indicating that phospholamban did not
affect the affinity, either real or apparent, of Ca2+-ATPase for Pi. Our results argue in
favor of phospholamban stabilizing the Ca2+-ATPase in the E2 state, which resists the
binding of Pi and subsequent phosphorylation. This is consistent with previous studies
showing that a conformational change is required to accept the phosphate molecule for
the formation of E2P, thus shifting the E2 + Pi → E2P equilibrium strongly toward E2P
(22, 23).
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It is generally accepted that phospholamban increases the [Ca2+] required to
produce maximal Ca2+-ATPase activity without affecting the actual Ca2+ binding affinity
of the enzyme (2, 10). When considered in conjunction with a preferential interaction
between phospholamban and the Ca2+-ATPase E2 intermediate (8, 9), Scheme 4-1 can be
generalized to account for the effect of phospholamban on the apparent Ca2+ affinity of
the Ca2+-ATPase (Scheme 4-2):
Scheme 4-2:

In the absence of substrate or ligands, the enzyme exists in equilibrium between the E2
and E1 forms (24, 25), but phospholamban will readily bind to E2 to form the inhibited
E2·PLB state (8, 9). According to the scheme, calcium binding to the Ca2+-ATPase E1
form activates the enzyme for ATP-dependent phosphoenzyme formation (10). By mass
action, calcium binding to E1 to E1·Ca2 will deplete E1, inducing E2 to convert to E1
according to the net equilibrium for this step (26). Phospholamban stabilization of the
Ca2+-ATPase E2 conformation will restrict the enzyme from transforming to the E1 state
followed by calcium binding and ATP-dependent phosphorylation. To overcome the
phospholamban shift in the E2 to E1 equilibrium, a greater [Ca2+] is required to drive the
formation of E1·Ca2, resulting in a shift in the [Ca2+]-dependence for phosphoenzyme
formation (10, 15) and ATPase turnover (15). Similarly, at sufficiently high [Ca2+], the
phospholamban effect can be completely overcome, consistent with reports that show that
phospholamban has no effect on Ca2+-ATPase Vmax at saturating Ca2+ levels (2, 13, 15,
16). Cantilina et al. (10) showed that phospholamban does not affect calcium-binding
affinity. However, in this model, no change in calcium-binding affinity is required to
account for the change in the apparent calcium affinity of the Ca2+-ATPase, because
simple mass action alone can account for the need for a greater [Ca2+] for enzyme
stimulation. Consistent with this argument, our results showed that phospholamban did
not affect the [Ca2+]-dependence of the inhibition of Ca2+-ATPase phosphorylation by Pi,
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only the level of E2P formation, as described above. Thus, phospholamban did not
decrease the affinity of the enzyme for calcium, but rather decreased the amount of
enzyme that is available for [Ca2+]-sensitive E2P formation with a concomitant decrease
in the observed E2P levels.
A final question we considered was why saturating [Pi] could not overcome the
observed phospholamban-dependent inhibition of Ca2+-ATPase phosphorylation by Pi in
this mass action model.

Only about half the available enzyme sites available are

phosphorylated by Pi, even at high [Pi], due to an equilibrium constant near unity for the
phosphorylation reaction (27). This suggests that phosphate binding to PLB·E2 may not
be strong enough to draw the enzyme entirely to the E2-P state from the PLB·E2 state.
Additional kinetics studies are underway to test this question more fully using the
phosphate analog monovanadate. Vanadate binds specifically to the Ca2+-ATPase E2
intermediate, forming a stoichiometric transition state analog of the E2P intermediate
(28-30). Furthermore, vanadate drives E2V formation to a much greater extent than Pi
drives E2P formation (27). Thus, a phospholamban-dependent change in the vanadate
inhibition profile of the Ca2+-ATPase should provide insight into the effect of
phospholamban on the ability of the Ca2+-ATPase E2 intermediate to undergo the
conformational transition to E2P, or more correctly, E2V (28, 31). The results of the
vanadate study show that phospholamban decreased Ca2+-ATPase sensitivity to vanadate,
but at sufficiently high [vanadate] the enzyme is completely inhibited. These results will
be reported elsewhere.
In conclusion, our study supports the proposal that phospholamban stabilizes the
Ca2+-ATPase in the E2 conformational state by showing that phospholamban inhibited
formation of the E2·Pi and E2-P states. Nevertheless, further physical and kinetic studies
are needed to characterize the PLB·E2 intermediate state and how it differs from the
E2·Pi and E2-P intermediate forms. When a high-resolution structure of the PLB·E2
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complex is solved, the structure of the phospholamban-bound enzyme relative to the
E1·Ca2 (21) and E2·TG (32) structures will be better understood.
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Abstract
We have used steady-state fluorescence spectroscopy to study the effect of
phospholamban on the cardiac muscle Ca2+-ATPase (SERCA) E2 to E1 conformational
equilibrium, in order to test the hypothesis that phospholamban stabilizes the Ca2+ATPase in the E2 intermediate state. Ca2+-ATPase was expressed either alone or coexpressed with phospholamban in High-Five insect cells, and isolated as insect cell
microsomes. Ca2+-ATPase in the insect cell microsomes was covalently labeled with the
probe 5-(2-((iodoacetyl)amino)ethyl) aminonaphthalene-1-sulfonic acid (IAEDANS).
[Ca2+]-jump experiments showed that the presence of phospholamban decreased the
amplitude of the Ca2+-ATPase E2 to E1 conformational transition by 45%. [Ca2+]dependence studies showed that the enzyme E2 to E1 conformational transition displayed
a hyperbolic increase with increasing [Ca2+], but the presence of phospholamban had no
significant effect on the KCa values of the curves compared to enzyme samples without
phospholamban. Using the non-hydrolyzable ATP analog AMPPNP, we also found that
phospholamban had no effect on the Ca2+-ATPase E1(Ca2) to E1(Ca2)•ATP
conformational transition. The results of our study show that phospholamban decreased
the amplitude of the E2 to E1 conformation transition, but phospholamban did not affect
the [Ca2+]-dependence of the E2 to E1 transition.

The results suggest that

phospholamban binding to the Ca2+-ATPase stabilizes the enzyme in the E2
conformational state, which resists the [Ca2+]-dependent transition to the E1 intermediate.
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Introduction
The sarcoplasmic reticulum (SR) Ca2+-ATPase is a 110 kDa integral membrane
protein that utilizes ATP to drive the transport of Ca2+ ions into the SR to promote muscle
relaxation (1).

Phospholamban, a 52-amino acid phosphoprotein, is the principal

regulator of the Ca2+-ATPase in the cardiac SR and inhibits its activity by decreasing the
apparent affinity of the ATPase for calcium (2). Phosphorylation of phospholamban at
Ser-16 or Thr-17 relieves Ca2+-ATPase inhibition, giving an increase in the rate of
cardiac muscle relaxation as well as a positive inotropic effect (3-5). Abnormal Ca2+ATPase regulation by phospholamban has been implicated as a causative factor for
diastolic dysfunction, cardiac hypertrophy, and heart failure. This has led to a great deal
of interest in understanding the physical and functional interaction between the Ca2+ATPase and phospholamban (6). Several studies have shown that mutations that effect
this interaction result in heart disease (7, 8). Therefore, a key step in understanding
important cardiac pathologies is elucidating the molecular details of the phospholamban
Ca2+-ATPase interaction (4).
A widely accepted model for the enzymatic cycle of the Ca2+-ATPase (Scheme 51) involves two fundamental conformations, E1 and E2, which couple ATP hydrolysis to
calcium transport through differences in their affinities and specificities for ATP and Ca2+
(9-11).
Scheme 5-1:

129

The resting enzyme exists as a mixture of E1 and E2 states, which represent the high
Ca2+-affinity and low Ca2+-affinity conformations of the Ca2+-ATPase, respectively. The
presence of micromolar calcium shifts the E2-E1conformational equilibrium toward
E1(Ca2) (9, 12, 13). By mass action, calcium binding to E1 to form E1(Ca2) will deplete
E1, inducing E2 to convert to E1, according to the net equilibrium for this step (14). The
E1(Ca2) state binds MgATP with high affinity (15) and this interaction triggers a
conformational change to E1′(Ca2)•ATP (16-18). ATP-dependent phosphorylation and
formation of the phosphoenzyme is followed by calcium translocation that involves a
rapid conformational change (10). After the translocation, calcium is released into the
SR lumen (10, 19) and the E2P state is hydrolyzed to E2 and Pi (20, 21), resulting in the
regeneration of the E2 conformational state.
It is well accepted that phospholamban inhibits Ca2+-ATPase by decreasing the
apparent calcium affinity of the enzyme (2). However, the physical and kinetic basis by
which this occurs is not yet fully understood. Most functional studies of phospholamban
Ca2+-ATPase interaction agree that inhibition by phospholamban occurs at very low
calcium levels, which favors the Ca2+-ATPase E2 intermediate state, whereas the
inhibition is eliminated at high calcium levels, which favors the calcium-bound E1(Ca2)
enzyme state.

For example, Jones and co-workers (22, 23) reported site-specific

crosslinking between phospholamban and Ca2+-ATPase at low calcium, which was
eliminated in the presence of micromolar calcium levels. This study demonstrates a
preferential interaction between phospholamban and the Ca2+-ATPase E2 state. However,
the mechanism by which phospholamban interaction with the Ca2+-ATPase E2 state leads
to a decreased apparent calcium affinity of the enzyme remains an open question. A
likely hypothesis is that phospholamban binding to the Ca2+-ATPase E2 state shifts the
enzyme E2 to E1 conformational equilibrium toward E2, which by mass action decreases
the site density of high affinity enzyme calcium binding sites. In this model, higher
calcium levels are needed to overcome the phospholamban stabilization of the E2 state
and drive the E2 to E1 conformational equilibrium toward E1(Ca2), giving rise to a
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change in the apparent calcium affinity of the enzyme. However, this model remains to
be tested quantitatively.
In the present study, we have used steady-state fluorescence spectroscopy to study
the effect of phospholamban on the Ca2+-ATPase E2 to E1 conformational equilibrium.
For this work, we used the baculovirus High-Five insect cell expression system to
produce cellular microsomes containing Ca2+-ATPase (the SERCA2a isoform) expressed
alone or Ca2+-ATPase co-expressed with phospholamban (24). The use of an expression
system allowed the direct comparison of the Ca2+-ATPase E2 to E1 conformational
transition in the absence or presence of phospholamban while alleviating the need to
perform physical studies on microsomes pre-treated with reagents required to physically
uncouple phospholamban from the Ca2+-ATPase (i.e., phospholamban phosphorylation or
treatment of the sample with an anti-phospholamban monoclonal antibody). We selected
the probe 5-(2-((iodoacetyl)amino)ethyl) aminonaphthalene-1-sulfonic acid (IAEDANS)
because it binds with specificity to the Ca2+-ATPase in the enzyme phosphorylation
domain, with minimal effects on Ca2+-ATPase activity. The results of our study show
that phospholamban decreased the amplitude of the E2 to E1 conformation transition, but
phospholamban did not affect the [Ca2+]-dependence of the E2 to E1 transition. The
results suggest that phospholamban binding to the Ca2+-ATPase stabilizes the enzyme in
the E2 conformational state, which resists the [Ca2+]-dependent transition to the E1
intermediate.
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Materials and Methods
Materials
IAEDANS was purchased from Molecular Probes.
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I-labeled protein A was

purchased from Perkin Elmer Life Sciences. Prestained molecular weight standards and
polyvinylidene difluoride (PVDF) membranes were purchased from Bio-Rad. High-Five
insect cells were purchased from Invitrogen, and the BaculoGold system was obtained
from Pharmingen-BD Biosciences.

All other reagents were of the highest purity

available.

Protein Expression, Isolation, and Characterization
Canine cardiac Ca2+-ATPase (the SERCA2a iosform) and canine phospholamban
were co-expressed in High-Five cells as described elsewhere (24). Microsomes were
harvested 48 h after baculovirus infections and stored in small aliquots at –50 oC. Protein
concentrations were determined by the method of Lowry et al. (25), using bovine serum
albumin (Sigma) as a standard. The amount of SERCA2a and phospholamban in the
microsomes was quantified by gel electrophoresis and immunoblotting, and the [Ca2+]dependent ATPase activity of the SERCA2a, as affected by phospholamban, were
measured using methods described previously (24).

Microsomes were also prepared

from control, uninfected cells (denoted control microsomes) and were assayed in a
similar fashion to those containing the expressed proteins. The control microsomes
contained no detectible SERCA2a or phospholamban protein.
Labeling of Ca2+-ATPase with IAEDANS
The Ca2+-ATPase expressed in insect cell microsomes was labeled by IAEDANS
according to Suzuki et al. (17) with substantial modifications. Prior to each labeling
procedure, a fresh stock of IAEDANS was prepared from powder, using
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dimethylformamide as the solvent. The microsomes (5 mg/ml) were labeled with 85 µM
IAEDANS in the presence of labeling buffer (20 mM MOPS, 80 mM KCl, 1 mM CaCl2,
5 mM MgCl2), and 5 mM ATP at pH 6.88 for 30 min at room temperature. Excess
reagent was removed by centrifugation for 30 min at 30,000 rpm (70,000 X g), 4 oC, in a
Beckman Ti45 rotor.

The pellet, containing the AEDANS-labeled Ca2+-ATPase

(henceforth denoted AEDANS-Ca2+-ATPase), was resuspended in 0.3 M sucrose, 20 mM
MOPS, 0.1 mM CaCl2 (pH 7.0). The stoichiometry of IAEDANS bound per Ca2+ATPase was determined in a solution of 1% SDS in 0.1 M NaOH, using an extinction
coefficient of 6.1 X 103 M-1·cm-1 at 340 nm (26). The amount of Ca2+-ATPase in the
sample was quantified separately by protein assay and quantitative immunoblot, as
described above. The labeling protocol used was developed by constructing labeling
curves (data not shown) to determine the relationship between the concentration of
IAEDANS in the microsome incubation mixture, the resultant ratio of bound AEDANS
to the enzyme, and Ca2+-ATPase activity at each labeling level (cf., Fig.1 in ref. [27]).
Once established, this protocol provided a reproducible method for Ca2+-ATPase labeling
that provided consistent fluorescence results.

Fluorescence Measurements
Measurements of the fluorescence intensity were performed at 25 oC using a
Photon Technology International QM-2000-4 spectrofluorimeter equipped with a cuvette
stirrer. Excitation and emission spectra of the AEDANS-Ca2+-ATPase showed optimal
excitation and emission wavelengths of 352 nm and 475 nm, respectively (data not
shown).
To measure fluorescence intensity changes following a [Ca2+]-jump, microsomal
AEDANS-Ca2+-ATPase (0.35 mg/ml) was suspended in a standard buffer (50 mM
MOPS, 100 mM KCl, 3mM MgCl2, 1 mM EGTA, pH 7.0) containing either 0 mM CaCl2
added (~ 0 µM Ca2+free, designed to favor formation of the Ca2+-free E2 state initially) or
1.0 mM CaCl2 added (~ 15 µM Ca2+free, designed to favor formation of the calcium bound
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E1(Ca2) state initially). The addition of 1.25 mM Ca2+ to the standard buffer containing ~
0 mM CaCl2 (final ionized [Ca2+] ~ 15 µM) promoted formation of the E1(Ca2)
conformation, whereas the addition of 1.25 mM EGTA to the standard buffer with 1.0
mM CaCl2 (final ionized [Ca2+] ~ 0 µM) promoted formation of the E2 conformation.
The fluorescence intensity was measured by summing the total fluorescence emission
over 20 s before (initial fluorescence intensity, Fo) and after (final fluorescence intensity,
F) the respective additions. Fluorescence intensity changes were quantified as percent
changes, according to the formula 100 x (F – Fo) / Fo.
To measure incremental [Ca2+]-dependent fluorescence changes, microsomal
AEDANS-Ca2+-ATPase (0.35 mg/ml) was suspended in the standard buffer containing 0
mM CaCl2 added (~ 0 µM Ca2+free), which favored formation of the E2 state. The initial
fluorescence intensity (Fo) of the sample was measured, and then CaCl2 was added in 0.1
mM increments up to 1 mM final Ca2+ (1.0 mM CaCl2 total added Ca2+, ~ 15 µM Ca2+free
final) in stepwise additions. The total volume of CaCl2 added was 20 µl, which had a
negligible effect on the sample volume (2 ml total). Total fluorescence emission over 20
s after each addition of CaCl2 was summed, and the percent change from the initial
fluorescence level (Fo) was determined as described above.
The effect of the non-hydrolyzable ATP analog AMPPNP on AEDANS-Ca2+ATPase fluorescence intensity was measured by suspending AEDANS-labeled Ca2+ATPase microsomes (0.35 mg/ml) initially in the standard buffer containing 1.25 mM
CaCl2 (~ 15 µM Ca2+free), which favored formation of the Ca2+-bound E1(Ca2) state. The
initial fluorescence intensity (Fo) of the sample was measured, and then AMPPNP was
added to 50 µM, 0.5 mM, or 5 mM AMPPNP by a single addition to promote formation
of the E1(Ca2)•AMPPNP intermediate state. Total fluorescence emission over 20 s after
each addition of AMPPNP was summed, and the percent change from the initial
fluorescence level (Fo) was determined as described above.
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Curve Fitting
Calcium-dependent ATPase activity data and [Ca2+]-dependent fluorescent
enhancement data were fit using the program KFIT written by N. C. Millar, which was
obtained

from

Dr.

Carl

Frieden

www.wuarchive.wustl.edu/packages/kinsim/uploads.
chosen on minimization of the sum-of-squares error, χ2.
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via

his

website:

The best fits of the data were

Results
Protein Expression and Characterization
For these studies, the SERCA2a Ca2+-ATPase isoform was expressed in HighFive insect cells alone or co-expressed with phospholamban, isolated as High-Five insect
cell microsomes, and assayed for enzyme activity and Ca2+-ATPase-phospholamban
coupling, all as detailed previously (24). Two separate preparations each were used from
the eleven Ca2+-ATPase alone and nine Ca2+-ATPase + phospholamban sample
preparations previously prepared and characterized by Waggoner et al. (24). For the
samples used in this study, the Ca2+-ATPase accounted for approximately 16% of the
protein by weight in the insect cell microsomes for both sample types, and for the
samples containing Ca2+-ATPase and phospholamban, the molar stoichiometry of the two
proteins was 1.3 ± 0.1 phospholamban to 1 Ca2+-ATPase (24).
IAEDANS Labeling of the Ca2+-ATPase
Insect cell microsomes containing Ca2+-ATPase expressed alone or Ca2+-ATPase
co-expressed with phospholamban were labeled with the fluorescence probe IAEDANS
(henceforth denoted AEDANS-Ca2+-ATPase) as described in the Methods. The labeled
Ca2+-ATPase-only sample was analyzed by SDS-PAGE (Fig. 5-1), which indicated a
single major band containing bound fluorescence probe and corresponded to the Ca2+ATPase protein band. Likewise, similar labeling results were observed for insect cell
microsomes that contained Ca2+-ATPase co-expressed with phospholamban (data not
shown). For comparison, parallel labeling studies were conducted using Ca2+-ATPase in
native cardiac SR vesicles, which produced nearly identical results (Fig. 5-1). The
stoichiometry of Ca2+-ATPase labeling by IAEDANS for the insect cell microsome
samples was approximately 1 : 1, determined by UV spectroscopic analysis of the bound
probe and protein concentration corrected for the content of Ca2+-ATPase by weight (see
Methods).
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Figure 5-1.

IAEDANS specifically labels SERCA2a in High-Five insect cell

microsomes and cardiac SR vesicles. Ca2+-ATPase expressed in insect cell microsomes
(SERCA2a) was labeled with IAEDANS, and the samples were analyzed by SDS-PAGE:
Lane 1, molecular weight standards as defined on the left; Lane 2, Coomassie stain of the
expressed SERCA2a sample, showing a predominant band at ~110 kDa corresponding to
the Ca2+-ATPase (confirmed by Western blot, not shown); Lane 3 is a photograph
(negative image is shown to enhance the proteins labeled) of the SERCA2a sample
shown in Lane 2 illuminated by a UV lightsource. The results show that the band
corresponding to the Ca2+-ATPase is the only band labeled by IAEDANS.

The bands

located between 17 and 43 kDa disappeared after washing for several hours.

We

concluded that they were unbound label. Parallel labeling studies were conducted using
Ca2+-ATPase in cardiac SR vesicles (Lane 4), which produced nearly identical results.
The stoichiometry of labeling was 1:1.
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The Ca2+-ATPase activity of the AEDANS-Ca2+-ATPase samples in the HighFive cell microsomes were measured at 37 oC at a series of ionized [Ca2+] (Fig. 5-2). The
enzyme activity displayed the typical sigmoidal [Ca2+] dependence, and the maximum
steady-state activities per mg of microsomal protein for the two sample types were 0.81 ±
0.05 µmol•mg-1•min-1 for microsomes containing AEDANS-Ca2+-ATPase expressed
alone and 0.61 ± 0.06 µmol•mg-1•min-1 for microsomes containing AEDANS-Ca2+ATPase and phospholamban. The result indicated that AEDANS-Ca2+-ATPase samples
retained greater than 80% of their pre-label activity, which was 1.00 µmol•mg-1•min-1 for
Ca2+-ATPase expressed alone and 0.75 µmol•mg total protein-1•min-1 for Ca2+-ATPase
co-expressed with phospholamban. Control experiments in our laboratory indicated the
loss of enzyme activity following labeling arose primarily from the physical handling of
the sample during the washing steps to remove unbound label and microsome
resuspension, rather than from the labeling reaction itself. Because the activity of the
Ca2+-ATPase + phospholamban preparations were depressed relative to the Ca2+-ATPase
alone preparations, we normalized the activity data from the two samples to their
respective Vmax values to facilitate a direct comparison of the [Ca2+]-dependence of the
ATPase activity for each labeled sample (Fig. 5-2). The AEDANS-labeled Ca2+-ATPAse
expressed without phospholamban had a high apparent calcium affinity (denoted as KCa,
the ionized [Ca2+] giving half-maximal activation of the Ca2+-ATPase), which was 280 ±
20 nM. In the presence of phospholamban, the AEDANS-Ca2+-ATPase activity curve
was shifted to the right relative to that of AEDANS-Ca2+-ATPase alone, resulting in an
increase in the KCa to 540 ± 20 nM (∆KCa = 260 nM; p < 0.05). Treatment of the
phospholamban-containing sample with a phospholamban monoclonal antibody, 2D12,
shifted the activation curve to the left, resulting in a two-fold decreased KCa value (310 ±
20 nM), equivalent to that obtained for AEDANS-Ca2+-ATPase in the absence of
phospholamban (p > 0.05).

The KCa values obtained for the labeled samples were

nearly identical to those obtained for the samples prior to labeling (24). This result
indicated that labeling the Ca2+-ATPase with IAEDANS did not significantly affect the
physical or functional effects of phospholamban on the enzyme.
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Figure 5-2. Effect of phospholamban on [Ca2+]-dependent Ca2+-ATPase activity.
The ATPase activity of High-Five cellular microsomes containing either the IAEDANS
labeled Ca2+-ATPase expressed alone (□) or co-expressed with phospholamban (○, ●)
was measured at 37 oC using 5 mM MgATP in 50 mM MOPS (pH 7.0), 3 mM MgCl2,
100 mM KCl, 1 mM EGTA and various [Ca2+] (between 0 – 1mM) to promote an ionized
[Ca2+] between 10 nM and 10 µM. Regulatory phospholamban decreased the apparent
calcium affinity of the Ca2+-ATPase (i.e., increased the [Ca2+] required for half-maximal
activity) relative to the sample treated with anti-PLB monoclonal antibody 2D12 (●),
which uncoupled phospholamban from the Ca2+-ATPase. The presence of the IAEDANS
label had no effect on the inhibitory interaction between phospholamban and SERCA2a.
The data were normalized to the calculated Vmax for both of SERCA2a and SERCA2a +
phospholamban samples, respectively. Curves represent the nonlinear least squares fits
to the Hill equation for the data. Symbols represent the average of the activity (n = 3)
and the error bars represent the standard error of the mean.
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The Effect of Phospholamban on the Distribution of the E2 and E1 Intermediate States
The fluorescence intensity of AEDANS-Ca2+-ATPase is sensitive to the Ca2+ATPase E1to E2 conformational transition (28). To test the effect of phospholamban on
the E2 to E1 equilibrium, we measured Ca2+-dependent changes in AEDANS-Ca2+ATPase fluorescence for the labeled enzyme alone or co-expressed with phospholamban
in insect cell microsomes suspended in experimental buffer, which contained 50 mM
MOPS, pH 7.0, 3 mM MgCl2, 100 mM KCl and variable amounts of EGTA and CaCl2 as
indicated. The addition of calcium to samples pre-incubated in EGTA (to promote
formation of the enzyme E2 state initially) increased AEDANS-Ca2+-ATPase
fluorescence intensity, indicating a shift toward the enzyme E1 state (Fig. 5-3, left panel),
whereas the addition of EGTA to samples pre-incubated in calcium (to promote
formation of the enzyme E1 state initially) decreased AEDANS-Ca2+-ATPase
fluorescence intensity, indicating a shift toward the enzyme E2 state (Fig. 5-3, right
panel).

Specifically, addition of 1.25 mM Ca2+ to AEDANS-Ca2+-ATPase-only

microsomes pre-incubated in experimental buffer containing 0 mM CaCl2 (change in free
[Ca2+] from ~ 0 to 15 µM) increased the fluorescence intensity of the sample by 11.01 ±
0.54% (n = 6), whereas the fluorescence intensity of the AEDANS-Ca2+-ATPase +
phospholamban sample increased only by 6.09 ± 0.2% (n = 6). Thus, the presence of
phospholamban decreased the E2 to E1 conformational shift by 45% (p < 0.05). When
1.25 mM EGTA was added to AEDANS-Ca2+-ATPase-only microsomes pre-incubated in
experimental buffer containing ~ 1.0 mM CaCl2 (change in free [Ca2+] from 15 µM to ~
0) decreased the fluorescence intensity of the sample by 10.74 ± 0.98% (n = 6), whereas
the fluorescence intensity of the AEDANS-Ca2+-ATPase + phospholamban sample
decreased the fluorescence intensity by only 5.73 ± 0.19% (n = 6). Therefore, the
presence of phospholamban decreased the E1 to E2 conformational shift by 46% (p <
0.05), similar to the result above. The results suggested that phospholamban promoted a
larger fraction of AEDANS-Ca2+-ATPase E2 state than that observed in the absence of
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Figure 5-3. [Ca2+]-jump dependent fluorescence intensity changes of AEDANSCa2+-ATPase at 25 oC. Fluorescence intensity changes were measured in standard
buffer containing either 1 mM EGTA (control, E2 state) or 15 µM Ca2+(Free) (control, E1
state) at 25 oC. The addition of 1.25 mM calcium (final ionized [Ca2+] ~ 15 µM)
promoted formation of the E1(Ca2) conformation (left panel) for the SERCA2a alone
sample (shaded). The presence of phospholamban (open) decreased the fluorescence
intensity by a significant 45% (p < 0.05). In the second experiment, the IAEDANSlabeled samples were incubated first in buffer containing ~ 15 µM ionized calcium to
promote formation of the E1(Ca2) conformation (right panel). The addition of 1.25 mM
EGTA decreased the free calcium to near zero, promoting the E2 conformation. The
presence of phospholamban decreased the fluorescence intensity associated with the shift
from E1 to E2 by a significant 46% (p < 0.05) compared to the SERCA2a alone sample.
Data represent the average of six experiments and the error bars represent the standard
error of the mean.
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phospholamban, concomitant with a smaller amplitude of transition between the enzyme
E2 and E1 states, even after preincubation at saturating [Ca2+].
Identical experiments using insect cell microsomes (denoted control microsomes)
from uninfected cells were also conducted. SDS-PAGE gels of the IAEDANS-labeled
control microsomes contained no discernable fluorescence bands (data not shown).
Nevertheless, control microsomes labeled with IAEDANS pre-incubated in experimental
buffer containing 0 mM CaCl2 (~ 0 µM Ca2+free) displayed a 1.55 ± 0.41% (n = 6)
increase in fluorescence intensity after the addition of 1.25 mM Ca2+. The addition of
1.25 mM EGTA to IAEDANS-labeled control microsomes pre-incubated in experimental
buffer containing 1.0 mM CaCl2 (~ 15 µM Ca2+free) resulted in a 0.58 ± 0.12% (n = 6)
decrease in AEDANS fluorescence.

To determine whether these fluorescence changes

arose from nonspecific binding of the probe to microsomal proteins or to any endogenous
SERCA present in the insect microsomes (which might be affected by phospholamban),
we repeated the control microsome fluorescence experiments in the presence of
thapsigargin. Thapsigargin is known to bind to SERCA and lock the enzyme into the E2
state (29), thus preventing the E2 to E1 conformational change in the presence of
calcium. The addition of thapsigargin to the samples had negligible effects on the
fluorescence intensity changes. Therefore, we conclud that the fluorescence intensity
change observed for the control microsomes was the result of nonspecific binding of the
IAEDANS probe to non-SERCA proteins.
[Ca2+]-Dependence of E2 to E1 Conformational Transition
The [Ca2+]-jump experiments indicated that phospholamban decreased the
amplitude of the AEDANS-Ca2+-ATPase E2-E1 conformational transitions by shifting
the equilibrium toward the E2 state. To determine the effect of phospholamban on the
[Ca2+]-dependence of the E2 to E1 conformational transition, we measured the
fluorescence intensity of AEDANS-Ca2+-ATPase during the stepwise addition of calcium
in 0.1 mM amounts to microsomes pre-incubated in experimental buffer containing 1
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mM EGTA to promote formation of the AEDANS-Ca2+-ATPase E2 state initially. The
titration provided ionized [Ca2+] between 0.01 µM and 15 µM, with the concomitant
progression of the enzyme to the E1 state. For both the AEDANS-Ca2+-ATPase only and
AEDANS-Ca2+-ATPase + phospholamban microsomal samples, the fluorescence
intensity change of each sample type displayed a hyperbolic increase with increasing
[Ca2+] (Fig. 5-4). There was a significant difference between the maximum levels of
fluorescence intensity change between the two sample types: microsomes containing
AEDANS-Ca2+-ATPase only displayed a maximum fluorescence change of 9.14 ± 0.14%
(n = 4), whereas the presence of phospholamban resulted in a 38% decrease in the
maximum fluorescence intensity change to 5.69 ± 0.38% (n = 4).

In contrast,

phospholamban had no significant effect on the KCa values of the curves:

for the

2+

AEDANS-Ca -ATPase only microsomes, the KCa was 137 ± 31 nM, whereas the
AEDANS-Ca2+-ATPase + phospholamban microsomes displayed a KCa of 378 ± 130 nM
(p > 0.05).

Identical experiments using insect cell microsomes (denoted control

microsomes) from uninfected cells were also conducted. The addition of calcium to the
samples had negligible effects on the [Ca2+]-dependence fluorescence intensity changes.
Effect of Phospholamban on the Formation of the E1(Ca2)•ATP Complex Using the Nonhydrolyzable ATP Analog AMPPNP
Obara et al. (28) reported that AEDANS-Ca2+-ATPase fluorescence detects an
enzyme conformational change that accompanies ATP binding to the E1 intermediate in
the presence of Ca2+ [denoted E1(Ca2+)] to form E1(Ca2)•ATP.

Therefore, we

investigated the effect of phospholamban on this conformational transition, to test the
ability of the E1(Ca2) intermediate state to undergo a conformational transition in the
presence of phospholamban.

It is well accepted that saturating [Ca2+] uncouples

phospholamban from the Ca2+-ATPase (2), suggesting that phospholamban should have
no effect on the E1(Ca2) to E1(Ca2)•ATP transition. For these experiments, we measured
AEDANS-Ca2+-ATPase fluorescence intensity following the addition of the nonhydrolyzable ATP analog AMPPNP to the enzyme pre-incubated in experimental buffer
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Figure 5-4. Effect of phospholamban on the [Ca2+]-dependence of AEDANS-Ca2+ATPase fluorescence intensity at 25 oC. Insect cell microsomes containing IAEDANSlabeled expressed SERCA2a alone (●) or with co-expressed phospholamban (○) were
incubated initially in 1 mM EGTA, and CaCl2 was added in 0.1 mM increments up to 1
mM final Ca2+ (~15 µM ionized Ca2+).

After each addition of calcium, the resulting

increase in IAEDANS fluorescence intensity was recorded and plotted as a percent
change.

The IAEDANS fluorescence intensity change displayed a hyperbolic

dependence on ionized [Ca2+], with a KCa of 137 ± 31 nM for the SERCA2a alone (n = 4)
and a KCa of 378 ± 130 nM with phospholamban present (n = 4). These values were not
significantly different (p > 0.05).

In contrast, the amplitude of the curve for the

SERCA2a + phospholamban samples was 38% lower than the curve for the SERCA2a
alone samples and was significantly different (p < 0.05). Curves represent the nonlinear
least squares fit to a hyperbolic function for the data.
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containing 1.0 mM EGTA + 1.0 mM CaCl2 (ionized [Ca2+] = 15 µM).

Three

concentrations of AMPPNP were utilized: 50 µM to study high affinity nucleotide
binding effects, an intermediate level of 0.5 mM, and saturating level of 5 mM (Fig. 5-5).
The addition of AMPPNP to the AEDANS-Ca2+-ATPase samples resulted in a
[AMPPNP]-dependent decrease in fluorescence intensity, similar to that reported by
Obara et al. (28).

For convenience, these fluorescence intensity changes are plotted as

absolute values in Figure 5-5. Addition of 50 µM AMPPNP to microsomes containing
AEDANS-Ca2+-ATPase only changed the fluorescence intensity by 0.64 ± 0.20% (n = 6),
whereas the AEDANS-Ca2+-ATPase + phospholamban sample fluorescence intensity
changed by 0.95 ± 0.33% (n = 6). The addition of 0.50 mM AMPPNP to IAEDANSCa2+-ATPase-only sample changed the fluorescence intensity by 1.86 ± 0.70% (n = 6)
compared to a change of 2.66 ± 0.49% (n = 6) for the AEDANS-Ca2+-ATPase +
phospholamban sample. The addition of 5 mM AMPPNP to AEDANS-Ca2+-ATPase
sample resulted in a 6.70 ± 0.19% (n = 6) change in fluorescence, which was almost
identical to the fluorescence change observed for AEDANS-Ca2+-ATPase in the presence
of phospholamban, 6.83 ± 77% (n = 6). As expected, none of the fluorescence intensity
changes were significantly different (p > 0.05) between the AEDANS-Ca2+-ATPase only
and the AEDANS-Ca2+-ATPase + phospholamban samples. The results confirmed that
phospholamban had no direct effect on the ability of the E1(Ca2) intermediate to undergo
a conformational transition. Thus, we concluded that phospholamban inhibited the Ca2+ATPase E2 to E1 conformational equilibrium by disrupting the ability of the E2 state to
undergo a conformational change, without any direct effects on the E1 intermediate state.
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Figure 5-5.

Effect of phospholamban on the E1(Ca2) to E1(Ca2)•AMPPNP

conformational equilibrium at 25 oC. Insect cell microsomes containing IAEDANSlabeled expressed SERCA2a alone (shaded) or with co-expressed phospholamban (open)
were incubated initially in the standard buffer containing 1.0 mM CaCl2

(15 µM

Ca2+(Free)). 50 µM, 0.5 mM, or 5 mM of AMPPNP was added to promote formation of
the transition state E1(Ca2)•AMPPNP. After each addition of AMPPNP, the resulting
decrease in IAEDANS fluorescence intensity was recorded as an absolute value for
convenience and plotted as a percent change.

There was no significant difference

between the SERCA2a alone samples and the samples with SERCA2a + phospholamban
at each level of AMPPNP added (p > 0.05).

Data represent the average of six

experiments and the error bars represent the standard error of the mean.
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Discussion

Summary of Results
We have used fluorescence spectroscopy to determine the effect of
phospholamban on the Ca2+-ATPase E2 to E1 conformational change in order to test the
hypothesis that phospholamban stabilizes the enzyme in the E2 conformation.

Our

labeling studies (Fig. 5-1 and Fig. 5-2) showed that the Ca2+-ATPase was the only protein
in the insect cell microsomes that was significantly labeled by IAEDANS and that
IAEDANS labeling of the Ca2+-ATase had no effect on the functional coupling or
inhibitory interaction of phospholamban with the enzyme. The results validated the
feasibility of using AEDANS-Ca2+-ATPase to measure the effects of phospholamban on
the Ca2+-dependent E2 to E1 enzyme conformational change. The [Ca2+]-jump (Fig. 5-3)
and

[Ca2+]-dependence

(Fig.

5-4)

fluorescence

experiments

indicated

that

phospholamban decreased the amplitude of the E2 to E1 conformational transition
without affecting the [Ca2+]-dependence of this transition.

Additional studies of

AMPPNP binding to the AEDANS-Ca2+-ATPase E1(Ca2) state showed that
phospholamban did not affect this conformational transition, confirming many previous
observations that phospholamban does not appreciably affect the Ca2+-ATPase E1(Ca2)
state. Therefore, we conclude that phospholamban inhibits the Ca2+-ATPase E2 to E1
transition by specifically interacting with the E2 state (22, 23, 30) and stabilizing the
enzyme in this conformation, making it resistant to the E2 to E1 conformational change.
Likewise, in the presence of calcium, enzyme bound to phospholamban is already in the
E2 state, giving rise to a smaller amplitude of transition from E1 to E2 when calcium is
removed from the medium (Fig. 5-3). That phospholamban did not change the [Ca2+]dependence of the E2 to E1 transition is consistent with this model, since enzyme affinity
for calcium is not dependent on the concentration of enzyme.
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The Ca2+-ATPase has been studied previously using various fluorescent probes,
but the most widely used probes for fluorescent studies are fluorescein isothiocyanante
(FITC)

and

5-(2-((iodoacetyl)amino)ethyl)

aminonaphthalene-1-sulfonic

acid

(IAEDANS) (17, 31, 32, 33, 34). FITC specifically labels Lys-515 in the Ca2+-ATPase
nucleotide-binding domain (35, 36), resulting in the inhibition of ATP binding to the
Ca2+-ATPase and thus, inhibition of ATP-dependent Ca2+-ATPase activity (37, 38). In
contrast, IAEDANS specifically labels Cys-674 (17) in the phosphorylation domain of
the Ca2+-ATPase (36, 39, 40), and covalent modifications with IAEDANS results in little
or no Ca2+-ATPase inhibition (17, 41).

Unfortunately, the emission intensity of

IAEDANS is much weaker than that of FITC due to differences in the quantum yields for
the two compounds.

Likewise, the fluorescence intensity change of IAEDANS
2+

associated with the Ca -ATPase E2 to E1 conformational transition is smaller than that
of FITC, partly because of smaller structural changes in the phosphorylation domain
(IAEDANS) compared to the nucleotide binding domain (FITC) during this transition
(39). However, as mentioned above, labeling the Ca2+-ATPase with FITC results in
enzyme inhibition, whereas IAEDANS does not. Furthermore, the IAEDANS probe is
sensitive to a number of conformational changes associated with specific steps in the
Ca2+-ATPase cycle (28). This makes IAEDANS the fluorescence probe of choice for
correlating physical and kinetic studies of the effects of phospholamban on the Ca2+ATPase E2 to E1 transition.
Stabilization of the Ca2+-ATPase by Phospholamban
It is now fairly well accepted that phospholamban interacts specifically and most
potently with the Ca2+-ATPase E2 state (2, 22, 23, 30).

However, it is not well

understood how this interaction leads to Ca2+-ATPase inhibition. Some studies suggest
that phospholamban affects the kinetics of individual partial reactions of the enzyme
cycle other than those involving E2 (42, 43) whereas others suggest that phospholamban
transiently holds the enzyme in the E2 state (23), thereby delaying enzyme reentry into
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the cycle. The latter model is appealing, because it can account for the phospholambandependent decrease in the apparent Ca2+-affinity of the enzyme.

If phospholamban

transiently holds the Ca2+-ATPase in the E2 state, this interaction can be overcome by
increasing the [Ca2+]. By mass action, the increased calcium would pull the enzyme
entirely over to E1(Ca2), but increased [Ca2+] would be required. Equally intriguing is the
question about whether phospholamban binds to all Ca2+-ATPase units in the membrane,
thereby decreasing total calcium transport activity by decreasing slightly the activity of
all pumps as a whole, or whether phospholamban interacts with a small subset of pumps,
thereby decreasing total calcium transport activity by inactivating completely a subset of
pumps while leaving the majority of pumps unaffected. Our results support the model
whereby phospholamban binding to E2 has a more definitive effect on the enzyme than a
simple transient interaction that delays the E2 to E1 transition. Because our fluorescence
results show an amplitude effect, we propose that phospholamban binds to a fraction of
the Ca2+-ATPase in the E2 state and holds (i.e., stabilizes) the enzyme in an inactivated
state. Our calcium titration results argue against a mass action model, in that calcium
could not overcome the phospholamban-dependent depression of the maximum change in
fluorescence intensity, even at very high [Ca2+] (Figures 5-3 and 5-4). Therefore, we
conclude that the fraction of Ca2+-ATPase associated with phospholamban is blocked
from undergoing the Ca2+-dependent E2 to E1 conformational transition.
Two other kinetics studies in our laboratory provide additional support for this
model. Waggoner et al. (Chapter 4, manuscript in preparation) studied the effect of
phospholamban on Ca2+-ATPase phosphorylation by inorganic phosphate (Pi). Inorganic
phosphate binds reversibly to the Ca2+-ATPase E2 state, promoting formation of the
covalently bound E2-P intermediate state. Similarly, Mahaney et al. (44) studied the
effect of phospholamban on Ca2+-ATPase phosphorylation by ATP, starting with the
enzyme in the Ca2+-free E2 intermediate state. Because ATP can only phosphorylate the
E1(Ca2) form of the enzyme, the phosphorylation kinetics were dependent on the E2 to
E1 transition. The results of these studies were similar: phospholamban decreased the
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amplitude (i.e., the amount) of enzyme phosphorylation in each study without affecting
the affinity for Pi or the rate of ATP-dependent phosphorylation. Since reaction rates and
ligand affinities do not depend on the concentration of active enzyme, but the amount of
phosphorylated enzyme does, we concluded, similar to the present study, the
phospholamban stabilized a fraction of the total Ca2+-ATPase in the E2 state and
prevented its transformation to a phosphorylated intermediate.
obtained in inhibition studies in our laboratory.

Similar results were

Mahaney and Jones (unpublished

observations) studied the effect of phospholamban on monovanadate inhibition of the
Ca2+-ATPase. Monovanadate is an analog of Pi, which binds irreversibly to the enzyme
E2 state to form the dead-end complex E2V, a structural analog of the E2P intermediate.
Likewise, Mahaney et al. (29) studied the effect of phospholamban on thapsigargin
inhibition of the Ca2+-ATPase. As mentioned above, thapsigargin binds irreversibly to
the enzyme E2 state, locking it into the TG E2 form.

In both of these studies,

phospholamban decreased the sensitivity of the Ca2+-ATPase to these inhibitors,
consistent with the interpretation that phospholamban held a fraction of the enzyme in a
state that was unresponsive to these agents.
By definition, the Ca2+-ATPase E2 state is the enzyme state that is reactive
towards Pi, monovanadate, thapsigargin, and in the presence of calcium will transform to
the E1 state (39). Chemical cross linking studies also show that conditions that favor
formation of the Ca2+-ATPase E2 intermediate state (i.e., very low [Ca2+]) also favor the
association of phospholamban with the enzyme (22, 23). However, our results show that
the phospholamban-associated enzyme is resistant to ligands that bind specifically to the
E2 state. Therefore, we propose that the phospholamban-associated enzyme is in a
conformation that is structurally distinct from E2, yet still possesses many of the
attributes of the E2 state. As such, phospholamban binding to the Ca2+-ATPase will
sequester the enzyme into a separate state that reduces enzyme reactivity toward the E2specific ligands, while at the same time reducing the number of enzyme units that can
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undergo the Ca2+-dependent E2 to E1 conformational transition, as shown in the present
study. This is depicted in the scheme below:
Scheme 5-2:

A recent study (45) demonstrated that the Ca2+-ATPase E2 structure is altered slightly by
the binding of phospholamban. Specifically, the orientation of the N domain is very
similar to that of the E2 intermediate, but it is rotated approximately 10o. The authors
stated that the interaction of phospholamban with the Ca2+-ATPase stabilized the
backbone of phospholamban and this in turn altered the range of motion of the N domain.
Given the direct linkage of the N-domain with the P-domain and the transmembrane
helices, this phospholamban-dependent change could easily account for differences in
enzyme reactivity toward ligands that bind specifically to the Ca2+-ATPase E2
intermediate form reported by our laboratory.

Conclusions and Future Directions
We have used fluorescence spectroscopy to show that phospholamban stabilizes
the Ca2+-ATPase in an E2-like conformational state. However, several key questions
remain. We need to know to what extent phospholamban holds the Ca2+-ATPase in the
E2 form.

We found that saturating [Ca2+] could not overcome the phospholamban

depression of the fluorescence intensity, suggesting that phospholamban inhibited a
fraction of enzyme even at high calcium levels. Future studies to examine the ability of
phospholamban phosphorylation or treatment with an anti-phospholamban monoclonal
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antibody to uncouple phospholamban from the enzyme should help resolve this question.
Likewise, it is important to know what fraction of enzyme is held in the inhibited state by
phospholamban.

Future studies using site-specific cross linking methods like those

described above should provide this insight. Finally, we are interested in exploring
further the nature of the E-state that is formed by association of the enzyme with
phospholamban. Additional spectroscopic and protein chemistry experiments should
help to test the validity of this state as a unique structure of the enzyme, and to better
define this state.
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Chapter 6: Discussion
The overall objective of this dissertation research was to determine the physical
mechanism by which phospholamban regulates Ca2+-ATPase kinetics and, in particular,
how phospholamban physically reduces Ca2+-ATPase affinity for calcium. Our goal was
to test the hypothesis that phospholamban disrupts the Ca2+-ATPase E2 to E1
conformational change, which facilitates high affinity calcium binding to the enzyme E1
state. To test this hypothesis and its alternatives, we used fluorescence spectroscopy to
measure the physical effects of phospholamban on the Ca2+-ATPase E2 to E1
conformational change correlated with kinetic measurements of inorganic phosphate (Pi)
binding to the E2 state. We used the baculovirus insect cell expression system to produce
large amounts of microsomal vesicles from High-Five insect cells that contained either
SERCA2a expressed alone or SERCA2a co-expressed with phospholamban.
Several groups have developed expression systems to produce wild type and
mutant forms of Ca2+-ATPase and phospholamban for in vitro physical and functional
studies. Most notably, the baculovirus-Sf21 insect cell method developed by Autry and
Jones (1997) has been the most beneficial in producing Ca2+-ATPase and phospholamban
in sufficient quantities for detailed physical, functional and kinetics studies. However,
certain spectroscopic experiments, such as electron paramagnetic resonance (Southall et
al., 2001), and kinetics experiments, such as rapid-mixing kinetics (Froehlich et al.,
2002), require even larger amounts of protein, especially if these studies are conducted in
parallel to correlate directly spectroscopic and kinetic data using the same preparation
(Mahaney et al., 2003).

It was advantageous to modify the baculovirus-insect cell

expression system to utilize cells in a serum-free medium that could produce large
amounts of microsomal Ca2+-ATPase and phospholamban with physical and functional
properties similar to those of the proteins in native cardiac SR vesicles. In chapter 3 we
described a baculovirus expression system using High-Five insect cells that produced
large amounts of microsomal vesicles, which contained either SERCA2a expressed alone
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or SERCA2a co-expressed with phospholamban. Detailed analyses of the preparations
indicated that the expressed proteins had physical and functional characteristics similar to
those observed for the Ca2+-ATPase and phospholamban in native cardiac SR vesicles.
The results validated the preparations for use in biochemical and biophysical
experiments. After optimizing this system for expressing large quantities of the Ca2+ATPase, we were then able to proceed with experiments to test our hypothesis that
phospholamban disrupts the Ca2+-ATPase E2 to E1 conformational change.
We used our expressed Ca2+-ATPase and phospholamban samples to measure the
effect of phospholamban on cardiac muscle Ca2+-ATPase phosphorylation by
radiolabeled Pi, in order to test the hypothesis that phospholamban stabilizes the Ca2+ATPase in the E2 intermediate state. The results of our study, described in Chapter 4,
showed that phospholamban decreased the level of Ca2+-ATPase phosphorylation by Pi
without affecting the [Pi]-dependence of phosphorylation or the [Ca2+]-dependence of
inhibition of E2P formation by Pi. These results suggested that phospholamban stabilized
the Ca2+-ATPase in the E2 conformation, which would decrease the number of E2 units
that could be available to bind phosphate to form the E2-P complex.
We then used fluorescence spectroscopy to determine the effect of
phospholamban on the Ca2+-ATPase E2 to E1 conformational change. The fluorescence
intensity of the covalently bound IAEDANS probe was sensitive to the E1/E2
conformational changes in the Ca2+-ATPase. Our results, described in Chapter 5, showed
that phospholamban decreased the amount of Ca2+-ATPase that underwent the E2 to
E1(Ca2) transition in response to Ca2+. This suggested that phospholamban held the
Ca2+-ATPase in a conformation that did not allow the enzyme to undergo the transition
from E2 to E1 or E1 to E2. We then measured the [Ca2+]-dependence of the E2 to E1
conformational transition.

These results also supported our hypothesis that

phospholamban stabilized the Ca2+-ATPase in a non-E1 conformation, resulting in a
decreased amplitude of the E2 to E1(Ca2) transition without affecting the calcium
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sensitivity of the transition. Finally, we measured the conformational change that is
associated with formation of the Michaelis complex, E1(Ca2) to E1(Ca2)ATP. We saw
no difference in the amplitude of the conformational change associated with formation of
the Michaelis complex between the SERCA2a alone samples and the SERCA2a +
phospholamban samples. Therefore, we concluded that phospholamban had no effect on
this conformational change; rather, phospholamban inhibited the E2 to E1 conformational
change by stabilizing the enzyme E2 state.
A popular assumption for Ca2+-ATPase studies and molecular models is that
phospholamban stabilizes the Ca2+-ATPase in the E2 conformational state. Indeed, our
results with Pi phosphorylation and fluorescence spectroscopy support the model
whereby phospholamban stabilizes the calcium pump E2 state.

However, there are

certain aspects of our data that do not fit the simple E2 to E1 transition model. We find
that phospholamban binds to and sequesters a fraction of enzyme into an E2-like state
that is resistant to the conformational change that accompanies the E2 to E1 transition
(Ch. 5) and phosphorylation by Pi (Ch.4).
fluorescence studies.

This is particularly striking from our

It is generally accepted that saturating [Ca2+] can overcome

phospholamban inhibition of the enzyme, but we found that saturating [Ca2+] could not
overcome phospholamban stabilization of the E2 state. Therefore, we proposed an
alternate enzyme state for phospholamban binding, specifically “E”, which most likely is
E2-like based on the IAEDANS fluorescence properties (Ch. 5) and chemical crosslinking studies (Jones et al. 2002). In support of this argument, a recent study (Li et al.,
2004) showed that the orientation of the N domain of the Ca2+-ATPase is altered by
phospholamban binding, which stabilizes the N-domain into a conformation that is
similar to that of E2, but rotated approximately 10o.

The authors stated that the

phospholamban interaction with the Ca2+-ATPase stabilized the backbone of
phospholamban and this in turn altered the range of motion of the N domain. The limited
range of motion would result in a decreased efficiency of nucleotide utilization and
phosphoryl transfer, thus breaking the connection between ATP hydrolysis and calcium
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transport. Therefore, this is good evidence for a distinct E2-like state of regulation by
phospholamban. This phospholamban-dependent conformation needs to be tested more
quantitatively, and will be a focus of future experiments in the lab.
Recent cross linking studies (Jones et al., 2002; Chen et al., 2003) have been used
to determine the location of interaction between phospholamban and the Ca2+-ATPase.
We know from these studies that the E state must resemble the E2 state, and probably the
E2P state, since vanadate did not have any affect on the phospholamban:Ca2+-ATPase
cross link. These studies also showed that the presence of thapsigargin, which locks the
enzyme into the E2-TG state (which is distinct from the E2 state (Hutter et al., 2000)) and
prevents the binding of ATP to the Ca2+-ATPase (DeJesus, 1993; Inesi, 1992), also
prevented cross linking to phospholamban (Jones et al., 2002; Chen et al., 2003). While
these studies support the model of phospholamban stabilization of the calcium pump E2
state, they could also be interpreted in terms of a separate E·PLB state that could stabilize
the enzyme in a state that hinders the Ca2+-ATPase’s ability to bind calcium or Pi.
There are also alternate models for Ca2+-ATPase function apart from the
traditional E1E2 model (Jencks, 1989; Tanford, 1984; Scarborough, 2002; Scarborough,
2003a; Scarborough, 2003b). Most of the models still have similar mechanisms and
partial reactions, but different explanations of the vectoral specificity of calcium
transport. However, all of the models use the known crystal structures of the Ca2+ATPase in a calcium and calcium free environment (Toyoshima et al., 2000; Toyoshima
and Nomura, 2002; Xu et al., 2002) and these structures show different conformational
states that exist in the absence and presence of calcium. Nevertheless, we stayed with the
traditional E2E1 model due to the overwhelming evidence in the literature that supports
this model. Likewise, there are a growing number of molecular models, based on the
crystal structures of the Ca2+-ATPase (either as is or slightly refolded) and the solution
structures of phospholamban (Li et al., 2004; Toyoshima et al., 2003; Hutter et al., 2002).
Still, the modeling of the phospholamban:Ca2+-ATPase interaction is just that, modeling.

161

Currently, there is no crystal structure available with phospholamban and the Ca2+ATPase present. Therefore, the physical interaction of phospholamban and the Ca2+ATPase remains an open question. When a Ca2+-ATPase-phopholamban co-crystal
structure is obtained, it will go a long way toward helping the field understand the
mechanism of regulation of the Ca2+-ATPase by phospholamban.
This work has contributed to the field of Ca2+-ATPase research in a number of
ways. It is fairly well established now that phospholamban binds to the Ca2+-ATPase E2
(or E2 like) state, but little is known about how this interaction affects enzyme activity.
For example, does the phospholamban-Ca2+-ATPase interaction block all conformational
changes, and thereby inhibit enzyme activity, by effectively decreasing the enzyme
concentration?

This is the thermodynamic inhibition model. Or does bound

phospholamban decrease the rate of certain partial reactions in the enzyme cycle and
thereby slowing enzyme turnover? This is the kinetic inhibition model. Our results
argue in favor of the thermodynamic inhibition model, where phospholamban decreases
enzyme concentration.
The link between abnormal Ca2+-ATPase:phospholamban interaction and heart
disease is well established. Determination of the regulation of phospholamban inhibitory
properties of the Ca2+-ATPase is a major focus of therapies aimed at rescuing the failing
heart (MacLennan and Kranias, 2003; Marx, 2003; Schmitt et al., 2003; Schwinger and
Frank, 2003). However, designing these therapies to disrupt or alter phospholamban’s
inhibition on the Ca2+-ATPase will require determining the mechanism of inhibition of
the Ca2+-ATPase by phospholamban. We believe this work has taken us a step closer to
this goal.
As for future work, there are some studies that would build on the progress
accomplished by this dissertation work. 1) We could repeat some of the kinetic and
fluorescence experiments with even more varied calcium levels, including greatly
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elevated [Ca2+] to try to uncouple phospholamban from the enzyme. This would give us
an even broader grasp of what is occurring between phospholamban and the Ca2+-ATPase
over the course of a contraction and relaxation cycle. 2) There are mutants, both in the
Ca2+-ATPase and phospholamban that we would like to use in these experiments to
provide more insight in to the physical coupling of phospholamban and the Ca2+-ATPase.
For example, point mutations are known that shift the E2 to E1 conformational
equilibrium toward E2, even in the presence of high Ca2+, and specific phospholamban
mutations are known that affect the potency of phospholamban inhibition. With the
availability of molecular modeling, we could also identify novel mutations that would
affect the interaction between the two proteins and then test these mutants kinetically and
spectroscopically. 3) We could also perform vanadate inhibition studies. Monovanadate
is a structural analog of inorganic phosphate, which binds stoichiometrically to the Ca2+ATPase. The advantage of using vanadate over Pi is that it converts the Ca2+-ATPase
100% to the E2V state, allowing clearer conclusions about the effect of phospholamban
on the E2 to E2V transition compared to the E2 to E2P transition. 4) Last, and probably
the most important follow up studies would involve cross linking studies. The E1 and E2
states of the Ca2+-ATPase have been characterized using various enzymes for digestion.
The more compact structure of the E2 state shows more resistance to certain proteinases
than the more open E1 state. It would be interesting to cross link phospholamban with
the Ca2+-ATPase and determine if this alters Ca2+-ATPase resistance to the proteinases
compared to the E2 or E1 states. If it does, it would suggest that phospholamban is
stabilizing the calcium pump in an E2-like state distinct from either E2 or E1, which
would argue in favor of our hypothesis.
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Additional Tables and Figures

168

Table A-1
Isolation of SERCA2a expressed in High-Five insect cellsa
Preparation
Fractionb
Homogenate
1,075g Spin (S)
9,680g Spin (S)
52,885g Spin (P)
a

Volume
(mL)
272
267
310
11.4

Protein
(mg)
2660
1607
1742
93

Activityc
(U)
425
208
162
63

Specific
Activityd(U mg-1)
0.16
0.13
0.09
0.68

Yield
(%)
100
47
37
15

Fold
Purification
1
0.95
0.68
5

Representative data obtained from a single SERCA2a preparation. The starting

material was 1.2 L of cell culture. The average expression and activity data for all
SERCA2a preparations are presented in Table 3-2.
b

Preparation fractions denoted as supernatant (S) or resuspended pellet (P).

c

ATPase activity assays of each sample were done at 37 oC as described in Fig. 3-

3. Activity units U defined as µmol Pi produced•min-1.
d

Specific activity is defined as U per mg of total microsomal protein.
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Figure A-1. Immunofluorescent detection of the nucleus in control cells and cells
infected with Ca2+-ATPase and phospholamban baculoviruses.

SERCA2a and

phospholamban were expressed in High-Five cells grown in tissue culture chambered
slides. The short chain carbocyanine DiOC6, which stains primarily ER membranes, was
used as a background stain in both pictures and is colored green. The cell nucleus was
visualized with 4’, 6’-diamidino-2-phenylindole (DAPI) and is colored blue in both
pictures.

A.

Control cells that were not infected with either the Ca2+-ATPase or

phospholamban baculoviruses. B. Cells that were infected with the Ca2+-ATPase or
phospholamban baculoviruses.
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Figure A-2.

Immunofluorescent detection of Ca2+-ATPase and phospholamban

expression in control microsomes.

High-Five cells were grown in tissue culture

chambered slides. These control cells were not infected with either baculovirus. A. The
short chain carbocyanine DiOC6, which stains primarily ER membranes, was used as a
background stain.

B.

SERCA2a was detected with an anti-SERC2a mouse IgG1

antibody and visualized with a goat anti-mouse IgG1 secondary antibody conjugated to
CY5.

C.

Phospholamban was detected with an anti-phospholamban mouse IgG2a

antibody and visualized with a goat anti-mouse IgG2a secondary antibody conjugated to
rhodamine. D. A differential interference contrast image (DIC) was also collected.
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Figure A-3. Effect of phospholamban on [Ca2+]-dependent Ca2+ uptake. Ca2+ uptake
assays of High-Five cellular microsomes containing either the Ca2+-ATPase expressed
alone (□, ■) or co-expressed with phospholamban (○, ●) were done at 37 oC. Samples
were pre-incubated in the absence (-Ab) or presence (+Ab) of anti-phospholamban
monoclonal antibody, 2D12, for 20 minutes on ice prior to the start of the uptake assays.
Regulatory phospholamban decreased the apparent Ca2+ affinity of the Ca2+-ATPase (i.e.,
increased the [Ca2+] required for half-maximal uptake) relative to the sample treated with
anti-PLB monoclonal antibody 2D12 (●), which uncoupled phospholamban from the
Ca2+-ATPase. There was no change in the apparent Ca2+ affinity for the SERCA2a
sample expressed alone when the anti-phospholamban monoclonal antibody (■) was
added. The maximum uptake (Vmax) and [Ca2+] required for half-maximal uptake (KCa)
were determined from Hill fits of the [Ca2+]-dependent Ca2+ uptake for each sample. The
data was normalized to the calculated Vmax for both of SERCA2a and SERCA2a +
phospholamban samples, respectively. The values represent triplicate determinations and
the error represents the standard error of the mean.
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